<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/224135-novel-arylamidine-derivative-or-salt-thereof by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 03:31:12 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 224135:NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF.</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF.</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>An arylamidine derivative represented by a general formula described below or a salt thereof has an excellent antifungal action and high safety, and it is useful as an antifungal agent with good pharmacokinetics and pharmacodynamic properties: wherein X represents an unsubstituted or substituted lower alkylene or alkenylene group; G1 represents an oxygen atom, a sulfur atom, or an imino group; G2 represents a carbon atom or a nitrogen atom; Ra represents at least one group selected from the group consisting of a hydrogen atom, a halogen atom, and unsubstituted or substituted alkyl, cycloalkyl and alkoxy groups; R1 represents an unprotected or protected or unsubstituted or substituted amidino group; and R2 represents a substituted amino or substituted cyclic amino group, or the like.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>DESCRIPTION<br>
NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF<br>
TECHNICAL FIELD<br>
The present invention relates to a novel<br>
arylamidine derivative having an antifungal activity,<br>
or a salt thereof. In addition, it relates to an<br>
antifungal agent containing the arylamidine derivative<br>
as active ingredients.<br>
BACKGROUND ART<br>
Serious deep mycosis such as invasive<br>
candidiasis often becomes a fatal disease. Originally,<br>
it has been considered that a principal protective<br>
mechanism on the side of a host organism to Mycomycetes<br>
such as Candida would be nonspecific immunization by<br>
neutrophils. When this protective mechanism normally<br>
functions, there is a little risk of becoming infected<br>
with Mycomycetes. However, in recent years, a risk of<br>
developing deep mycosis has been increased because of<br>
increase in the number of patients with underlying<br>
diseases decreasing the immunological function of an<br>
organism, such as malignant tumors (in particular,<br>
hemopoietic malignant tumors such as acute leukemia or<br>
malignant lymphoma) or AIDS, heavy use of anticancer<br>
agents or immunosuppressive agents, heavy use of<br>
antibacterial antibiotics or steroid hormone, long-term<br><br>
use of central venous hyperalimentation or venous<br>
catheterization, and so on (Rinsho to Biseibutsu<br>
(Clinics and Microorganisms), vol. 17, p. 265, 1990).<br>
The number of agents applied to a treatment<br>
for such deep mycosis is much smaller than that of<br>
antibacterial agents. There are only 6 types of<br>
agents, such as amphotericin B, flucytosine,<br>
miconazole, fluconazole, itraconazole, and micafungin.<br>
Amphotericin B has an extremely strong<br>
fungicidal action to Mycomycetes. However, at the same<br>
time, it has a problem regarding strong side effects<br>
such as nephrotoxicity, and therefore, to use the agent<br>
in a clinical situation is limited. In addition,<br>
flucytosine has a problem that the agent causes rapid<br>
development of resistance when it is chronically used.<br>
Accordingly, at present, this agent is seldom used<br>
singly. Micafungin has a low activity to the<br>
Cryptococcus species. Other agents are generically<br>
called azole antifungal agents in terms of their<br>
structural characteristics. There is a general<br>
tendency that the fungicidal action of these agents to<br>
Mycomycetes is poorer than that of amphotericin B.<br>
However, considering both effectiveness and safety,<br>
azole antifungal agents are most frequently used at<br>
present ((Rinsho to Biseibutsu (Clinics and<br>
Microorganisms), vol. 21, p. 277, 1994).<br>
Currently, fluconazole-resistant Candida<br>
albicans (C. albicans) has been detected with a high<br><br>
frequency of 30% or more in oropharyngeal candidiasis<br>
lesion of AIDS patients to whom fluconazole had been<br>
repeatedly administered. Moreover, most of the<br>
resistant strains show cross resistance to itraconazole<br>
and other azole agents. Furthermore, separation of the<br>
resistant strains has also been reported regarding non-<br>
AIDS patients who developed chronic mucocutaneous<br>
candidiasis or deep candidiasis {Rinsho to Biseibutsu<br>
(Clinics and Microorganisms), vol. 28, p. 57, 2001).<br>
Thus, if a limited number of agents have a<br>
problem regarding resistance, it will inevitably affect<br>
the management of patients with deep mycosis, the<br>
number of which is being increased (Rinsho to<br>
Biseibutsu (Clinics and Microorganisms), vol. 28, p.<br>
51, 2001).<br>
Accordingly, it is strongly desired that an<br>
antifungal agent will be developed, whose action<br>
mechanism differs from those of the existing agents and<br>
which has effects on Mycomycetes resistant to azole<br>
agents, while having a little side effects.<br>
DISCLOSURE OF THE INVENTION<br>
Under such circumstances, the present<br>
inventors have intensively studied. As a result, they<br>
have found that an arylamidine derivative formed by<br>
introducing an amidino group into an aryl ring,<br>
represented by general formula [1] described below, or<br>
a salt thereof, has an excellent antifungal activity,<br><br>
thereby completing the present invention:<br><br>
wherein X represents an unsubstituted or substituted<br>
lower alkylene or alkenylene group; G1 represents an<br>
oxygen atom, a sulfur atom, or an imino group; G2<br>
represents a carbon atom or a nitrogen atom; Ra<br>
represents at least one group selected from the group<br>
consisting of a hydrogen atom, a halogen atom, and an<br>
unsubstituted or substituted alkyl, cycloalkyl and<br>
alkoxy group; R1 represents an unprotected or protected<br>
or unsubstituted or substituted amidino group; and R2<br>
represents a group represented by the following formula<br>
(1), (2) or (3):<br>
(1) <br>
wherein R3 represents a hydrogen atom, an amino<br>
protecting group, or an unsubstituted or substituted<br>
cycloalkyl or alkenyl group, or group represented by<br>
the following formula:<br><br><br>
wherein W represents an unsubstituted or<br>
substituted lower alkylene group or a direct bond; Yc<br>
represents an unsubstituted or substituted C2-4 lower<br>
alkylene group; Yc' represents an unsubstituted or<br>
substituted C1-4 lower alkylene group; and R7b represents<br>
a hydrogen atom, an amino protecting group, or an<br>
unsubstituted or substituted alkyl, cycloalkyl or<br>
alkenyl group, or group represented by the following<br>
formula:<br><br>
wherein Zb represents an unsubstituted or<br>
substituted lower alkylene or alkenylene group; G3b<br>
represents an oxygen atom, a sulfur atom, an imino<br>
group, or a direct bond; G5b represents a carbon atom or<br>
a nitrogen atom; Rbb represents at least one group<br>
selected from the group consisting of a hydrogen atom,<br>
a halogen atom, and an unsubstituted or substituted<br>
alkyl, cycloalkyl and alkoxy group; and R8b represents<br>
an unprotected or protected or unsubstituted or<br>
substituted amidino group, which is bonded at the para<br>
or meta position of the position connected to G3b;<br>
R4 represents a hydrogen atom, an amino<br>
protecting group, or an unsubstituted or substituted<br><br>
alkyl, cycloalkyl or alkenyl group;<br>
(2) <br>
wherein Y represents an unsubstituted or substituted C2-6<br>
lower alkylene or C3-6 alkenylene group; each of R5 and<br>
R6, which may be the same or different, represents a<br>
hydrogen atom, an amino protecting group, or an<br>
unsubstituted or substituted alkyl, cycloalkyl or<br>
alkenyl group; and R7 represents a hydrogen atom, an<br>
amino protecting group, or an unsubstituted or<br>
substituted alkyl, cycloalkyl or alkenyl group, or a<br>
group represented by the following formula:<br><br>
wherein Z represents an unsubstituted or<br>
substituted lower alkylene or alkenylene group; G3<br>
represents an oxygen atom, a sulfur atom, an imino<br>
group, or a direct bond; Gb represents a carbon atom or<br>
a nitrogen atom; Rb represents at least one group<br>
selected from the group consisting of a hydrogen atom,<br>
a halogen atom and an unsubstituted or substituted<br>
alkyl, cycloalkyl and alkoxy group; and R8 represents an<br><br>
unprotected or protected or unsubstituted or<br>
substituted amidino group, which is bonded at the para<br>
or meta position of the position connected to G3; or<br>
(3) <br>
wherein Ya represents an unsubstituted or substituted C2-4<br>
lower alkylene group; Yb represents an unsubstituted<br>
or substituted C1-4 lower alkylene group; G4 represents a<br>
carbon atom or a nitrogen atom; R7a represents an alkyl<br>
group substituted by at least one group selected from<br>
the group consisting of a cyano group, a nitro group, a<br>
halogen atom, a sulfo group, a phosphoryl group, an<br>
unprotected or protected hydroxyl group, an unprotected<br>
or protected amino group, an unprotected or protected<br>
carbamoyl group, an unprotected or protected<br>
hydroxycarbamoyl group, an unprotected or protected<br>
aminosulfonyl group, an unprotected or protected cyclic<br>
amino group, an unprotected or protected lower<br>
alkylamino group, a lower alkenyl group, a lower alkoxy<br>
group, a heterocyclic group, a cycloalkyl group, a<br>
lower alkylidene group, a mercapto group, an<br>
amidinophenylaryloxy group, an aryloxy group, a lower<br>
alkylthio group, a lower alkylsulfinyl group, a lower<br>
alkylsulfonyl group, a lower alkylcarbamoyl group, a<br>
lower alkylsulfonylamino group, a lower<br><br>
alkylaminosulfonyl group, a carboxyl lower alkenyl<br>
group, a hydroxyl heterocyclic group, a lower alkyl<br>
heterocyclic group, a lower alkoxy-lower alkoxy group,<br>
and a lower alkoxyimino group, or an unsubstituted or<br>
substituted phenyl, cycloalkyl or alkenyl group, or<br>
group represented by the following formula:<br><br>
wherein Za represents an unsubstituted or<br>
substituted lower alkylene or alkenylene group; G3a<br>
represents an oxygen atom, a sulfur atom, an imino<br>
group, or a direct bond; G5a represents a carbon atom or<br>
a nitrogen atom; Rba represents at least one group<br>
selected from the group consisting of a hydrogen atom,<br>
a halogen atom, and an unsubstituted or substituted<br>
alkyl, cycloalkyl and alkoxy groups; and R8a represents<br>
an unprotected or protected or unsubstituted or<br>
substituted amidino group, which is bonded at the para<br>
or meta position of the position connected to G3a<br>
(provided that where G1 represents an imino group, X<br>
represents an unsubstituted or substituted C3-6 lower<br>
alkylene group, or an unsubstituted or substituted<br>
alkenylene group).<br>
Moreover, these compounds or salts thereof<br>
are highly safe and exhibit excellent pharmacokinetics<br><br>
and pharmacodynamic properties. Accordingly, these are<br>
useful as excellent antifungal agents.<br>
The compound of the present invention will be<br>
described in detail below.<br>
In the present invention, unless otherwise<br>
specified, the term "halogen atom" is used to mean a<br>
fluorine atom, a chlorine atom, a bromine atom, and an<br>
iodine atom; the term "alkyl group" is used to mean a<br>
linear or branched C1-12 alkyl group such as methyl,<br>
ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,<br>
isobutyl, tert-butyl, pentyl, isopentyl, hexyl, heptyl,<br>
or octyl; the term "lower alkyl group" is used to mean<br>
a linear or branched C1-6 alkyl group such as methyl,<br>
ethyl, n-propyl, isopropyl, n-butyl, sec-butyl,<br>
isobutyl, tert-butyl, pentyl, or isopentyl; the term<br>
"halogeno lower alkyl group" is used to mean a linear<br>
or branched halogeno-C1-6 alkyl group such as<br>
fluoromethyl, chloromethyl, bromomethyl,<br>
dichloromethyl, trifluoromethyl, trichloromethyl,<br>
chloroethyl, dichloroethyl, trichloroethyl, or<br>
chloropropyl; the term "lower alkoxy-lower alkyl group"<br>
is used to mean a linear or branched C1-6 alkoxy-C1-6<br>
alkyl group such as methoxymethyl, ethoxymethyl, n-<br>
propoxymethyl, methoxyethyl, or ethoxyethyl; the term<br>
"hydroxy lower alkyl group" is used to mean a linear or<br>
branched hydroxy-C1-6 alkyl group such as hydroxymethyl,<br>
hydroxyethyl, or hydroxypropyl; the term "amino lower<br>
alkyl group" is used to mean a linear or branched<br><br>
amino-C1-6 alkyl group such as aminomethyl, aminoethyl,<br>
or aminopropyl; the term "carboxyl lower alkyl group"<br>
is used to mean a linear or branched C1-6 alkyl group,<br>
which is substituted by a carboxyl group; the term<br>
"alkenyl group" is used to mean a linear or branched C2-<br>
12 alkenyl group such as vinyl, allyl, propenyl,<br>
isopropenyl, butenyl, isobutenyl, pentenyl, hexenyl,<br>
heptenyl, or octenyl; the term "lower alkenyl group" is<br>
used to mean a linear or branched C2-6 alkenyl group such<br>
as vinyl, allyl, propenyl, isopropenyl, butenyl,<br>
isobutenyl, or pentenyl; the term "cycloalkyl group" is<br>
used to mean a C3-7 cycloalkyl group such as cyclopropyl,<br>
cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl;<br>
the term "lower alkylene group" is used to mean a<br>
linear or branched C1-6 alkylene group such as methylene,<br>
ethylene, propylene, butylene, amylene, or hexylene;<br>
the term "alkenylene group" is used to mean a linear or<br>
branched C2-6 alkenylene group such as vinylene,<br>
propenylene, 2-butenylene, 1-butenylene, or<br>
isopropenylene; the term "aryl group" is used to mean a<br>
group such as phenyl, tolyl, or naphthyl; the term<br>
"aralkyl group" is used to mean an ar C1-12 alkyl group<br>
such as benzyl, diphenylmethyl, trityl, phenethyl, 4-<br>
methylbenzyl, or naphthylmethyl; the term "aryloxy<br>
group" is used to mean a group such as phenoxy or<br>
naphthoxy; the term "aryloxycarbonyl group" is used to<br>
mean a group such as phenoxycarbonyl or<br>
naphthoxycarbonyl; the term "amidinophenylaryloxy<br><br>
group" is used to mean an aryloxy group substituted by<br>
an amidinophenyl group, such as 4-(4-amidinophenyl)<br>
phenyloxy, 4-(4-amidinophenyl)-2-fluoro-phenyloxy, or<br>
4-(3-amidinophenyl) phenyloxy; the term "alkoxy group"<br>
is used to mean a linear or branched C1-12 alkoxy group<br>
such as methoxy, ethoxy, n-propoxy, isopropoxy, n-<br>
butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy,<br>
isopentyloxy, hexyloxy, heptyloxy, or octyloxy; the<br>
term "lower alkoxy group" is used to mean a linear or<br>
branched C1-6 alkoxy group such as methoxy, ethoxy, n-<br>
propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy,<br>
tert-butoxy, pentyloxy, or isopentyloxy; the term<br>
"lower alkoxycarbonyl group" is used to mean a linear<br>
or branched C1-6 alkyloxycarbonyl group such as<br>
methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, or<br>
n-propoxycarbonyl; the term "lower alkoxycarbonyl-lower<br>
alkyl group" is used to mean a linear or branched C1-6<br>
alkoxycarbonyl-C1-6 alkyl group such as<br>
methoxycarbonylmethyl, ethoxycarbonylmethyl, n-<br>
propoxycarbonylmethyl, methoxycarbonylethyl, or<br>
ethoxycarbonylethyl; the term "lower alkoxyimino group"<br>
is used to mean a linear or branched C1-6 alkoxyimino<br>
group such as methoxyimino or ethoxyimino; the term<br>
"lower alkylamino group" is used to mean a linear or<br>
branched mono- or di-C1-6 alkylamino group such as<br>
methylamino, ethylamino, isopropylamino, n-propylamino,<br>
dimethylamino, diethylamino, or methylethylamino; the<br>
term "lower alkylamino-lower alkyl group" is used to<br><br>
mean a mono- or di-C1-6 alkylamino-C1-6 alkyl group such<br>
as methylaminomethyl, methylaminoethyl,<br>
ethylaminomethyl, methylaminopropyl,<br>
isopropylaminoethyl, n-propylaminoethyl,<br>
dimethylaminomethyl, diethylaminomethyl,<br>
diethylaminoethyl, or dimethylaminopropyl; the term<br>
"lower alkylidene group" is used to mean a C1-6<br>
alkylidene group such as methylene, ethylidene,<br>
propylidene, or isopropylidene; the term "nitrogen-<br>
containing heterocyclic group" is used to mean a 5- or<br>
6-membered ring, condensed ring, or bridge ring<br>
heterocyclic group, which contains at least one<br>
nitrogen atom as a heterocyclic atom forming the above<br>
described heterocyclic ring of a group such as<br>
pyrrolyl, pyrrolidinyl, piperidyl, piperazinyl,<br>
imidazolyl, pyrazolyl, pyridyl, tetrahydropyridyl,<br>
pyrimidinyl, morpholinyl, thiomorpholinyl, quinolyl,<br>
quinolizinyl, tetrahydroquinolinyl,<br>
tetrahydroisoquinolinyl, quinuclidinyl, quinazolyl,<br>
thiazolyl, tetrazolyl, thiadiazolyl, pyrrolinyl,<br>
imidazolinyl, imidazolidinyl, pyrazolinyl,<br>
pyrazolidinyl, purinyl, or indazolyl, and which may<br>
further contain at least one oxygen or sulfur atom; the<br>
term "heterocyclic group" is used to include the above<br>
described nitrogen-containing heterocyclic group, and a<br>
5- or 6-membered ring, condensed ring, or bridge ring<br>
heterocyclic group, which contains at least one<br>
heterocyclic atom selected from the group consisting of<br><br>
nitrogen, oxygen, and sulfur atoms, and which may<br>
further contain at least one oxygen or sulfur atom as a<br>
heterocyclic atom forming the above described<br>
heterocyclic ring of a group such as furyl, thienyl,<br>
benzothienyl, pyranyl, isobenzofuranyl, oxazolyl,<br>
benzofuranyl, indolyl, benzimidazolyl, benzoxazolyl,<br>
benzothiazolyl, quinoxalyl, dihydroquinoxalinyl, 2,3-<br>
dihydrobenzothienyl, 2,3-dihydrobenzopyrrolyl, 2,3-<br>
dihydro-4H-1-thianaphthyl, 2,3-dihydrobenzofuranyl,<br>
benzo [b] dioxanyl, imidazo [2,3-a] pyridyl, benzo [b]<br>
piperazinyl, chromenyl, isothiazolyl, isoxazolyl,<br>
thiadiazolyl, oxadiazolyl, pyridazinyl, isoindolyl, or<br>
isoquinolyl; the term "acyl group" is used to mean, for<br>
example, a formyl group, a linear or branched C2-12<br>
alkanoyl group such as acetyl, isovaleryl, or<br>
propionyl, an aralkylcarbonyl group such as<br>
benzylcarbonyl, an aroyl group such as benzoyl or<br>
naphthoyl, and a heterocyclic carbonyl group such as a<br>
nicotinoyl, thenoyl, pyrrolidinocarbonyl or furoyl<br>
group; the term "cyclic amino group" is used to mean,<br>
for example, either a saturated or unsaturated cyclic<br>
amino group, which may contain one or more heterocyclic<br>
atom such as a nitrogen, oxygen, or sulfur atom, and<br>
carbonyl carbon, and which may be monocyclic, bicyclic,<br>
or tricyclic. Specific examples of such a cyclic amino<br>
group may include: saturated or unsaturated monocyclic<br>
3- to 7-membered cyclic amino groups containing one<br>
nitrogen atom, such as aziridin-1-yl, azetidin-1-yl,<br><br>
azetidin-2-yl, pyrrolidin-1-yl, pyrrolidin-2-yl,<br>
pyrrolidin-3-yl, 1-methylpyrrolidin-2-yl, 1-<br>
methylpyrrolidin-3-yl, pyrolin-1-yl, pyrrol-1-yl,<br>
dihydropyridin-1-yl, piperidin-1-yl, piperidin-2-yl,<br>
piperidin-3-yl, piperidin-4-yl, 1-methylpiperidin-2-yl,<br>
1-methylpiperidin-3-yl, 1-methylpiperidin-4-yl,<br>
dihydroazepin-1-yl, or perhydroazepin-1-yl; saturated<br>
or unsaturated monocyclic 3- to 7-membered cyclic amino<br>
groups containing two nitrogen atoms, such as imidazol-<br>
1-yl, imidazolidin-1-yl, imidazolin-1-yl, pyrazolidin-<br>
1-yl, piperazin-1-yl, 4-methylpiperazin-1-yl, 1,4-<br>
dihydropyrazin-1-yl, 1,2-dihydropyrimidin-1-yl, 4-<br>
methylhomopiperazin-1-yl, perhydropyrazin-1-yl, or<br>
homopiperazin-1-yl; saturated or unsaturated monocyclic<br>
3- to 7-membered cyclic amino groups containing 3 or<br>
more nitrogen atoms, such as 1,2,4-triazol-1-yl, 1,2,3-<br>
triazol-1-yl, 1,2-dihydro-1,2,4-triazin-1-yl, or<br>
perhydro-S-triazin-1-yl; saturated or unsaturated<br>
monocyclic 3- to 7-membered cyclic amino groups<br>
containing 1 to 4 hetero atoms selected from the group<br>
consisting of oxygen and sulfur atoms, as well as<br>
nitrogen atoms, such as oxazolidin-3-yl, isoxazolidin-<br>
2-yl, morpholino, thiazolidin-3-yl, isothiazolidin-2-<br>
yl, thiomorpholino, homothiomorpholin-4-yl, or 1,2,4-<br>
thiadiazolin-2-yl; saturated or unsaturated bicyclic or<br>
tricyclic amino groups such as isoindolin-2-yl,<br>
indolin-1-yl, lH-indazol-1-yl, purin-7-yl, or<br>
tetrahydroquinolin-1-yl; and spiro or bridged saturated<br><br>
or unsaturated 5- to 12-membered cyclic amino groups<br>
such as quinuclidin-1-yl, 5-azaspiro [2.4] heptan-5-yl,<br>
2,8-diazabicyclo [4.3.0] nonan-8-yl, 3-azabicyclo<br>
[3.1.0] hexan-3-yl, 2-oxa-5,8-diazabicyclo [4.3.0]<br>
nonan-8-yl, 2,8-diazaspiro [4.4] nonan-2-yl, or 7-<br>
azabicyclo [2.2.1] heptan-7-yl. The term "lower<br>
alkylthio group" is used to mean a linear or branched<br>
C1-6 alkylthio group such as methylthio, ethylthio, n-<br>
propylthio, isopropylthio, n-butylthio, isobutylthio,<br>
sec-butylthio, tert-butylthio, pentylthio, or<br>
isopentylthio; the term "alkylsulfonyl group" is used<br>
to mean a linear or branched C1-12 alkylsulfonyl group<br>
such as methylsulfonyl, ethylsulfonyl, n-<br>
propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl,<br>
isobutylsulfonyl, sec-butylsulfonyl, tert-<br>
butylsulfonyl, pentylsulfonyl, isopentylsulfonyl,<br>
hexylsulfonyl, heptylsulfonyl, or octylsulfonyl; the<br>
term "arylsulfonyl group" is used to mean an aryl-SO2-<br>
group such as phenylsulfonyl or naphthylsulfonyl; the<br>
term "lower alkylsulfinyl group" is used to mean a<br>
linear or branched C1-6 alkylsulfinyl group such as<br>
methylsulfinyl, ethylsulfinyl, n-propylsulfinyl,<br>
isopropylsulfinyl, n-butylsulfinyl, isobutylsulfinyl,<br>
sec-butylsulfinyl, tert-butylsulfinyl, pentylsulfinyl,<br>
cr hexylsulfinyl; the term "lower alkylsulfonyl group"<br>
is used to mean a linear or branched C1-6 alkylsulfonyl<br>
group such as methylsulfonyl, ethylsulfonyl, n-<br>
propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl,<br><br>
isobutylsulfonyl, sec-butylsulfonyl, tert-<br>
butylsulfonyl, or pentylsulfonyl; the term "lower<br>
alkylcarbamoyl group" is used to mean a mono- or di-C1-6<br>
alkylcarbamoyl group such as methylcarbamoyl,<br>
ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl,<br>
dimethylcarbamoyl, diethylcarbamoyl, or<br>
methylethylcarbamoyl; the term "lower<br>
alkylsulfonylamino group" is used to mean a linear or<br>
branched C1-6 alkylsulfonylamino group such as<br>
methylsulfonylamino, ethylsulfonylamino, n-<br>
propylsulfonylamino, isopropylsulfonylamino, n-<br>
butylsulfonylamino, isobutylsulfonylamino, sec-<br>
butylsulfonylamino, tert-butylsulfonylamino, or<br>
pentylsulfonylamino; the term "lower<br>
alkylsulfonylcarbamoyl group" is used to mean a linear<br>
or branched C1-6 alkylsulfonylcarbamoyl group such as<br>
methylsulfonylcarbamoyl, ethylsulfonylcarbamoyl, n-<br>
propylsulfonylcarbamoyl, isopropylsulfonylcarbamoyl, n-<br>
butylsulfonylcarbamoyl, isobutylsulfonylcarbamoyl, sec-<br>
butylsulfonylcarbamoyl, tert-butylsulfonylcarbamoyl, or<br>
pentylsulfonylcarbamoyl; the term "lower<br>
alkylaminosulfonyl group" is used to mean a mono- or<br>
di-C1-6 alkylaminosulfonyl group such as<br>
methylaminosulfonyl, ethylaminosulfonyl, n-<br>
propylaminosulfonyl, isopropylaminosulfonyl,<br>
dimethylaminosulfonyl, diethylaminosulfonyl, or<br>
methylethylaminosulfonyl; the term "carboxyl lower<br>
alkenyl group" is used to mean, for example, a linear<br><br>
or branched C2-6 alkenyl group substituted by a carboxyl<br>
group; the term "hydroxy heterocyclic group" is used to<br>
mean, for example, a heterocyclic group substituted by<br>
a hydroxyl group; the term "lower alkyl heterocyclic<br>
group" is used to mean, for example, a heterocyclic<br>
group substituted by a linear or branched lower alkyl;<br>
the term "lower alkoxy-lower alkoxy group" is used to<br>
mean a linear or branched C1-6 alkoxy group substituted<br>
by lower alkoxy; the term "leaving group" is used to<br>
include halogen atoms such as a fluorine atom, chlorine<br>
atom, bromine atom, or iodine atom, alkylsulfonyloxy<br>
groups such as methanesulfonyloxy or<br>
trifluoromethanesulfonyloxy, arylsulfonyloxy groups<br>
such as paratoluenesulfonyloxy or benzenesulfonyloxy,<br>
and acyloxy groups such as acetyloxy or<br>
trifluoroacetyloxy.<br>
Any protecting group can be used as a<br>
protecting group of a carboxyl group, as long as it can<br>
be used as an ordinary carboxyl protecting group.<br>
Examples of such a protecting group may include: alkyl<br>
groups such as methyl, ethyl, n-propyl, isopropyl, 1,1-<br>
dimethylpropyl, n-butyl, or tert-butyl; aryl groups<br>
such as phenyl or naphthyl; aralkyl groups such as<br>
benzyl, diphenylmethyl, trityl, p-nitrobenzyl, p-<br>
methoxybenzyl, or bis (p-methoxyphenyl) methyl;<br>
acylalkyl groups such as acetylmethyl, benzoylmethyl,<br>
p-nitrobenzoylmethyl, p-bromobenzoylmethyl, or p-<br>
methanesulfonylbenzoylmethyl; oxygen-containing<br><br>
heterocyclic groups such as 2-tetrahydropyranyl or 2-<br>
tetrahydrofuranyl; halogenoalkyl groups such as 2,2,2-<br>
trichloroethyl; alkylsilylalkyl groups such as 2-<br>
(trimethylsilyl)ethyl; acyloxyalkyl groups such as<br>
acetoxymethyl, propionyloxymethyl, or<br>
pivaloyloxymethyl; nitrogen-containing heterocyclic<br>
alkyl groups such as phthalimidomethyl or<br>
succinimidomethyl; cycloalkyl groups such as<br>
cyclohexyl; alkoxyalkyl groups such as methoxymethyl,<br>
methoxyethoxymethyl, or 2-(trimethylsilyl)<br>
ethoxymethyl; aralkoxyalkyl groups such as<br>
benzyloxymethyl; lower alkylthioalkyl groups such as<br>
methylthiomethyl or 2-methylthioethyl; arylthioalkyl<br>
groups such as phenylthiomethyl; alkenyl groups such as<br>
1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, or allyl;<br>
and substituted silyl groups such as trimethylsilyl,<br>
triethylsilyl, triisopropylsilyl,<br>
diethylisopropylsilyl, tert-butyldimethylsilyl, tert-<br>
butyldiphenylsilyl, diphenylmethylsilyl, or tert-<br>
butylmethoxyphenylsilyl. Preferred examples may<br>
include alkyl groups, aralkyl groups, and substituted<br>
silyl groups.<br>
Any protecting group can be used as a<br>
protecting group of an amino group, as long as it can<br>
be used as an ordinary amino protecting group.<br>
Examples of such a protecting group may include: acyl<br>
groups such as (mono-, di-, or tri-)chloroacetyl,<br>
trifluoroacetyl, phenylacetyl, formyl, acetyl, benzoyl,<br><br>
phthaloyl, succinyl, or an amino acid residue with an<br>
unprotected or protected N-terminus (examples of amino<br>
acid may include glycine, alanine, valine, leucine,<br>
isoleucine, serine, threonine, cysteine, methionine,<br>
aspartic acid, glutamic acid, asparagine, glutamine,<br>
arginine, lysine, histidine, hydroxylysine,<br>
phenylalanine, tyrosine, tryptophan, proline, and<br>
hydroxyproline); alkyloxycarbonyl groups such as<br>
methoxycarbonyl, diphenylmethoxycarbonyl,<br>
ethoxycarbonyl, trichloroethoxycarbonyl,<br>
tribromoethoxycarbonyl, 1,1-dimethylpropoxycarbonyl,<br>
isopropoxycarbonyl, 2-ethylhexyloxycarbonyl, tert-<br>
pentyloxycarbonyl, tert-butoxycarbonyl, or 1-<br>
adamantyloxycarbonyl; aralkyloxycarbonyl groups such as<br>
benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, o-<br>
bromobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl,<br>
3,4-dimethoxybenzyloxycarbonyl, or 4-<br>
(phenylazo)benzyloxycarbonyl; aryloxycarbonyl groups<br>
such as phenyloxycarbonyl, 4-fluorophenyloxycarbonyl,<br>
4-methoxyphenyloxycarbonyl, 8-quinolyloxycarbonyl, or<br>
2-furfuryloxycarbonyl; aralkyl groups such as benzyl,<br>
diphenylmethyl, or trityl; alkoxyalkyl groups such as<br>
methoxymethyl, benzyloxymethyl, 2-methoxyethoxymethyl,<br>
2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)<br>
ethoxymethyl, or 1-ethoxyethyl; arylthio groups such as<br>
2-nitrophenylthio or 2,4-dinitrophenylthio;<br>
alkylsulfonyl or arylsulfonyl groups such as<br>
methanesulfonyl or p-toluenesulfonyl;<br><br>
dialkylaminoalkylidene groups such as N,N-<br>
dimethylaminomethylene; aralkylidene groups such as<br>
benzylidene, 2-hydroxybenzylidene, 2-hydroxy-5-<br>
chlorobenzylidene, or 2-hydroxy-1-naphthylmethylene;<br>
nitrogen-containing heterocyclic alkylidene groups such<br>
as 3-hydroxy-4-pyridylmethylene; cycloalkylidene groups<br>
such as cyclohexylidene, 2-<br>
ethoxycarbonylcyclohexylidene, 2-<br>
ethoxycarbonylcyclopentylidene, 2-<br>
acetylcyclohexylidene, or 3,3-dimethyl-5-<br>
oxycyclohexylidene; diaryl- or diaralkylphosphoryl<br>
groups such as diphenylphosphoryl or<br>
dibenzylphosphoryl; oxygen-containing heterocyclic<br>
alkyl groups such as 5-methyl-2-oxo-2H-1,3-dioxol-4-yl-<br>
methyl; and substituted silyl groups such as<br>
trimethylsilyl.<br>
Any protecting group can be used as a<br>
protecting group of a hydroxyl group, as long as it can<br>
be used as an ordinary hydroxyl protecting group.<br>
Examples of such a protecting group may include: acyl<br>
groups such as benzyloxycarbonyl, 4-<br>
nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-<br>
methoxybenzyloxycarbonyl, 3,4-<br>
dimethoxybenzyloxycarbonyl, methoxycarbonyl,<br>
ethoxycarbonyl, tert-butoxycarbonyl, 1,1-<br>
dimethylpropoxycarbonyl, isopropoxycarbonyl,<br>
isobutyloxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-<br>
trichloroethoxycarbonyl, 2,2,2-tribromoethoxycarbonyl,<br><br>
2-(trimethylsilyl) ethoxycarbonyl, 2-(phenylsulfonyl)<br>
ethoxycarbonyl, 2-(triphenylphosphonio) ethoxycarbonyl,<br>
2-furfuryloxycarbonyl, 1-adamantyloxycarbonyl,<br>
vinyloxycarbonyl, allyloxycarbonyl, S-<br>
benzylthiocarbonyl, 4-ethoxy-1-naphthyloxycarbonyl, 8-<br>
quinolyloxycarbonyl, acetyl, formyl, chloroacetyl,<br>
dichloroacetyl, trichloroacetyl, trifluoroacetyl,<br>
methoxyacetyl, phenoxyacetyl, pivaloyl, or benzoyl;<br>
alkyl groups such as methyl, isopropyl, isobutyl, tert-<br>
butyl, 2,2,2-trichloroethyl, or 2-trimethylsilylethyl;<br>
alkenyl groups such as allyl; aralkyl groups such as<br>
benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl,<br>
diphenylmethyl, or trityl; oxygen- or sulfur-containing<br>
heterocyclic groups such as tetrahydrofuryl,<br>
tetrahydropyranyl, or tetrahydrothiopyranyl;<br>
alkoxyalkyl groups such as methoxymethyl,<br>
benzyloxymethyl, 2-methoxyethoxymethyl, 2,2,2-<br>
trichloroethoxymethyl, 2-(trimethylsilyl) ethoxymethyl,<br>
or 1-ethoxyethyl; alkylsulfonyl or arylsulfonyl groups<br>
such as methanesulfonyl or p-toluenesulfonyl; and<br>
substituted silyl groups such as trimethylsilyl,<br>
triethylsilyl, triisopropylsilyl,<br>
diethylisopropylsilyl, tert-butyldimethylsilyl, tert-<br>
butyldiphenylsilyl, diphenylmethylsilyl, or tert-<br>
butylmethoxyphenylsilyl.<br>
Any protecting group can be used as a<br>
protecting group of an aldehyde group, as long as it<br>
can be used as an ordinary aldehyde protecting group.<br><br>
Examples of such a protecting group may include<br>
dialkylacetals such as dinaethylacetal, and 5- or 6-<br>
membered cyclic acetals such as 1,3-dioxolane or 1,3-<br>
dioxane.<br>
Any protecting group can be used as a<br>
protecting group of an amidino group as long as it can<br>
be used as an ordinary amidino protecting group.<br>
Examples of such a protecting group may include: acyl<br>
groups such as (mono-, di-, or tri-)chloroacetyl,<br>
trifluoroacetyl, phenylacetyl, formyl, acetyl, benzoyl,<br>
phthaloyl, succinyl, or an amino acid residue with an<br>
unprotected or protected N-terminus (examples of amino<br>
acid may include glycine, alanine, valine, leucine,<br>
isoleucine, serine, threonine, cysteine, methionine,<br>
aspartic acid, glutamic acid, asparagine, glutamine,<br>
arginine, lysine, histidine, hydroxylysine,<br>
phenylalanine, tyrosine, tryptophan, proline, and<br>
hydroxyproline); alkyloxycarbonyl groups such as<br>
methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl,<br>
butyloxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl,<br>
heptyloxycarbonyl, morpholinoethoxycarbonyl,<br>
trichloroethoxycarbonyl, tribromoethoxycarbonyl, 1-<br>
acetoxyethoxycarbonyl, 5-methyl-2-oxo-1,3-dioxol-4-yl-<br>
methoxycarbonyl, tert-pentyloxycarbonyl, tert-<br>
butoxycarbonyl, diphenylmethoxycarbonyl, 1,1-<br>
dimethylpropoxycarbonyl, isopropoxycarbonyl, or 1-<br>
adamantyloxycarbonyl; cycloalkyloxycarbonyl groups such<br>
as cyclopentyloxy or cyclohexyloxy; aralkyloxycarbonyl<br><br>
groups such as benzyloxycarbonyl, o-<br>
bromobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, p-<br>
methoxybenzyloxycarbonyl, or 3,4-<br>
dimethoxybenzyloxycarbonyl; aryloxycarbonyl groups such<br>
as phenyloxycarbonyl, 4-fluorophenyloxycarbonyl, 4-<br>
methoxyphenyloxycarbonyl, or 8-quinolyloxycarbonyl;<br>
alkylthiocarbonyl groups such as ethylthiocarbonyl;<br>
aralkyl groups such as benzyl, diphenylmethyl, or<br>
trityl; alkoxyalkyl groups such as methoxymethyl,<br>
benzyloxymethyl, 2-methoxyethoxymethyl, 2,2,2-<br>
trichloroethoxymethyl, 2-(trimethylsilyl) ethoxymethyl,<br>
or 1-ethoxyethyl; arylthio groups such as 2-<br>
nitrophenylthio or 2,4-dinitrophenylthio; alkylsulfonyl<br>
or arylsulfonyl groups such as methanesulfonyl or p-<br>
toluenesulfonyl; dialkylaminoalkylidene groups such as<br>
N,N-dimethylaminomethylene; aralkylidene groups such as<br>
benzylidene, 2-hydroxybenzylidene, 2-hydroxy-5-<br>
chlorobenzylidene, or 2-hydroxy-l-naphthylmethylene;<br>
nitrogen-containing heterocyclic alkylidene groups such<br>
as 3-hydroxy-4-pyridylmethylene; cycloalkylidene groups<br>
such as cyclohexylidene, 2-<br>
ethoxycarbonylcyclohexylidene, 2-<br>
ethoxycarbonylcyclopentylidene, 2-<br>
acetylcyclohexylidene, or 3,3-dimethyl-5-<br>
oxycyclohexylidene; oxygen-containing heterocyclic<br>
alkyl groups such as 5-methyl-2-oxo-2H-l,3-dioxol-4-yl-<br>
methyl; and substituted silyl groups such as<br>
trimethylsilyl.<br><br>
With regard to the compound represented by<br>
general formula [1] or a salt thereof, examples of such<br>
a salt of the compound may include publicly known salts<br>
of basic groups such as an amino group, or of acidic<br>
groups such as a hydroxyl or carboxyl group. Examples<br>
of such a salt of a basic group may include: salts<br>
produced with mineral acids such as hydrochloric acid,<br>
hydrobromic acid, or sulfuric acid; salts produced with<br>
organic carboxylic acids such as tartaric acid, formic<br>
acid, acetic acid, citric acid, trichloroacetic acid,<br>
or trifluoroacetic acid; and salts produced with<br>
sulfonic acids such as methanesulfonic acid,<br>
benzenesulfonic acid, p-toluenesulfonic acid,<br>
mesitylenesulfonic acid, or naphthalenesulfonic acid.<br>
Examples of such a salt of an acidic group may include:<br>
salts produced with alkaline metals such as sodium or<br>
potassium; salts produced with alkaline earth metals<br>
such as calcium or magnesium; ammonium salts; and salts<br>
produced with nitrogen-containing organic bases such as<br>
trimethylamine, triethylamine, tributylamine, pyridine,<br>
N,N-dimethylaniline, N-methylpiperidine, N-<br>
methylmorpholine, diethylamine, dicyclohexylamine,<br>
procaine, dibenzylamine, N-benzyl-ÃŸ-phenethylamine, or<br>
N,N'-dibenzylethylenediamine. Among the above<br>
described salts, preferred salts of the compound<br>
represented by general formula [1] may include<br>
pharmacologically acceptable salts.<br>
The substituents of the present invention, R3,<br><br>
R3c, R3f, R4, R4c, R4f, R5 R5d, R5g, R6, R6d, R6g, R7, R7a, R7b<br>
R7d, R7g, Ra, Rb, Rba, and Rbb, may further be substituted<br>
by at least one group selected from the group<br>
consisting of a cyano group, a nitro group, a halogen<br>
atom, a sulfo group, a phosphoryl group, unprotected or<br>
protected carboxyl, hydroxyl, amino, carbamoyl,<br>
hydroxycarbamoyl, aminosulfonyl, hydroxyl lower alkyl,<br>
amino lower alkyl, cyclic amino, lower alkylamino and<br>
lower alkylamino-lower alkyl groups, a lower alkyl<br>
group, a lower alkenyl group, a lower alkoxy group, a<br>
lower alkoxycarbonyl group, an acyl group, an aryl<br>
group, a heterocyclic group, a cycloalkyl group, an<br>
aralkyl group, a lower alkylidene group, a mercapto<br>
group, a lower alkylthio group, a lower alkylsulfinyl<br>
group, a lower alkylsulfonyl group, a lower<br>
alkylcarbamoyl group, a lower alkylsulfonylamino group,<br>
a lower alkylaminosulfonyl group, a carboxyl lower<br>
alkyl group, a carboxyl lower alkenyl group, a hydroxyl<br>
heterocyclic group, a lower alkyl heterocyclic group, a<br>
lower alkoxy-lower alkoxy group, a halogeno lower alkyl<br>
group, a lower alkoxy-lower alkyl group, a lower<br>
alkoxycarbonyl-lower alkyl group, and a lower<br>
alkoxyimino group.<br>
Substituents, R1, R8, R8a, RSb, R8d, RSe, R89, and<br>
R8h, may further be substituted by at least one group<br>
selected from the group consisting of an unprotected or<br>
protected hydroxyl group, a lower alkyl group, a lower<br>
alkenyl group, a lower alkoxy group, a lower<br><br>
alkoxycarbonyl group, an acyl group, an aryl group, a<br>
heterocyclic group, a cycloalkyl group, and an aralkyl<br>
group.<br>
Substituents, X, Y, Ya, Yc, Yd, Ye, Yg, Yh, Z,<br>
Za, Zb, Zd, Ze Zg, Zh, and W, may further be substituted<br>
by at least one group selected from the group<br>
consisting of a cyano group, a nitro group, a halogen<br>
atom, an unprotected or protected amino, hydroxyl,<br>
carboxyl, carbamoyl, hydroxycarbamoyl and lower<br>
alkylamino group, a lower alkoxycarbonyl group, an acyl<br>
group, an aryl group, a heterocyclic group, a<br>
cycloalkyl group, a lower alkenyl group, a lower<br>
alkylsulfonylcarbamoyl group, a lower alkylcarbamoyl<br>
group, a lower alkoxy group, and a lower alkoxycarbonyl<br>
group.<br>
Substituents, Yb, Yc', Ye, and Yh', may further<br>
be substituted by at least one group selected from the<br>
group consisting of a cyano group, a nitro group, a<br>
halogen atom, an unprotected or protected amino,<br>
carboxyl, carbamoyl, hydroxycarbamoyl, hydroxyl group,<br>
a lower alkylamino group, a lower alkoxycarbonyl group,<br>
an acyl group, an aryl group, a heterocyclic group, a<br>
cycloalkyl group, a lower alkylsulfonylcarbamoyl group,<br>
a lower alkylcarbamoyl group, a lower alkoxy group, a<br>
lower alkoxycarbonyl group, and a keto group.<br>
The above described substituents may further<br>
be substituted by groups exemplified as substituents<br>
for each substituent.<br><br>
Moreover, a heterocyclic group and a cyclic<br>
amino group as the above substituents for each<br>
substituent may also be substituted by keto groups.<br>
The following compounds can preferably be<br>
used as compounds of the present invention:<br>
A compound wherein R1 is an unprotected or<br>
protected amidino group is preferable. A compound<br>
wherein R1 is an amidino group is more preferable.<br>
A compound wherein X is an unsubstituted or<br>
substituted lower alkylene group is preferable. A<br>
compound wherein X is a lower alkylene group is more<br>
preferable, and a compound wherein X is a C2-4 lower<br>
alkylene group is further more preferable.<br>
A compound wherein G1 is an oxygen atom is<br>
preferable.<br>
A compound wherein G2 is a carbon atom is<br>
preferable.<br>
A compound wherein Ra is at least one group<br>
selected from a hydrogen atom or a halogen atom is<br>
preferable, and a compound wherein Ra is a hydrogen atom<br>
is more preferable.<br>
In a preferred compound, R2 preferably<br>
represents a group represented by the following formula<br>
(1), (2) or (3) :<br>
(1) <br><br>
wherein R3c represents a hydrogen atom, an amino<br>
protecting group, or an unsubstituted or substituted<br>
cycloalkyl or an alkenyl group; and R4c represents a<br>
hydrogen atom, an amino protecting group, or an<br>
unsubstituted or substituted alkyl, cycloalkyl or<br>
alkenyl group,<br>
(2) <br>
wherein Yd represents an unsubstituted or substituted<br>
C2-6 lower alkylene or C3-6 alkenylene group; each of R5d<br>
and R6d, which may be the same or different, represents<br>
a hydrogen atom, an amino protecting group, or an<br>
unsubstituted or substituted alkyl, cycloalkyl or<br>
alkenyl group; and R7d represents a hydrogen atom, an<br>
amino protecting group, or an unsubstituted or<br>
substituted alkyl, cycloalkyl or alkenyl group, or a<br>
group represented by the following formula:<br><br>
wherein Zd represents an unsubstituted or<br>
substituted lower alkylene or alkenylene group, R8d<br>
represents an unprotected or protected or unsubstituted<br>
or substituted amidino group, or<br><br>
(3)<br><br>
wherein each of Ye and Ye', which may be the same or<br>
different, represents an unsubstituted or substituted<br>
C2-4 lower alkylene group; Ze represents an unsubstituted<br>
or substituted lower alkylene or alkenylene group; and<br>
R8e represents an unprotected or protected or<br>
unsubstituted or substituted amidino group. In a more<br>
preferred compound, R2 more preferably represents a<br>
group represented by the following formula:<br><br>
wherein each of Ye and Ye', which may be the same or<br>
different, represents an unsubstituted or substituted<br>
C2-4 lower alkylene group; Ze represents an unsubstituted<br>
or substituted lower alkylene or alkenylene group; and<br>
R8e represents an unprotected or protected or<br>
unsubstituted or substituted amidino group.<br>
Moreover, in a preferred compound, R2<br>
preferably represents a group represented by the<br>
following formula (1), (2) or (3):<br>
(1)<br><br><br>
wherein R3f represents a hydrogen atom, an amino<br>
protecting group, or an unsubstituted or substituted<br>
cycloalkyl or alkenyl group; and R4f represents a<br>
hydrogen atom, an amino protecting group, or an<br>
unsubstituted or substituted alkyl, cycloalkyl or<br>
alkenyl group,<br>
(2) <br>
wherein Y9 represents an unsubstituted or substituted<br>
C2-6 lower alkylene or C3-6 alkenylene group; each of R5g<br>
and R6g, which may be the same or different, represents<br>
a hydrogen atom, an amino protecting group, an<br>
unsubstituted or substituted alkyl, cycloalkyl or<br>
alkenyl group; and R7g represents a hydrogen atom, an<br>
amino protecting group, or an unsubstituted or<br>
substituted alkyl, cycloalkyl or alkenyl group, or<br>
group represented by the following formula:<br><br>
wherein Zg represents an unsubstituted or<br><br>
substituted lower alkylene or alkenylene group, R8g<br>
represents an unprotected or protected or unsubstituted<br>
or substituted amidino group, or<br>
(3)<br><br>
wherein each of Yh and Yh', which may be the same or<br>
different, represents an unsubstituted or substituted<br>
C2-4 lower alkylene group; Zh represents an unsubstituted<br>
or substituted lower alkylene or alkenylene group; and<br>
R8h represents an unprotected or protected or<br>
unsubstituted or substituted amidino group.<br>
Furthermore, in a more preferred compound, R2 more<br>
preferably represents a group represented by the<br>
following formula:<br><br>
wherein each of Yh and Yh', which may be the same or<br>
different, represents an unsubstituted or substituted<br>
C2-4 lower alkylene group; Zh represents an unsubstituted<br>
or substituted lower alkylene or alkenylene group; and<br>
R8h represents an unprotected or protected or<br>
unsubstituted or substituted amidino group.<br><br>
In a preferred compound, R3c, a preferred<br>
substituent of R2, is a hydrogen atom, an amino<br>
protecting group, or an unsubstituted or substituted<br>
cycloalkyl group. In a more preferred compound, R3c, a<br>
preferred substituent of R2, is a hydrogen atom or an<br>
amino protecting group.<br>
Moreover, in a preferred compound, R4C, a<br>
preferred substituent of R2, is a hydrogen atom, an<br>
amino protecting group, or an unsubstituted or<br>
substituted alkyl or cycloalkyl group. In a more<br>
preferred compound, R4c, a preferred substituent of R2,<br>
is a hydrogen atom, an amino protecting group, or an<br>
unsubstituted or substituted alkyl group. In a further<br>
more preferred compound, R4c, a preferred substituent of<br>
R2, is a hydrogen atom, an amino protecting group, or an<br>
alkyl group that may be substituted by a carboxyl<br>
group.<br>
Furthermore, in a preferred compound, R5d, a<br>
preferred substituent of R2, is a hydrogen atom, an<br>
amino protecting group, or an unsubstituted or<br>
substituted alkyl or cycloalkyl group. In a more<br>
preferred compound, R5d, a preferred substituent of R2,<br>
is a hydrogen atom, an amino protecting group, or an<br>
unsubstituted or substituted alkyl group. In a further<br>
more preferred compound, R5d, a preferred substituent of<br>
R2, is a hydrogen atom or an amino protecting group.<br>
Still further, in a preferred compound, R6d, a<br>
preferred substituent of R2, is a hydrogen atom, an<br><br>
amino protecting group, or an unsubstituted or<br>
substituted alkyl or cycloalkyl group. In a more<br>
preferred compound, R6d, a preferred substituent of R2,<br>
is a hydrogen atom, an amino protecting group, or an<br>
unsubstituted or substituted alkyl group. In a further<br>
more preferred compound, R6d, a preferred substituent of<br>
R2, is a hydrogen atom or an amino protecting group.<br>
Still further, in a preferred compound, R7d, a<br>
preferred substituent of R2, is a hydrogen atom, an<br>
amino protecting group, or an unsubstituted or<br>
substituted alkyl or cycloalkyl group. In a more<br>
preferred compound, R7d, a preferred substituent of R2,<br>
is a hydrogen atom, an amino protecting group, or an<br>
unsubstituted or substituted alkyl group. In a further<br>
more preferred compound, R7d, a preferred substituent of<br>
R2, is a hydrogen atom, an amino protecting group, or an<br>
alkyl group that may be substituted by a lower<br>
alkoxycarbonyl or carboxyl group.<br>
Still further, in a preferred compound, R8d, a<br>
preferred substituent of R2, is an unprotected or<br>
protected amidino group. In a more preferred compound,<br>
R8d, a preferred substituent of R2, is an amidino group.<br>
Still further, in a preferred compound, Yd, a<br>
preferred substituent of R2, is an unsubstituted or<br>
substituted C2-6 lower alkylene group. In a more<br>
preferred compound, Yd, a preferred substituent of R2,<br>
is a C2-6 lower alkylene group. In a further more<br>
preferred compound, Yd, a preferred substituent of R2,<br><br>
is a C2-3 lower alkylene group.<br>
Still further, in a preferred compound, Zd, a<br>
preferred substituent of R2, is an unsubstituted or<br>
substituted lower alkylene group. In a more preferred<br>
compound, Zd, a preferred substituent of R2, is a lower<br>
alkylene group. In a further more preferred compound,<br>
Zd, a preferred substituent of R2, is a C2-4 lower<br>
alkylene group.<br>
Still further, in a preferred compound, Ye, a<br>
preferred substituent of R2, is a C2-4 lower alkylene<br>
group. In a more preferred compound, Ye, a preferred<br>
substituent of R2, is a C2-3 lower alkylene group.<br>
Still further, in a preferred compound, Ye', a<br>
preferred substituent of R2, is a C2-4 lower alkylene<br>
group. In a more preferred compound, Ye', a preferred<br>
substituent of R2, is a C2-3 lower alkylene group.<br>
Still further, in a preferred compound, Ze, a<br>
preferred substituent of R2, is an unsubstituted or<br>
substituted lower alkylene group. In a more preferred<br>
compound, Ze, a preferred substituent of R2, is a lower<br>
alkylene group. In a further more preferred compound,<br>
Ze, a preferred substituent of R2, is a C2-4 lower<br>
alkylene group.<br>
Still further, in a preferred compound, R8e, a<br>
preferred substituent of R2, is an unprotected or<br>
protected amidino group. In a more preferred compound,<br>
R8e, a preferred substituent of R2, is an amidino group.<br>
Still further, in a preferred compound, R8g, a<br><br>
preferred substituent of R2, is an unprotected or<br>
protected amidino group. In a more preferred compound,<br>
R8g, a preferred substituent of R2, is an amidino group.<br>
Still further, in a preferred compound, Y9, a<br>
preferred substituent of R2, is an unsubstituted or<br>
substituted C2-6 lower alkylene group. In a more<br>
preferred compound, Y9, a preferred substituent of R2,<br>
is a C2-6 lower alkylene group. In a further more<br>
preferred compound, Y9, a preferred substituent of R2,<br>
is a C2-3 lower alkylene group.<br>
Still further, in a preferred compound, Yh, a<br>
preferred substituent of R2, is a C2-4 lower alkylene<br>
group. In a more preferred compound, Yh, a preferred<br>
substituent of R2, is a C2-3 lower alkylene group.<br>
Still further, in a preferred compound, Yh', a<br>
preferred substituent of R2, is a C2-4 lower alkylene<br>
group. In a more preferred compound, Yh', a preferred<br>
substituent of R2, is a C2-3 lower alkylene group.<br>
Still further, in a preferred compound, Z9, a<br>
preferred substituent of R2, is an unsubstituted or<br>
substituted lower alkylene group. In a more preferred<br>
compound, Z9, a preferred substituent of R2, is a lower<br>
alkylene group. In a further more preferred compound,<br>
Zg, a preferred substituent of R2, is a C2-4 lower<br>
alkylene group.<br>
Still further, in a preferred compound, Zh, a<br>
preferred substituent of R2, is an unsubstituted or<br>
substituted lower alkylene group. In a more preferred<br><br>
compound, Zn, a preferred substituent of R2, is a lower<br>
alkylene group. In a further more preferred compound,<br>
Zh, a preferred substituent of R2, is a C2-4 lower<br>
alkylene group.<br>
Still further, in a preferred compound, R8h, a<br>
preferred substituent of R2, is an unprotected or<br>
protected amidino group. In a more preferred compound,<br>
R8h, a preferred substituent of R2, is an amidino group.<br>
In the present invention, examples of a<br>
preferred amino protecting group may include an acyl<br>
group, an alkyloxycarbonyl group, an aryloxycarbonyl<br>
group, an aralkyloxycarbonyl group, an aralkyl group,<br>
an alkoxyalkyl group, an arylthio group, an<br>
alkylsulfonyl group, an arylsulfonyl group, a<br>
dialkylaminoalkylidene group, an aralkylidene group, a<br>
nitrogen-containing heterocyclic aralkylidene group, a<br>
cycloalkylidene group, an oxygen-containing<br>
heterocyclic alkyl group, and a substituted silyl<br>
group. Examples of a more preferred amino protecting<br>
group may include an acyl group, an alkyloxycarbonyl<br>
group, an aryloxycarbonyl group, an aralkyloxycarbonyl<br>
group, an aralkyl group, and an alkoxyalkyl group.<br>
In the present invention, examples of a<br>
preferred amidino protecting group may include an acyl<br>
group, an alkyloxycarbonyl group, an aryloxycarbonyl<br>
group, an aralkyloxycarbonyl group, aralkyl group, an<br>
alkoxyalkyl group, an arylthio group, an alkylsulfonyl<br>
group, an arylsulfonyl group, an oxygen-containing<br><br>
heterocyclic alkyl group, and a substituted silyl<br>
group. Examples of a more preferred example may<br>
include an acyl group, an aralkyl group, and an<br>
alkoxyalkyl group.<br>
Compounds shown in Tables 1 to 13 below are<br>
representative compounds of the present invention. In<br>
the tables, Me represents methyl; Et represents ethyl;<br>
Pr represents propyl; Bu represents butyl; Bn<br>
represents benzyl; c-Pr represents cyclopropyl; Cbz<br>
represents benzyloxycarbonyl; Ac represents acetyl; Ph<br>
represents phenyl; Boc represents tert-butoxycarbonyl;<br>
and Phe represents a phenylalanine residue.<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
[Table 13]<br><br>
When an isomer (e.g., optical isomer,<br>
geometric isomer, tautomer, etc.) exists in the<br>
compound represented by general formula [1] or a salt<br>
thereof, these isomers are included in the present<br>
invention. In addition, a solvate, a hydrate, and<br>
various forms of crystals are also included in the<br>
present invention.<br>
Next, a method for producing the compound of<br>
the present invention will be described.<br>
The compound of the present invention is<br>
produced by combined use of known methods. For<br>
example, it can be produced by the following schemes.<br>
[Scheme 1]<br>
A compound represented by general formula<br>
[1a] can be produced, for example, by the following<br><br><br>
wherein R3a represents a hydrogen atom, R3b represents<br>
the same substituent as for R3, except for a hydrogen<br>
atom; R9 represents a cyano group or an amide group; L<br>
represents a leaving group; each of X, R1, R3, R4, Ra,<br>
G1, and G2 has the same meaning as described above.<br>
The compounds represented by general formulas<br>
[2] and [3] can be produced by a method described in<br>
International Publication WO96/16947, or methods<br>
equivalent thereto.<br>
(1-a)<br>
The compounds represented by general formulas<br>
[1a] and [1aa] can be produced by reacting the compound<br><br>
represented by general formula [2] with the compounds<br>
represented by general formulas [4] and [4a],<br>
respectively, in the presence or absence of a base.<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, isopropanol, or tert-<br>
butanol; amides such as N,N-dimethylformamide, N,N-<br>
dimethylacetamide, or 1-methyl-2-pyrrolidone;<br>
halogenated hydrocarbons such as methylene chloride,<br>
chloroform, or dichloroethane; aromatic hydrocarbons<br>
such as benzene, toluene, or xylene; ethers such as<br>
dioxane, tetrahydrofuran, anisole, diethylene glycol<br>
diethyl ether, or ethylene glycol monomethyl ether;<br>
nitriles such as acetonitrile; and sulfoxides such as<br>
dimethyl sulfoxide. These solvents may be used in<br>
combination.<br>
Examples of a base that is used in this<br>
reaction as desired may include: metal alkoxides such<br>
as sodium methoxide, sodium ethoxide, potassium tert-<br>
butoxide, or sodium tert-butoxide; inorganic bases such<br>
as sodium hydroxide, potassium hydroxide, sodium<br>
bicarbonate, sodium carbonate, potassium carbonate,<br>
sodium hydride, or potassium hydride; and organic bases<br>
such as triethylamine or pyridine. Such a base may be<br>
used with respect to the compound represented by<br>
general formula [2] at a molar ratio of 1 : 1 or<br>
greater, and preferably at a molar ratio of 1 : 1 to<br><br>
3:1.<br>
In this reaction, the compounds represented<br>
by general formulas [4] and [4a] may be used with<br>
respect to the compound represented by general formula<br>
[2] at a molar ratio of 1 : 1 or greater, and<br>
preferably at a molar ratio of 1 : 1 to 5 : 1.<br>
This reaction may be carried out at 0Â°C to<br>
200Â°C, preferably at 0Â°C to 150Â°C, for 1 minute to 24<br>
hours.<br>
(1-b)<br>
The compound represented by general formula<br>
[1a] can be produced by reacting the compound<br>
represented by general formula [1aa] with the compound<br>
represented by general formula [4b] in the presence or<br>
absence of a base.<br>
This reaction may be carried out in the same<br>
manner as the reaction described in the scheme 1-a.<br>
In this reaction, the compound represented by<br>
general formula [4b] may be used with respect to the<br>
compound represented by general formula [1aa] at a<br>
molar ratio of 1 : 1 or greater, and preferably at a<br>
molar ratio of 1 : 1 to 5 : 1.<br>
This reaction may be carried out at 0Â°C to<br>
200Â°C, preferably at 0Â°C to 150Â°C, for 1 minute to 24<br>
hours.<br>
(1-c)<br>
Each of the compounds represented by general<br>
formulas [5] and [5a] can be produced by reacting the<br><br>
compound represented by general formula [3] with each<br>
of the compounds represented by general formulas [4],<br>
[4a] and [4b] according to the schemes 1-a and 1-b.<br>
(1-d)<br>
The compounds [1a] and [1aa] can be produced<br>
by amidinating the compounds [5] and [5a],<br>
respectively.<br>
When R9 is a cyano group, amidination may be<br>
carried out according to the methods described in<br>
International Publication WO96/16947; the Journal of<br>
Medicinal Chemistry (J. Med. Chem.), vol. 36, pp. 1811<br>
to 1819, 1993; the Journal of Organic Chemistry (J.<br>
Org. Chem.), vol. 64, pp. 12 to 13, 1999; and the<br>
Journal of American Chemical Society (J. Am. Chem.<br>
Soc), vol. 107, pp. 2,743 to 2,748, 1985, or methods<br>
equivalent thereto.<br>
Otherwise, when amidination is carried out by<br>
way of amidoxime or an analog thereof, the reaction may<br>
be carried out according to the methods described in<br>
Tetrahedron, vol. 51, pp. 12,047 to 12,068, 1995;<br>
Synthetic Communication, vol. 26, pp. 4,351 to 4,367,<br>
1996; the Journal of Medicinal Chemistry (J. Med.<br>
Chem.), vol. 43, pp. 4,063 to 4,070, 2000; the same<br>
publication, vol. 44, pp. 1,217 to 1,230, 2001; and the<br>
Chemical and Pharmaceutical Bulletin (Chem. Pharm.<br>
Bull.), vol. 49, pp. 268 to 277, 2001, or methods<br>
equivalent thereto.<br>
More specifically, the reaction may be<br><br>
carried out by the method described as "scheme 2."<br>
When R9 is an amide group, amidination may be<br>
carried out according to the methods described in the<br>
Journal of Organic Chemistry (J. Org. Chem.), vol. 33,<br>
pp. 1,679 to 1,681, 1968, or methods equivalent<br>
thereto.<br>
(1-e)<br>
A compound from which an amino protecting<br>
group is eliminated can be produced, as appropriate,<br>
from the compounds represented by general formulas<br>
[1aa] and [5a] wherein, in the compounds represented by<br>
general formulas [1a] and [5], both R3 and R4 are amino<br>
protecting groups, or either one of R3 and R4 is an<br>
amino protecting group.<br>
[Scheme 2]<br>
A compound represented by general formula<br>
[la] can be produced, for example, by the following<br>
scheme:<br><br><br>
wherein each of X, Ra, R1, R3, R4, G1, G2, and L has the<br>
same meaning as described above; each of R10 and R11<br>
represents an alkyl group; L2 represents a halogen atom<br>
or an acyloxy group; and R13 represents a hydrogen atom,<br>
or an unsubstituted or substituted acyl group.<br>
(2-a)<br>
The compound represented by general formula<br><br>
[6] can be produced by reacting the compound<br>
represented by general formula [5a] with the compound<br>
represented by general formula [7] in the presence of<br>
acid.<br>
As a solvent used in this reaction, the<br>
compound represented by general formula [7] may be used<br>
as the solvent, or any other solvents may be used as<br>
long as they do not affect the reaction. Examples of a<br>
solvent may include: ethers such as dioxane,<br>
tetrahydrofuran, anisole, or diethylene glycol diethyl<br>
ether; ketones such as acetone or 2-butanone; and<br>
halogenated hydrocarbons such as methylene chloride,<br>
chloroform, or 1,2-dichloroethane. These solvents may<br>
be used in combination.<br>
Examples of acid used in this reaction may<br>
include hydrogen chloride, hydrobromic acid, perchloric<br>
acid, p-toluenesulfonic acid, and methanesulfonic acid.<br>
Such acid may be used with respect to the compound<br>
represented by general formula [5a] at a molar ratio of<br>
1 : 1 to 200 : 1, and preferably at a molar ratio of<br>
5 : 1 to 100 : 1.<br>
In this reaction, the compound represented by<br>
general formula [7] may be used with respect to the<br>
compound represented by general formula [5a] at a molar<br>
ratio of 1 : 1 to 1,000 : 1, and preferably at a molar<br>
ratio of 10 : 1 to 100 : 1.<br>
This reaction may be carried out at -30Â°C to<br>
150Â°C, and preferably at 10Â°C to 50Â°C, for 30 minutes to<br><br>
24 hours.<br>
The compound represented by general formula<br>
[la] can be produced by reacting the compound<br>
represented by general formula [6] with ammonia, the<br>
compound represented by general formula [8], or an<br>
amine compound or a salt thereof, in the presence or<br>
absence of a base.<br>
Any solvent may be used in this reaction, as<br>
long as it does not affect the reaction. Examples of a<br>
solvent may include: alcohols such as methanol,<br>
ethanol, isopropanol, or tert-butanol; ethers such as<br>
dioxane, tetrahydrofuran, anisole, diethylene glycol<br>
diethyl ether, or ethylene glycol monomethyl ether;<br>
amides such as N,N-dimethylformamide or N,N-<br>
dimethylacetamide; and sulfoxides such as dimethyl<br>
sulfoxide. These solvents may also be used in<br>
combination.<br>
Examples of the compound represented by<br>
general formula [8] may include ammonium salts such as<br>
ammonium chloride, ammonium bromide, or ammonium<br>
acetate.<br>
Examples of an amine compound may include<br>
aliphatic amines such as methylamine, ethylamine,<br>
allylamine, or methoxyamine; and hydroxylamine. Such<br>
an amine compound may be used with respect to the<br>
compound represented by general formula [6] or a salt<br>
thereof at a molar ratio of 1 : 1 to 100 : 1, and<br>
preferably 1 : 1 to 10 : 1.<br><br>
This reaction may be carried out usually at<br>
0Â°C to 150Â°C, and preferably at 20Â°C to 120Â°C, for 1<br>
minute to 2 4 hours.<br>
(2-b)<br>
The compound represented by general formula<br>
[9] can be produced by reacting the compound<br>
represented by general formula [5a] with hydrogen<br>
sulfide in the presence of a base.<br>
Examples of a base used in this reaction may<br>
include ammonia, pyridine, triethylamine, and<br>
diisopropylethylamine.<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, isopropanol, or tert-<br>
butanol; ethers such as tetrahydrofuran or dioxane;<br>
ketones such as acetone or 2-butanone; and<br>
heteroaromatics such as pyridine. These solvents may<br>
be used in combination.<br>
Hydrogen sulfide and a base may be used with<br>
respect to the compound represented by general formula<br>
[5a] at a molar ratio of 1 : 1 to 500 : 1 and 1 : 1 to<br>
100 : 1, respectively.<br>
This reaction may be carried out usually at<br>
0Â°C to 150Â°C, and preferably at 10Â°C to 100Â°C, for 1<br>
minute to 24 hours.<br>
The compound represented by general formula<br>
[10] can be produced by reacting the compound<br><br>
represented by general formula [9] with the compound<br>
represented by general formula [11].<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, isopropanol, or tert-<br>
butanol; ethers such as dioxane, tetrahydrofuran,<br>
anisole, diethylene glycol diethyl ether, or ethylene<br>
glycol monomethyl ether; sulfoxides such as dimethyl<br>
sulfoxide; amides such as N,N-dimethylformamide or N,N-<br>
dimethylacetamide; ketones such as acetone or 2-<br>
butanone; and esters such as ethyl acetate. These<br>
solvents may be used in combination.<br>
The compound represented by general formula<br>
[11] may be used with respect to the compound<br>
represented by general formula [9] at a molar ratio of<br>
1 : 1 to 100 : 1, and preferably at a molar ratio of<br>
1 : 1 to 10 : 1.<br>
This reaction may be carried out usually at<br>
-10Â°C to 150Â°C, and preferably at 20Â°C to 120Â°C, for 1<br>
minute to 24 hours.<br>
The compound represented by general formula<br>
[la] can be produced by reacting the compound<br>
represented by general formula [10] with ammonia, the<br>
compound represented by general formula [8], or an<br>
amine compound or a salt thereof, in the presence or<br>
absence of a base.<br>
A solvent used in this reaction is not<br><br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, isopropanol, or tert-<br>
butanol; ethers such as dioxane, tetrahydrofuran,<br>
anisole, diethylene glycol diethyl ether, or ethylene<br>
glycol monomethyl ether; amides such as N,N-<br>
dimethylformamide or N,N-dimethylacetamide; and<br>
sulfoxides such as dimethyl sulfoxide. These solvents<br>
may be used in combination.<br>
As in the case described above, examples of<br>
the compound represented by general formula [8] may<br>
include ammonium salts such as ammonium chloride,<br>
ammonium bromide, or ammonium acetate. Examples of an<br>
amine compound may include aliphatic amines such as<br>
methylamine, ethylamine, allylamine, or methoxyamine;<br>
and hydroxylamine. Such an amine compound may be used<br>
with respect to the compound represented by general<br>
formula [10] at a molar ratio of 1 : 1 to 100 : 1, and<br>
preferably 1 : 1 to 10 : 1.<br>
This reaction may be carried out usually at<br>
0Â°C to 150Â°C, and preferably at 20Â°C to 120Â°C, for 1<br>
minute to 24 hours.<br>
(2-c)<br>
The compound represented by general formula<br>
[50] can be produced by reacting the compound<br>
represented by general formula [5a] with hydroxylamine<br>
or a salt thereof in the presence or absence of a base.<br>
Any solvent may be used in this reaction, as<br><br>
long as it does not affect the reaction. Examples of a<br>
solvent may include: alcohols such as methanol,<br>
ethanol, isopropanol, or tert-butanol; ethers such as<br>
dioxane, tetrahydrofuran, anisole, diethylene glycol<br>
diethyl ether, or ethylene glycol monomethyl ether;<br>
amides such as N,N-dimethylformamide or N,N-<br>
dimethylacetamide; sulfoxides such as dimethyl<br>
sulfoxide; and heteroaromatics such as pyridine. These<br>
solvents may also be used in combination.<br>
Examples of a base that is used in this<br>
reaction as desired may include: metal alkoxides such<br>
as sodium methoxide, sodium ethoxide, potassium tert-<br>
butoxide, or sodium tert-butoxide; inorganic bases such<br>
as sodium hydroxide, potassium hydroxide, sodium<br>
bicarbonate, sodium carbonate, potassium carbonate,<br>
sodium hydride, or potassium hydride; and organic bases<br>
such as triethylamine or pyridine.<br>
Hydroxylamine or a salt thereof may be used<br>
with respect to the compound represented by general<br>
formula [5a] at a molar ratio of 1 : 1 or greater, and<br>
preferably at a molar ratio of 1 : 1 to 3 : 1.<br>
This reaction may be carried out at 0Â°C to<br>
150Â°C, and preferably at 50Â°C to 150Â°C, for 1 minute to<br>
24 hours.<br>
The compound represented by general formula<br>
[52] can be produced by reacting the compound<br>
represented by general formula [50] with an acid<br>
anhydride or acid halide in the presence or absence of<br><br>
a base.<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: amides<br>
such as N,N-dimethylformamide, N,N-dimethylacetamide,<br>
or 1-methyl-2-pyrrolidone; halogenated hydrocarbons<br>
such as methylene chloride, chloroform, or<br>
dichloroethane; aromatic hydrocarbons such as benzene,<br>
toluene, or xylene; ethers such as dioxane,<br>
tetrahydrofuran, anisole, diethylene glycol diethyl<br>
ether, or ethylene glycol monomethyl ether; esters such<br>
as ethyl acetate; carboxylic acids such as acetic acid;<br>
ketones such as acetone or 2-butanone; and nitriles<br>
such as acetonitrile. These solvents may be used in<br>
combination.<br>
Examples of an acid anhydride may include<br>
formic acetic anhydride, acetic anhydride,<br>
trichloroacetic anhydride, and trifluoroacetic<br>
anhydride. Such an acid anhydride may be used with<br>
respect to the compound represented by general formula<br>
[50] at a molar ratio of 1 : 1 or greater, and<br>
preferably at a molar ratio of 1 : 1 to 5 : 1.<br>
Examples of an acid halide may include acetyl<br>
chloride, trichloroacetyl chloride, and trifluoroacetyl<br>
chloride.<br>
Examples of a base that is used in this<br>
reaction as desired may include sodium methoxide,<br>
sodium ethoxide, potassium tert-butoxide, sodium tert-<br><br>
butoxide, sodium hydroxide, potassium hydroxide, sodium<br>
bicarbonate, sodium carbonate, potassium carbonate,<br>
sodium hydride, potassium hydride, triethylamine, and<br>
pyridine.<br>
Each of such an acid anhydride, an acid<br>
halide, and a base may be used with respect to the<br>
compound represented by general formula [50] at a molar<br>
ratio of 1 : 1 or greater, and preferably at a molar<br>
ratio of 1 : 1 to 3 : 1.<br>
This reaction may be carried out at -20Â°C to<br>
100Â°C, and preferably at 0Â°C to 50Â°C, for 1 minute to 24<br>
hours.<br>
The compound represented by general formula<br>
[1a] can be produced by subjecting the compounds<br>
represented by general formulas [50] and [52] to a<br>
reduction reaction.<br>
Examples of a reduction reaction used herein<br>
may include catalytic hydrogenation, reduction with<br>
metal or metal salts, reduction with a metal hydrogen<br>
compound, reduction with a metal hydrogen complex<br>
compound, and reduction with hydrazine.<br>
More specifically, when the compound<br>
represented by general formula [52] is subject to<br>
catalytic hydrogenation using a metal catalyst, a<br>
solvent used herein is not particularly limited, as<br>
long as it does not affect the reaction. Examples of a<br>
solvent may include: alcohols such as methanol,<br>
ethanol, isopropanol, or tert-butanol; amides such as<br><br>
N,N-dimethylformamide, N,N-dimethylacetamide, or 1-<br>
methyl-2-pyrrolidone; halogenated hydrocarbons such as<br>
methylene chloride, chloroform, or dichloroethane;<br>
aromatic hydrocarbons such as benzene, toluene, or<br>
xylene; ethers such as dioxane, tetrahydrofuran,<br>
anisole, diethylene glycol diethyl ether, or ethylene<br>
glycol monomethyl ether; esters such as ethyl acetate;<br>
carboxylic acids such as acetic acid; mineral acids<br>
such as hydrochloric acid; and nitriles such as<br>
acetonitrile. These solvents may be used in<br>
combination.<br>
Examples of a metal catalyst may include<br>
palladium oxide, platinum oxide, and palladium-carbon.<br>
A metal catalyst may be used with respect to the<br>
compounds represented by general formulas [50] and [52]<br>
at a weight ratio (W/W) of 0.001 : 1 to 1 : 1, and<br>
preferably at a weight ratio (W/W) of 0.01 : 1 to 0.5 :<br>
1.<br>
Examples of a reducing agent may include<br>
zinc, formic acid, hydrazine, as well as hydrogen. The<br>
reducing agent may be used with respect to the<br>
compounds represented by general formulas [50] and [52]<br>
at a molar ratio of 1 : 1 to 100 : 1, and preferably<br>
1 : 1 to 10 : 1.<br>
This reaction may be carried out at 0Â°C to<br>
200Â°C, and preferably at 0Â°C to 100Â°C, for 1 minute to<br>
24 hours.<br><br>
[Scheme 3]<br>
A compound represented by general formula<br>
[1ab] can be produced, for example, by the following<br>
scheme:<br><br>
wherein each of X, Ra, R1, R9, G1, G2, and L has the same<br>
meaning as described above.<br>
(3-a)<br>
The compound represented by general formula<br>
[13] can be produced by reacting the compound<br>
represented by general formula [2] with the compound<br>
represented by general formula [12].<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, isopropanol, or tert-<br><br>
butanol; amides such as N,N-dimethylformamide, N,N-<br>
dimethylacetamide, or 1-methyl-2-pyrrolidone;<br>
halogenated hydrocarbons such as methylene chloride,<br>
chloroform, or dichloroethane; aromatic hydrocarbons<br>
such as benzene, toluene, or xylene; ethers such as<br>
dioxane, tetrahydrofuran, anisole, diethylene glycol<br>
diethyl ether, or ethylene glycol monomethyl ether;<br>
nitriles such as acetonitrile; ketones such as acetone<br>
or 2-butanone; and sulfoxides such as dimethyl<br>
sulfoxide. These solvents may be used in combination.<br>
Examples of the compound represented by<br>
general formula [12] used in this reaction may include<br>
sodium azide, lithium azide, barium azide, cesium<br>
azide, and trimethylsilyl azide. The compound<br>
represented by general formula [12] may be used with<br>
respect to the compound represented by general formula<br>
[2] at a molar ratio of 1 : 1 or greater, and<br>
preferably at a molar ratio of 1 : 1 to 5 : 1.<br>
This reaction may be carried out at 0Â°C to<br>
200Â°C, and preferably at 0Â°C to 150Â°C, for 1 minute to<br>
24 hours.<br>
The compound represented by general formula<br>
[13] can also be produced by amidinating the compound<br>
represented by general formula [14] according to the<br>
scheme 1-b or scheme 2.<br>
(3-b)<br>
The compound represented by general formula<br>
[1ab] can be produced by subjecting the compound<br><br>
represented by general formula [13] to known reduction<br>
reactions listed below.<br>
Examples of a reduction reaction may include<br>
(1) catalytic hydrogenation using a metal catalyst, (2)<br>
a reaction with triphenylphosphine, and the subsequent<br>
hydrolysis reaction (Tetrahedron Letters, vol. 24, pp.<br>
763 to 764, 1983, etc.), (3) a reaction with sodium<br>
borohydride (Synthesis, pp. 48 to 49, 1987, etc.), and<br>
(4) a reaction with inorganic and organic mercaptans<br>
(the Journal of Organic Chemistry (J. Org. Chem.), vol.<br>
44, pp. 4,712 to 4,713, 1979 etc.).<br>
More specifically, when catalytic<br>
hydrogenation using a metal catalyst is applied, a<br>
solvent used in the reaction is not particularly<br>
limited as long as it does not affect the reaction.<br>
Examples of a solvent may include: alcohols such as<br>
methanol, ethanol, isopropanol, or tert-butanol; amides<br>
such as N,N-dimethylformamide, N,N-dimethylacetamide,<br>
or 1-methyl-2-pyrrolidone; halogenated hydrocarbons<br>
such as methylene chloride, chloroform, or<br>
dichloroethane; aromatic hydrocarbons such as benzene,<br>
toluene, or xylene; ethers such as dioxane,<br>
tetrahydrofuran, anisole, diethylene glycol diethyl<br>
ether, or ethylene glycol monomethyl ether; ketones<br>
such as acetone or 2-butanone; and nitriles such as<br>
acetonitrile. These solvents may be used in<br>
combination.<br>
Examples of a metal catalyst may include<br><br>
palladium oxide, platinum oxide, and palladium-carbon.<br>
A metal catalyst may be used with respect to the<br>
compound represented by general formula [13] at a<br>
weight ratio (W/W) of 0.001 : 1 to 1 : 1, and<br>
preferably at a weight ratio (W/W) of 0.01 : 1 to 0.5 :<br>
1.<br>
Examples of a reducing agent may include<br>
hydrogen and formic acid. A reducing agent may be used<br>
with respect to the compound represented by general<br>
formula [13] at a molar ratio of 1 : 1 to 100 : 1, and<br>
preferably 1 : 1 to 10 : 1.<br>
This reaction may be carried out at 0Â°C to<br>
200Â°C, and preferably at 0Â°C to 100Â°C, for 1 minute to<br>
24 hours.<br>
(3-c)<br>
The compound represented by general formula<br>
[14] can be produced by reacting the compound<br>
represented by general formula [3] with the compound<br>
represented by general formula [12] according to the<br>
scheme 3-a.<br>
(3-d)<br>
The compound represented by general formula<br>
[lab] can be produced by amidinating the compound<br>
represented by general formula [14] according to the<br>
scheme 1-b or scheme 2, and then subjecting the<br>
resultant product to a reduction reaction according to<br>
the scheme 3-b.<br>
The compound represented by general formula<br><br>
[1ab] is reacted, for example, with R3a-L (wherein R3a<br>
represents a group for R3, other than a hydrogen atom;<br>
and L represents a leaving group), so as to produce<br>
another compound represented by general formula [1a].<br>
Moreover, the compound represented by general formula<br>
[14] is reduced, and then the resultant product is<br>
reacted, for example, with R3a-L (wherein R3a represents<br>
a group for R3, other than a hydrogen atom; and L<br>
represents a leaving group), followed by amidination,<br>
so as to produce a compound of interest of the<br>
invention of the present application.<br>
[Scheme 4]<br>
A compound represented by general formula<br>
[1b] can be produced, for example, by the following<br>
scheme:<br><br><br>
wherein each of X, Y, Ra, R1, L, R7, R9, G1, and G2 has<br>
the same meaning as described above.<br>
(4-a)<br>
The compound represented by general formula<br>
[16] can be produced by reacting the compound<br>
represented by general formula [2] with the compound<br>
represented by general formula [15] in the presence or<br>
absence of a base.<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br><br>
such as methanol, ethanol, isopropanol, or tert-<br>
butanol; amides such as N,N-dimethylformamide, N,N-<br>
dimethylacetamide, or 1-methyl-2-pyrrolidone;<br>
halogenated hydrocarbons such as methylene chloride,<br>
chloroform, or dichloroethane; aromatic hydrocarbons<br>
such as benzene, toluene, or xylene; ethers such as<br>
dioxane, tetrahydrofuran, anisole, diethylene glycol<br>
diethyl ether, or ethylene glycol monomethyl ether;<br>
nitriles such as acetonitrile; ketones such as acetone<br>
or 2-butanone; and sulfoxides such as dimethyl<br>
sulfoxide. These solvents may be used in combination.<br>
Examples of a base that is used in this<br>
reaction as desired may include: metal alkoxides such<br>
as sodium methoxide, sodium ethoxide, potassium tert-<br>
butoxide, or sodium tert-butoxide; inorganic bases such<br>
as sodium hydroxide, potassium hydroxide, sodium<br>
bicarbonate, sodium carbonate, potassium carbonate,<br>
sodium hydride, or potassium hydride; and organic bases<br>
such as triethylamine or pyridine. Such a base may be<br>
used with respect to the compound represented by<br>
general formula [2] at a molar ratio of 1 : 1 or<br>
greater, and preferably at a molar ratio of 1 : 1 to<br>
3:1.<br>
In this reaction, the compound represented by<br>
general formula [15] may be used with respect to the<br>
compound represented by general formula [2] at a molar<br>
ratio of 1 : 1 or greater, and preferably at a molar<br>
ratio of 1 : 1 to 5 : 1.<br><br>
This reaction may be carried out at 0Â°C to<br>
200Â°C, and preferably at 0Â°C to 150Â°C, for 1 minute to<br>
24 hours.<br>
In addition, the compound represented by<br>
general formula [16] can also be produced by<br>
amidinating the compound represented by general formula<br>
[17] according to the scheme 1-b or scheme 2.<br>
(4-b)<br>
The compound represented by general formula<br>
[1b] can be produced by hydrolysis of the compound<br>
represented by general formula [16] using acid or a<br>
base.<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, isopropanol, or tert-<br>
butanol; ethers such as tetrahydrofuran, ethyl ether,<br>
dioxane, or anisole; dimethyl sulfoxide; ketones such<br>
as acetone or 2-butanone; and sulfoxides such as water.<br>
These solvents may be used in combination.<br>
Examples of acid used in this reaction may<br>
include mineral acids such as hydrochloric acid,<br>
hydrobromic acid, or sulfuric acid. Such acid may be<br>
used with respect to the compound represented by<br>
general formula [16] at a molar ratio of 1 : 1 to<br>
1,000 : 1, and preferably at a molar ratio of 1 : 1 to<br>
100 : 1.<br>
Examples of a base used in this reaction may<br><br>
include hydroxides of alkaline metals or alkaline-earth<br>
metals, such as sodium hydroxide, potassium hydroxide,<br>
or barium hydroxide. Such a base may be used with<br>
respect to the compound represented by general formula<br>
[16] at a molar ratio of 1 : 1 to 1,000 : 1, and<br>
preferably at a molar ratio of 1 : 1 to 10 : 1.<br>
This reaction may be carried out at 0Â°C to<br>
150Â°C, and preferably at 0Â°C to 100Â°C, for 10 minutes to<br>
24 hours.<br>
(4-c)<br>
The compound represented by general formula<br>
[17] can be produced by reacting the compound<br>
represented by general formula [3] with the compound<br>
represented by general formula [15] in the presence or<br>
absence of a base according to the scheme 4-a.<br>
(4-d)<br>
Moreover, the compound represented by general<br>
formula [1b] can be produced by amidinating the<br>
compound represented by general formula [17] according<br>
to the scheme 1-b or scheme 2, and then subjecting the<br>
resultant product to a hydrolysis reaction according to<br>
the scheme 4-b.<br>
[Scheme 5]<br>
A compound represented by general formula<br>
[1b] can be produced, for example, by the following<br>
scheme:<br><br><br>
wherein R7c represents any one of the same substituents<br>
as R7, except for a hydrogen atom; each of X, Y, Ra, R1,<br>
R7, L, R9, G1, and G2 has the same meaning as described<br>
above; and R represents an amino protecting group.<br>
The compound represented by general formula<br>
[18] can be produced according to the method described<br>
in Yakugaku Zasshi (Journal of the Pharmaceutical<br>
Society of Japan, vol. 99, pp. 929 to 935, 1979) etc.,<br>
or methods equivalent thereto.<br><br>
Each of the compounds represented by general<br>
formulas [19] and [20] can be produced by reacting each<br>
of the compounds represented by general formulas [2]<br>
and [3] with the compound represented by general<br>
formula [18], and then deprotecting an amino protecting<br>
group according to, for example, the method described<br>
in International Publication WO96/16947, or methods<br>
equivalent thereto.<br>
In addition, the compound represented by<br>
general formula [19] can also be produced by<br>
amidinating the compound represented by general formula<br>
[20] according to the scheme 1-b or scheme 2.<br>
(5-a)<br>
The compound represented by general formula<br>
[16] can be produced by reacting the compound<br>
represented by general formula [19] with the compound<br>
represented by general formula [21] in the presence or<br>
absence of a base.<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, isopropanol, or tert-<br>
butanol; amides such as N, N-dimethylforrnamide, N,N-<br>
dimethylacetamide, or 1-methyl-2-pyrrolidone;<br>
halogenated hydrocarbons such as methylene chloride,<br>
chloroform, or dichloroethane; aromatic hydrocarbons<br>
such as benzene, toluene, or xylene; ethers such as<br>
dioxane, tetrahydrofuran, anisole, diethylene glycol<br><br>
diethyl ether, or ethylene glycol monomethyl ether;<br>
nitriles such as acetonitrile; ketones such as acetone<br>
or 2-butanone; and sulfoxides such as dimethyl<br>
sulfoxide. These solvents may be used in combination.<br>
Examples of a base that is used in this<br>
reaction as desired may include: metal alkoxides such<br>
as sodium methoxide, sodium ethoxide, potassium tert-<br>
butoxide, or sodium tert-butoxide; inorganic bases such<br>
as sodium hydroxide, potassium hydroxide, sodium<br>
bicarbonate, sodium carbonate, potassium carbonate,<br>
sodium hydride, or potassium hydride; and organic bases<br>
such as triethylamine or pyridine. Such a base may be<br>
used with respect to the compound represented by<br>
general formula [19] at a molar ratio of 1 : 1 or<br>
greater, and preferably at a molar ratio of 1 : 1 to<br>
3 : 1.<br>
In this reaction, the compound represented by<br>
general formula [21] may be used with respect to the<br>
compound represented by general formula [19] at a molar<br>
ratio of 1 : 1 or greater, and preferably at a molar<br>
ratio of 1 : 1 to 5 : 1.<br>
This reaction may be carried out at 0Â°C to<br>
200Â°C, and preferably at 0Â°C to 150Â°C, for 1 minute to<br>
24 hours.<br>
The compound represented by general formula<br>
[16] can also be produced by amidinating the compound<br>
represented by general formula [17] according to the<br>
scheme 1-b or scheme 2.<br><br>
(5-b)<br>
The compound represented by general formula<br>
[1b] can be produced by hydrolysis of the compound<br>
represented by general formula [16] or compound<br>
represented by general formula [19] according to the<br>
scheme 4-b.<br>
Moreover, the compound represented by general<br>
formula [1b] can be produced by amidinating the<br>
compound represented by general formula [17] according<br>
to the scheme 1-b or scheme 2, and then subjecting the<br>
resultant product to a hydrolysis reaction according to<br>
the scheme 4-b.<br>
(5-c)<br>
The compound represented by general formula<br>
[17] can be produced by reacting the compound<br>
represented by general formula [20] with the compound<br>
represented by general formula [21] in the presence or<br>
absence of a base according to the scheme 5-a.<br>
[Scheme 6]<br>
A compound represented by general formula<br>
[1c] can be produced, for example, by the following<br>
scheme:<br><br><br>
wherein R12 represents a cyano group, amide group, or<br>
unprotected or protected or unsubstituted or<br>
substituted amidino group, which binds with the binding<br>
site of G3 at its para or meta position; and each of X,<br>
Y, Z, Ra, Rb, R1, R8, R9, L, G1, G2, G3, and G5 has the<br>
same meaning as described above.<br>
(6-a)<br>
The compound represented by general formula<br>
[22] can be produced by reacting the compound<br>
represented by general formula [19] with the compound<br>
represented by general formula [2a], or by reacting the<br>
compound represented by general formula [2] with the<br><br>
compound represented by general formula [15a], in the<br>
presence or absence of a base.<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, isopropanol, or tert-<br>
butanol; amides such as N,N-dimethylformamide, N,N-<br>
dimethylacetamide, or 1-methyl-2-pyrrolidone;<br>
halogenated hydrocarbons such as methylene chloride,<br>
chloroform, or dichloroethane; aromatic hydrocarbons<br>
such as benzene, toluene, or xylene; ethers such as<br>
dioxane, tetrahydrofuran, anisole, diethylene glycol<br>
diethyl ether, or ethylene glycol monomethyl ether;<br>
nitriles such as acetonitrile; ketones such as acetone<br>
or 2-butanone; and sulfoxides such as dimethyl<br>
sulfoxide. These solvents may be used in combination.<br>
Examples of a base that is used in this<br>
reaction as desired may include: metal alkoxides such<br>
as sodium methoxide, sodium ethoxide, potassium tert-<br>
butoxide, or sodium tert-butoxide; inorganic bases such<br>
as sodium hydroxide, potassium hydroxide, sodium<br>
bicarbonate, sodium carbonate, potassium carbonate,<br>
sodium hydride, or potassium hydride; and organic bases<br>
such as triethylamine or pyridine. Such a base may be<br>
used with respect to the compound represented by<br>
general formula [19] at a molar ratio of 1 : 1 or<br>
greater, and preferably at a molar ratio of 1 : 1 to<br>
3 : 1.<br><br>
In this reaction, the compound represented by<br>
general formula [2a] may be used with respect to the<br>
compound represented by general formula [19] at a molar<br>
ratio of 1 : 1 or greater, and preferably at a molar<br>
ratio of 1 : 1 to 5 : 1.<br>
Moreover, the compound represented by general<br>
formula [15a] may be used with respect to the compound<br>
represented by general formula [2] at a molar ratio of<br>
0.5 : 1 or greater.<br>
This reaction may be carried out at 0Â°C to<br>
200Â°C, and preferably at 0Â°C to 150Â°C, for 1 minute to<br>
24 hours.<br>
(6-b)<br>
The compound represented by general formula<br>
[22] can also be produced by amidinating the compound<br>
represented by general formula [23] according to the<br>
scheme 1-b or scheme 2.<br>
(6-c)<br>
The compound represented by general formula<br>
[23] can be produced by reacting the compound<br>
represented by general formula [20] with the compound<br>
represented by general formula [3a], or by reacting the<br>
compound represented by general formula [3] with the<br>
compound represented by general formula [15a], in the<br>
presence or absence of a base according to the scheme<br>
6-a.<br>
(6-d)<br>
The compound represented by general formula<br><br>
[1c] can be produced by hydrolysis of the compound<br>
represented by general formula [22] according to the<br>
scheme 4-b.<br>
In addition, the compound represented by<br>
general formula [lc] can be produced by amidinating the<br>
compound represented by general formula [23] according<br>
to the scheme 1-b or scheme 2, and then subjecting the<br>
resultant product to a hydrolysis reaction according to<br>
the scheme 4-b.<br>
[Scheme 7]<br>
A compound represented by general formula<br>
[1d] can be produced, for example, by the following<br>
scheme:<br><br><br>
wherein each of R1, R5, R7, R9, Ra, X, Y, G1, G2, and L<br>
has the same meaning as described above; and Rc<br>
represents a protected aldehyde group; R15 represents a<br>
hydrogen atom or hydroxyl protecting group; Y1<br>
represents an unsubstituted or substituted C1-5 lower<br>
alkylene or C2-5 alkenylene group.<br>
(7-a)<br>
The compound represented by general formula<br>
[24] can be produced by reacting the compound<br><br>
represented by general formula [2] with the compound<br>
represented by general formula [26] according to the<br>
scheme 1-a, and then deprotecting an aldehyde<br>
protecting group.<br>
In addition, the compound represented by<br>
general formula [24] can also be produced by reacting<br>
the compound represented by general formula [2] with<br>
the compound represented by general formula [73]<br>
according to the scheme 1-a, and eliminating R15, as<br>
desired, to obtain a compound represented by general<br>
formula [74], and then subjecting the compound<br>
represented by general formula [74] to an oxidative<br>
reaction.<br>
The oxidative reaction of the compound<br>
represented by general formula [74] may be carried out<br>
according to the method described in, for example,<br>
"Yukikagakujikken no Tebiki [3] -Gosei Hanno [I]-"<br>
("Guide for Organic Chemistry Experiments [3],<br>
Synthetic Reaction [I]", Kagaku Dojin, pp. 1 to 5.)<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: amides<br>
such as N,N-dimethylformamide, N,N-dimethylacetamide,<br>
or 1-methyl-2-pyrrolidone; halogenated hydrocarbons<br>
such as methylene chloride, chloroform, or<br>
dichloroethane; aromatic hydrocarbons such as benzene,<br>
toluene, or xylene; ethers such as dioxane,<br>
tetrahydrofuran, anisole, diethylene glycol diethyl<br><br>
ether, or ethylene glycol monomethyl ether; nitriles<br>
such as acetonitrile; sulfoxides such as dimethyl<br>
sulfoxide; and ketones such as acetone or 2-butanone.<br>
These solvents may be used in combination.<br>
Examples of an oxidizing agent or oxidizing<br>
method used in this reaction may include: chromic acids<br>
such as the Collins reagent (chromium oxide (IV)-<br>
pyridine), pyridinium chlorochromate (PCC), or<br>
pyridinium dichromate (PDC); a method of performing the<br>
reaction by way of alkoxysulfonium salts (DMSO<br>
oxidization); and the Dess-Martin reagent described in<br>
the Journal of Organic Chemistry (J. Org. Chem.), vol.<br>
48, pp. 4,155 to 4,156, 1983.<br>
The use amount of an oxidizing agent is<br>
different depending on the type of the oxidizing agent.<br>
For example, such an oxidizing agent may be used with<br>
respect to the compound represented by general formula<br>
[74] at a molar ratio of 1 : 1 or greater. More<br>
preferably, where the oxidizing agent is chromic acid,<br>
it may be used in an amount much greater than the<br>
compound represented by general formula [74], and where<br>
the oxidizing agent is one other than chromic acids, it<br>
may be used with respect to the above compound at a<br>
molar ratio of 1 : 1 to 5 : 1.<br>
(7-b)<br>
The compound represented by general formula<br>
[28] can be produced by subjecting the compound<br>
represented by general formula [24] and the compound<br><br>
represented by general formula [27] to a dehydration<br>
reaction in the presence or absence of a dehydrating<br>
agent.<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, n-propanol, isopropanol, n-<br>
butanol, isobutanol, tert-butanol, n-hexanol,<br>
cyclopentanol, or cyclohexanol; amides such as N,N-<br>
dimethylformamide, N,N-dimethylacetamide, or 1-methyl-<br>
2-pyrrolidone; halogenated hydrocarbons such as<br>
methylene chloride, chloroform, or dichloroethane;<br>
aromatic hydrocarbons such as benzene, toluene, or<br>
xylene; ethers such as dioxane, tetrahydrofuran,<br>
anisole, diethylene glycol diethyl ether, or ethylene<br>
glycol monomethyl ether; nitriles such as acetonitrile;<br>
and sulfoxides such as dimethyl sulfoxide. These<br>
solvents may be used in combination.<br>
Examples of a dehydrating agent that is used<br>
in this reaction as desired may include anhydrous<br>
magnesium sulfate, sodium sulfate, calcium chloride,<br>
Zeolum, and molecular sieves. Such a dehydrating agent<br>
may be used with respect to the compound represented by<br>
general formula [24] at a weight ratio (W/W) of 1 : 1<br>
to 50 : 1, and preferably at a weight ratio (W/W) of<br>
1 : 1 to 10 : 1.<br>
In this reaction, the compound represented by<br>
general formula [27] may be used with respect to the<br><br>
compound represented by general formula [24] at a molar<br>
ratio of 1 : 1 or greater, and preferably at a molar<br>
ratio of 1 : 1 to 5 : 1.<br>
This reaction may be carried out at 0Â°C to<br>
200Â°C, and preferably at 0Â°C to 150Â°C, for 1 minute to<br>
24 hours.<br>
(7-c)<br>
The compound represented by general formula<br>
[1d] can be produced by subjecting the compound<br>
represented by general formula [28] to a reduction<br>
reaction.<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, n-propanol, isopropanol, n-<br>
butanol, isobutanol, tert-butanol, n-hexanol,<br>
cyclopentanol, or cyclohexanol; amides such as N,N-<br>
dimethylformamide, N,N-dimethylacetamide, or 1-methyl-<br>
2-pyrrolidone; halogenated hydrocarbons such as<br>
methylene chloride, chloroform, or dichloroethane;<br>
aromatic hydrocarbons such as benzene, toluene, or<br>
xylene; nitriles such as acetonitrile; and ethers such<br>
as dioxane, tetrahydrofuran, anisole, diethylene glycol<br>
diethyl ether, or ethylene glycol monomethyl ether.<br>
These solvents may be used in combination.<br>
Examples of a reducing agent used in this<br>
reaction may include: metal hydrides such as triacetoxy<br>
sodium borohydride, diisobutyl aluminum hydride, a tin<br><br>
hydride compound, borane, dialkylborane, or<br>
hydrosilane; boron hydride complex compounds such as<br>
sodium borohydride, lithium borohydride, potassium<br>
borohydride, or calcium borohydride; and aluminum<br>
hydride complex compounds such as lithium aluminum<br>
hydride. The use amount of a reducing agent is<br>
different depending on the type of the reducing agent.<br>
For example, in the case of a boron hydride complex<br>
compound, it may be used with respect to the compound<br>
represented by general formula [28] at a molar ratio of<br>
0.25 : 1 or greater, and preferably at a molar ratio of<br>
1 : 1 to 5 : 1.<br>
In addition, catalytic hydrogenation using a<br>
metal catalyst may be applied as a reduction reaction.<br>
Examples of a metal catalyst used therein may include<br>
palladium oxide, platinum oxide, and palladium-carbon.<br>
A metal catalyst may be used with respect to the<br>
compounds represented by general formulas [28] and [29]<br>
at a weight ratio (W/W) of 0.001 : 1 to 1 : 1, and<br>
preferably at a weight ratio (W/W) of 0.01 : 1 to 0.5 :<br>
1.<br>
This reaction may be carried out at -50Â°C to<br>
120Â°C, and preferably at 0Â°C to 80Â°C, for 10 minutes to<br>
24 hours.<br>
(7-d)<br>
The compound represented by general formula<br>
[1d] can be produced by subjecting the compound<br>
represented by general formula [24] and the compound<br><br>
represented by general formula [27] to a reductive<br>
amination reaction without isolating the compound<br>
represented by general formula [28.] .<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, n-propanol, isopropanol, n-<br>
butanol, isobutanol, tert-butanol, n-hexanol,<br>
cyclopentanol, or cyclohexanol; amides such as N,N-<br>
dimethylformamide, N,N-dimethylacetamide, or 1-methyl-<br>
2-pyrrolidone; halogenated hydrocarbons such as<br>
methylene chloride, chloroform, or dichloroethane;<br>
aromatic hydrocarbons such as benzene, toluene, or<br>
xylene; nitriles such as acetonitrile; and ethers such<br>
as dioxane, tetrahydrofuran, anisole, diethylene glycol<br>
diethyl ether, or ethylene glycol monomethyl ether.<br>
These solvents may be used in combination.<br>
Examples of a reducing agent used in this<br>
reaction may include: metal hydrides such as triacetoxy<br>
sodium borohydride, diisobutyl aluminum hydride, a tin<br>
hydride compound, a borane-tetrahydrofuran complex,<br>
diborane, dialkylborane, or hydrosilane; boron hydride<br>
complex compounds such as sodium borohydride, lithium<br>
borohydride, potassium borohydride, calcium<br>
borohydride, or triacetoxy sodium borohydride; and<br>
aluminum hydride complex compounds such as lithium<br>
aluminum hydride, which are described in the Journal of<br>
Medicinal Chemistry (J. Med. Chem.), vol. 43, pp. 27 to<br><br>
58, 2000. The use amount of a reducing agent is<br>
different depending on the type of the reducing agent.<br>
For example, in the case of triacetoxy sodium<br>
borohydride, it may be used with respect to the<br>
compound represented by general formula [24] at a molar<br>
ratio of 1 : 1 or greater, and preferably at a molar<br>
ratio of 1 : 1 to 5 : 1.<br>
In addition, catalytic hydrogenation using a<br>
metal catalyst may be applied as a reduction reaction.<br>
Examples of a metal catalyst used herein may include<br>
palladium oxide, platinum oxide, and palladium-carbon.<br>
A metal catalyst may be used with respect to the<br>
compounds represented by general formulas [24] and [25]<br>
at a weight ratio (W/W) of 0.001 : 1 to 1 : 1, and<br>
preferably at a weight ratio (W/W) of 0.01 : 1 to 0.5 :<br>
1.<br>
This reaction may be carried out at -50Â°C to<br>
120Â°C, and preferably at 0Â°C to 80Â°C, for 10 minutes to<br>
24 hours.<br>
(7-e)<br>
The compound represented by general formula<br>
[25] can be produced by reacting the compound<br>
represented by general formula [3] with the compound<br>
represented by general formula [26] according to the<br>
scheme 1-a, and then deprotecting an aldehyde<br>
protecting group.<br>
In addition, the compound represented by<br>
general formula [25] can also be produced by reacting<br><br>
the compound represented by general formula [3] with<br>
the compound represented by general formula [73]<br>
according to the scheme 1-a, and eliminating R15, as<br>
desired, to obtain a compound represented by general<br>
formula [75], and then subjecting the compound<br>
represented by general formula [75] to an oxidative<br>
reaction according to the scheme 7-a.<br>
The compound represented by general formula<br>
[29] can be produced by subjecting the compound<br>
represented by general formula [25] and the compound<br>
represented by general formula [27] to a dehydration<br>
reaction in the presence or absence of a dehydrating<br>
agent according to the scheme 7-b.<br>
The compound represented by general formula<br>
[30] can be produced by reducing the compound<br>
represented by general formula [29] according to the<br>
scheme 7-c.<br>
In addition, the compound represented by<br>
general formula [30] can also be produced by subjecting<br>
the compound represented by general formula [24] and<br>
the compound represented by general formula [27] to a<br>
reductive amination reaction according to the scheme 7-<br>
d.<br>
The compound represented by general formula<br>
[1d] can be produced by amidinating the compound<br>
represented by general formula [30] according to the<br>
scheme 1-b or scheme 2.<br>
[Scheme 8]<br><br>
A compound represented by general formula<br>
[1e] can be produced, for example, by the following<br>
scheme:<br><br>
wherein each of R1, R6, R7, R9, Ra, X, Y, Y1, G1, and G2<br>
has the same meaning as described above.<br>
(8-a)<br>
The compound represented by general formula<br>
[33] can be produced by subjecting the compound<br>
represented by general formula [1ab] and the compound<br>
represented by general formula [32] to a dehydration<br>
reaction in the presence or absence of a dehydrating<br>
agent.<br>
A solvent used in this reaction is not<br><br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: amides<br>
such as N,N-dimethylformamide, N,N-dimethylacetamide,<br>
or 1-methyl-2-pyrrolidone; halogenated hydrocarbons<br>
such as methylene chloride, chloroform, or<br>
dichloroethane; aromatic hydrocarbons such as benzene,<br>
toluene, or xylene; ethers such as dioxane,<br>
tetrahydrofuran, anisole, diethylene glycol diethyl<br>
ether, or ethylene glycol monomethyl ether; nitriles<br>
such as acetonitrile; and sulfoxides such as dimethyl<br>
sulfoxide. These solvents may be used in combination.<br>
Examples of a dehydrating agent that is used<br>
in this reaction as desired may include anhydrous<br>
magnesium sulfate, molecular sieves, sodium sulfate,<br>
Zeolum, and calcium chloride. Such a dehydrating agent<br>
may be used with respect to the compound represented by<br>
general formula [lab] at a weight ratio (W/W) of 1 : 1<br>
to 50 : 1, and preferably at a weight ratio (W/W) of<br>
1 : 1 to 10 : 1.<br>
In this reaction, the compound represented by<br>
general formula [32] may be used with respect to the<br>
compound represented by general formula [1ab] at a<br>
molar ratio of 1 : 1 or greater, and preferably at a<br>
molar ratio of 1 : 1 to 5 : 1.<br>
This reaction may be carried out at 0Â°C to<br>
200Â°C, and preferably at 0Â°C to 150Â°C, for 1 minute to<br>
24 hours.<br>
(8-b)<br><br>
The compound represented by general formula<br>
[1e] can be produced by subjecting the compound<br>
represented by general formula [33] to a reduction<br>
reaction.<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, n-propanol, isopropanol, n-<br>
butanol, isobutanol, tert-butanol, n-hexanol,<br>
cyclopentanol, or cyclohexanol; amides such as N,N-<br>
dimethylformamide, N,N-dimethylacetamide, or 1-methyl-<br>
2-pyrrolidone; halogenated hydrocarbons such as<br>
methylene chloride, chloroform, or dichloroethane;<br>
aromatic hydrocarbons such as benzene, toluene, or<br>
xylene; nitriles such as acetonitrile; and ethers such<br>
as dioxane, tetrahydrofuran, anisole, diethylene glycol<br>
diethyl ether, or ethylene glycol monomethyl ether.<br>
These solvents may be used in combination.<br>
Examples of a reducing agent used in this<br>
reaction may include: metal hydrides such as diisobutyl<br>
aluminum hydride, a tin hydride compound, borane,<br>
dialkylborane, or hydrosilane; boron hydride complex<br>
compounds such as sodium borohydride, lithium<br>
borohydride, potassium borohydride, or calcium<br>
borohydride; and aluminum hydride complex compounds<br>
such as lithium aluminum hydride.<br>
The use amount of a reducing agent is<br>
different depending on the type of the reducing agent.<br><br>
For example, in the case of a boron hydride complex<br>
compound, it may be used with respect to the compound<br>
represented by general formula [33] at a molar ratio of<br>
0.25 : 1 or greater, and preferably at a molar ratio of<br>
1 : 1 to 5 : 1.<br>
This reduction reaction may be carried out at<br>
-50Â°C to 120Â°C, and preferably at 0Â°C to 80Â°C, for 10<br>
minutes to 24 hours.<br>
In addition, the compound represented by<br>
general formula [1e] can also be produced by<br>
amidinating the compound represented by general formula<br>
[35] according to the scheme 1-b or scheme 2.<br>
(8-c)<br>
The compound represented by general formula<br>
[31] can be produced by reducing the compound<br>
represented by general formula [14] according to a<br>
method similar to the scheme 3-a.<br>
The compound represented by general formula<br>
[34] can be produced by subjecting the compound<br>
represented by general formula [31] and the compound<br>
represented by general formula [32] to a dehydration<br>
reaction in the presence or absence of a dehydrating<br>
agent according to a method similar to the scheme 7-b.<br>
The compound represented by general formula<br>
[35] can be produced by reducing the compound<br>
represented by general formula [34] according to the<br>
scheme 8-a.<br>
[Scheme 9]<br><br>
A compound represented by general formula<br>
[1ba] can be produced, for example, by the following<br>
scheme:<br><br>
wherein each of R1, R5, R6, R7, R9, Ra, X, Y, G1, G2, and L<br>
has the same meaning as described above; and each of R5a<br>
and R6a identically or differently represents an amino<br>
protecting group, or an unsubstituted or substituted<br>
alkyl, cycloalkyl or alkenyl group.<br>
(9-a)<br>
The compound represented by general formula<br>
[1ba] can be produced by reacting the compound<br>
represented by general formula [1da] with the compound<br>
represented by general formula [36], or by reacting the<br>
compound represented by general formula [1e] with the<br><br>
compound represented by general formula [36a], in the<br>
presence or absence of a base.<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, isopropanol, or tert-<br>
butanol; amides such as N,N-dimethylformamide, N,N-<br>
dimethylacetamide, or 1-methyl-2-pyrrolidone;<br>
halogenated hydrocarbons such as methylene chloride,<br>
chloroform, or dichloroethane; aromatic hydrocarbons<br>
such as benzene, toluene, or xylene; ethers such as<br>
dioxane, tetrahydrofuran, anisole, diethylene glycol<br>
diethyl ether, or ethylene glycol monomethyl ether;<br>
nitriles such as acetonitrile; ketones such as acetone<br>
or 2-butanone; and sulfoxides such as dimethyl<br>
sulfoxide. These solvents may be used in combination.<br>
Examples of a base that is used in this<br>
reaction as desired may include sodium methoxide,<br>
sodium ethoxide, potassium tert-butoxide, sodium tert-<br>
butoxide, sodium hydroxide, potassium hydroxide, sodium<br>
bicarbonate, sodium carbonate, potassium carbonate,<br>
sodium hydride, potassium hydride, triethylamine, and<br>
pyridine. Such a base may be used with respect to the<br>
compound represented by general formula [1da] or<br>
compound represented by general formula [1e] at a molar<br>
ratio of 1 : 1 or greater, and preferably at a molar<br>
ratio of 1 : 1 to 3 : 1.<br>
In this reaction, the compound represented by<br><br>
general formula [36] or compound represented by general<br>
formula [36a] may be used with respect to the compound<br>
represented by general formula [1da] or compound<br>
represented by general formula [1e] at a molar ratio of<br>
1 : 1 or greater, and preferably at a molar ratio of<br>
1	: 1 to 3 : 1.<br>
This reaction may be carried out at 0Â°C to<br>
200Â°C, and preferably at 0Â°C to 150Â°C, for 1 minute to<br>
2	4 hours.<br>
(9-b)<br>
The compound represented by general formula<br>
[37] can be produced by reacting the compound<br>
represented by general formula [30] with the compound<br>
represented by general formula [36], or by reacting the<br>
compound represented by general formula [35] with the<br>
compound represented by general formula [36a], in the<br>
presence or absence of a base according to the scheme<br>
9-a.<br>
In addition, the compound represented by<br>
general formula [1ba] can also be produced by<br>
amidinating the compound represented by general formula<br>
[37] according to the scheme 1-b or scheme 2.<br>
[Scheme 10]<br>
A compound represented by general formula<br>
[1f] can be produced, for example, by the following<br>
scheme:<br><br><br>
wherein each of R1, R5, R8, R9, R12, Ra, Rb, X, Y, Y1, Z,<br>
G1, G2, G3, and G5 has the same meaning as described<br>
above.<br>
(10-a)<br>
The compound represented by general formula<br>
[38] can be produced by subjecting the compound<br>
represented by general formula [24] and the compound<br>
represented by general formula [1ac] to a dehydration<br>
reaction in the presence or absence of a dehydrating<br>
agent according to the scheme 7-b.<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br><br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, isopropanol, or tert-<br>
butanol; amides such as N,N-dimethylformamide, N,N-<br>
dimethylacetamide, or 1-methyl-2-pyrrolidone;<br>
halogenated hydrocarbons such as methylene chloride,<br>
chloroform, or dichloroethane; aromatic hydrocarbons<br>
such as benzene, toluene, or xylene; ethers such as<br>
dioxane, tetrahydrofuran, anisole, diethylene glycol<br>
diethyl ether, or ethylene glycol monomethyl ether;<br>
nitriles such as acetonitrile; and sulfoxides such as<br>
dimethyl sulfoxide. These solvents may be used in<br>
combination.<br>
Examples of a dehydrating agent that is used<br>
in this reaction as desired may include anhydrous<br>
magnesium sulfate, molecular sieves, sodium sulfate,<br>
Zeolum, and calcium chloride. Such a dehydrating agent<br>
may be used with respect to the compound represented by<br>
general formula [24] at a weight ratio (W/W) of 1 : 1<br>
to 50 : 1, and preferably at a weight ratio (W/W) of<br>
1 : 1 to 10 : 1.<br>
In this reaction, the compound represented by<br>
general formula [1ac] may be used with respect to the<br>
compound represented by general formula [24] at a molar<br>
ratio of 1 : 1 or greater, and preferably at a molar<br>
ratio of 1 : 1 to 5 : 1.<br>
This reaction may be carried out at 0Â°C to<br>
200Â°C, and preferably at 0Â°C to 150Â°C, for 1 minute to<br>
24 hours.<br><br>
(10-b)<br>
The compound represented by general formula<br>
[1f] can be produced by subjecting the compound<br>
represented by general formula [38] to a reduction<br>
reaction according to the scheme 7-a.<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, n-propanol, isopropanol, n-<br>
butanol, isobutanol, tert-butanol, n-hexanol,<br>
cyclopentanol, or cyclohexanol; amides such as N,N-<br>
dimethylformamide, N,N-dimethylacetamide, or 1-methyl-<br>
2-pyrrolidone; halogenated hydrocarbons such as<br>
methylene chloride, chloroform, or dichloroethane;<br>
aromatic hydrocarbons such as benzene, toluene, or<br>
xylene; nitriles such as acetonitrile; and ethers such<br>
as dioxane, tetrahydrofuran, anisole, diethylene glycol<br>
diethyl ether, or ethylene glycol monomethyl ether.<br>
These solvents may be used in combination.<br>
Examples of a reducing agent used in this<br>
reaction may include: metal hydrides such as triacetoxy<br>
sodium borohydride, diisobutyl aluminum hydride, a tin<br>
hydride compound, a borane-tetrahydrofuran complex<br>
compound, diborane, dialkylborane, or hydrosilane;<br>
boron hydride complex compounds such as sodium<br>
borohydride, lithium borohydride, potassium<br>
borohydride, or calcium borohydride; and aluminum<br>
hydride complex compounds such as lithium aluminum<br><br>
hydride.<br>
The use amount of a reducing agent is<br>
different depending on the type of the reducing agent.<br>
For example, in the case of a boron hydride complex<br>
compound, it may be used with respect to the compound<br>
represented by general formula [38] at a molar ratio of<br>
0.25 : 1 or greater, and preferably at a molar ratio of<br>
1 : 1 to 5 : 1.<br>
This reaction may be carried out generally at<br>
-50Â°C to 120Â°C, and preferably at 0Â°C to 80Â°C, for 10<br>
minutes to 24 hours.<br>
In addition, the compound represented by<br>
general formula [1f] can also be produced by<br>
amidinating the compound represented by general formula<br>
[40] according to the scheme 1-b or scheme 2.<br>
(10-c)<br>
The compound represented by general formula<br>
[39] can be produced by subjecting the compound<br>
represented by general formula [25] and the compound<br>
represented by general formula [31a] to a dehydration<br>
reaction in the presence or absence of a dehydrating<br>
agent according to the scheme 7-b.<br>
The compound represented by general formula<br>
[40] can be produced by reducing the compound<br>
represented by general formula [39] according to the<br>
scheme 7-c.<br>
[Scheme 11]<br>
A compound represented by general formula<br><br>
[1ca] can be produced, for example, by the following<br>
scheme:<br><br>
wherein each of R1, R5, R5a, R6, R6a, R8, R9, R12, Ra, Rb, X,<br>
Y, Z, G1, G2, G3, G5, and L has the same meaning as<br>
described above.<br>
(11-a)<br>
The compound represented by general formula<br>
[1ca] can be produced by reacting the compound<br><br>
represented by general formula [1fa] with the compound<br>
represented by general formula [36], or by reacting the<br>
compound represented by general formula [1cb] with the<br>
compound represented by general formula [36a], in the<br>
presence or absence of a base.<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, isopropanol, or tert-<br>
butanol; amides such as N,N-dimethylformamide, N,N-<br>
dimethylacetamide, or 1-methyl-2-pyrrolidone;<br>
halogenated hydrocarbons such as methylene chloride,<br>
chloroform, or dichloroethane; aromatic hydrocarbons<br>
such as benzene, toluene, or xylene; ethers such as<br>
dioxane, tetrahydrofuran, anisole, diethylene glycol<br>
diethyl ether, or ethylene glycol monomethyl ether;<br>
nitriles such as acetonitrile; ketones such as acetone<br>
or 2-butanone; and sulfoxides such as dimethyl<br>
sulfoxide. These solvents may be used in combination.<br>
Examples of a base that is used in this<br>
reaction as desired may include: metal alkoxides such<br>
as sodium methoxide, sodium ethoxide, potassium tert-<br>
butoxide, or sodium tert-butoxide; inorganic bases such<br>
as sodium hydroxide, potassium hydroxide, sodium<br>
bicarbonate, sodium carbonate, potassium carbonate,<br>
sodium hydride, or potassium hydride; and organic bases<br>
such as triethylamine or pyridine. Such a base may be<br>
used with respect to the compounds represented by<br><br>
general formulas [1fa] and [1cb] at a molar ratio of<br>
1 : 1 or greater, and preferably at a molar ratio of<br>
1 : 1 to 3 : 1.<br>
In this reaction, the compounds represented<br>
by general formulas [36] and [36a] may be used with<br>
respect to the compounds represented by general<br>
formulas [1fa] and [1cb] at a molar ratio of 1 : 1 or<br>
greater, and preferably at a molar ratio of 1 : 1 to<br>
3 : 1, respectively.<br>
This reaction may be carried out at 0Â°C to<br>
200Â°C, and preferably at 0Â°C to 150Â°C, for 1 minute to<br>
24 hours.<br>
In addition, the compound represented by<br>
general formula [1ca] can also be produced by reacting<br>
the compound represented by general formula [2] or [2a]<br>
with the compound represented by general formula [76]<br>
according to the scheme 6-a.<br>
Moreover, the compound represented by general<br>
formula [1ca] can also be produced by amidinating the<br>
compound represented by general formula [41] according<br>
to the scheme 1-b or scheme 2.<br>
(11-b)<br>
The compound represented by general formula<br>
[41] can be produced by reacting the compound<br>
represented by general formula [40] with the compound<br>
represented by general formula [36] according to the<br>
scheme 11-a in the presence or absence of a base.<br>
In addition, the compound represented by<br><br>
general formula [41] can also be produced by reacting<br>
the compound represented by general formula [3] or [3a]<br>
with the compound represented by general formula [76]<br>
according to the scheme 6-a.<br>
[Scheme 12]<br>
A compound represented by general formula<br>
[1g] can be produced, for example, by the following<br>
scheme:<br><br>
wherein R12a represents a cyano group, amide group, or<br>
unprotected or protected or unsubstituted or<br><br>
substituted amidino group; and each of R, R1, R8a, R9,<br>
Ra, Rba, X, Ya, Yb, Za, G1, G2, G3a, G5a and L has the same<br>
meaning as described above.<br>
The compounds represented by general formulas<br>
[19a] and [20a] can be produced by reacting the<br>
compounds represented by general formulas [2] and [3]<br>
with the compound represented by general formula [77],<br>
respectively, according to the method described in, for<br>
example, International Publication WO96/16947, or<br>
method equivalent thereto, and then removing secondary<br>
amino protecting groups according to conventional<br>
methods.<br>
(12-a)<br>
The compound represented by general formula<br>
[1g] can be produced by reacting the compound<br>
represented by general formula [19a] with the compound<br>
represented by general formula [2a], or by reacting the<br>
compound represented by general formula [2] with the<br>
compound represented by general formula [82], according<br>
to the scheme 6-a.<br>
In addition, the compound represented by<br>
general formula [1g] can also be produced by reacting<br>
the compound represented by general formula [2] or [2a]<br>
with the compound represented by general formula [83]<br>
according to the scheme 6-a.<br>
(12-b)<br>
The compound represented by general formula<br>
[23a] can be produced by reacting the compound<br><br>
represented by general formula [20a] with the compound<br>
represented by general formula [3a], or by reacting the<br>
compound represented by general formula [3] with the<br>
compound represented by general formula [82], according<br>
to the scheme 6-a.<br>
In addition, the compound represented by<br>
general formula [23a] can also be produced by reacting<br>
the compound represented by general formula [3] or [3a]<br>
with the compound represented by general formula [83]<br>
according to the scheme 6-a.<br>
Further, the compound represented by general<br>
formula [1g] can also be produced by amidinating the<br>
compound represented by general formula [23a] according<br>
to the scheme 1-b or scheme 2.<br>
[Scheme 13]<br>
A compound represented by general formula<br>
[1g] can be produced, for example, by the following<br>
scheme:<br><br><br>
wherein each of R1, R8a, Ra, Rba, X, Ya, Yb, Za, G1, G2, G3a,<br>
G5a, and L has the same meaning as described above; and<br>
each of R9a and R12b represents a cyano group; and R'<br>
represents a protecting group of an amino, hydroxyl or<br>
thiol group.<br>
(13-a)<br>
The compound represented by general formula<br><br>
[86] can be produced by reacting the compound<br>
represented by general formula [84] with the compound<br>
represented by general formula [85] in the presence or<br>
absence of a base, and then removing a protecting<br>
group.<br>
A solvent used in this reaction is not<br>
particularly limited, as long as it does not affect the<br>
reaction. Examples of a solvent may include: alcohols<br>
such as methanol, ethanol, isopropanol, or tert-<br>
butanol; amides such as N,N-dimethylformamide, N,N-<br>
dimethylacetamide, or 1-methyl-2-pyrrolidone;<br>
halogenated hydrocarbons such as methylene chloride,<br>
chloroform, or dichloroethane; aromatic hydrocarbons<br>
such as benzene, toluene, or xylene; ethers such as<br>
dioxane, tetrahydrofuran, anisole, diethylene glycol<br>
diethyl ether, or ethylene glycol monomethyl ether;<br>
nitriles such as acetonitrile; ketones such as acetone<br>
or 2-butanone; and sulfoxides such as dimethyl<br>
sulfoxide. These solvents may be used in combination.<br>
Examples of a base that is used in this<br>
reaction as desired may include: metal alkoxides such<br>
as sodium methoxide, sodium ethoxide, potassium tert-<br>
butoxide, or sodium tert-butoxide; inorganic bases such<br>
as sodium hydroxide, potassium hydroxide, sodium<br>
bicarbonate, sodium carbonate, potassium carbonate,<br>
sodium hydride, or potassium hydride; and organic bases<br>
such as triethylamine or pyridine. Such a base may be<br>
used with respect to the compound represented by<br><br>
general formula [85] at a molar ratio of 1 : 1 or<br>
greater, and preferably at a molar ratio of 1 : 1 to<br>
3 : 1.<br>
In this reaction, the compound represented by<br>
general formula [84] may be used with respect to the<br>
compound represented by general formula [85] at a molar<br>
ratio of 1 : 1 or greater, and preferably at a molar<br>
ratio of 1 : 1 to 5 : 1.<br>
This reaction may be carried out at 0Â°C to<br>
200Â°C, and preferably at 0Â°C to 150Â°C, for 1 minute to<br>
24 hours.<br>
Moreover, a protecting group of an amino,<br>
hydroxyl or thiol group represented by R' may be<br>
removed by known methods.<br>
(13-b)<br>
The compound represented by general formula<br>
[88] can be produced by reacting the compound<br>
represented by general formula [86] with the compound<br>
represented by general formula [87], or by reacting the<br>
compound represented by general formula [84] with the<br>
compound represented by general formula [89], according<br>
to the scheme 13-a.<br>
In this reaction, the compound represented by<br>
general formula [84] may be used with respect to the<br>
compound represented by general formula [89] at a molar<br>
ratio of 2 : 1 or greater, and preferably at a molar<br>
ratio of 2 : 1 to 5 : 1.<br>
(13-c)<br><br>
The compound represented by general formula<br>
[1g] can be produced by amidinating the compound<br>
represented by general formula [88] according to the<br>
scheme 1-b or scheme 2.<br>
[Scheme 14]<br>
A compound represented by general formula<br>
[1h] can be produced, for example, by the following<br>
scheme:<br><br><br>
wherein each of R1, R7a, R9, Ra, X, Ya, Yb, G1, G2, and L<br>
has the same meaning as described above.<br>
The compound represented by general formula<br>
[1h] can be produced by reacting the compound<br>
represented by general formula [2] with the compound<br>
represented by general formula [90] according to the<br>
scheme 1-a.<br>
In addition, the compound represented by<br>
general formula [1h] can also be produced by<br>
amidinating the compound represented by general formula<br>
[91] according to the scheme 1-b or scheme 2.<br>
The compound represented by general formula<br>
[91] can be produced by reacting the compound<br>
represented by general formula [3] with the compound<br>
represented by general formula [90] according to the<br>
scheme 1-a.<br>
[Scheme 15]<br>
A compound represented by general formula<br>
[1i] can be produced, for example, by the following<br>
scheme:<br><br><br>
wherein G3aa represents a hydroxyl group, amino group, or<br>
thiol group; and each of R, R1, R8a, R9, R12a, Ra, Rba, X,<br>
Ya, Yb, Za, G1, G2, G3a, G5a, and L has the same meaning as<br>
described above.<br>
(15-a)<br>
The compound represented by general formula<br>
[96] can be produced by reacting the compound<br>
represented by general formula [93] with the compound<br>
represented by general formula [95] according to the<br>
scheme 1-1, and then removing a secondary amine<br>
protecting group according to known methods.<br>
Examples of the compound represented by<br><br>
general formula [95] may include: 1-tert-<br>
butoxycarbonyl-4-(iodomethyl) piperidine, 1-tert-<br>
butoxycarbonyl-4-(iodoethyl) piperidine, and 1-benzyl-<br>
4-(2-chloroethyl) piperidine, which are described in<br>
the Journal of Medicinal Chemistry (J. Med. Chem.),<br>
vol. 44, pp. 2,707 to 2,717, 2001; 4-[1-(tert-<br>
butoxycarbonyl)piperidin-4-yl] butylbromide and 3-[1-<br>
(tert-butoxycarbonyl)piperidin-4-yl] propylbromide,<br>
which are described in the same above publication, vol.<br>
37, pp. 2,537 to 2,551, 1994; 1-(tert-butoxycarbonyl)-<br>
3-(methanesulfonyloxymethyl) pyrrolidine and 1-(tert-<br>
butoxycarbonyl) -3-(methanesulfonyloxy) pyrrolidine,<br>
which are described in the same above publication, vol.<br>
42, pp. 677 to 690, 1999; and 1-tert-butoxycarbonyl-4-<br>
(hydroxymethyl) piperidine mesylate described in US<br>
Patent No. 9311623.<br>
(15-b)<br>
The compound represented by general formula<br>
[97] can be produced by reacting the compound<br>
represented by general formula [94] with the compound<br>
represented by general formula [95] according to the<br>
scheme 1-1, and then removing a secondary amine<br>
protecting group.<br>
The compound represented by general formula<br>
[99] can be produced by reacting the compound<br>
represented by general formula [97] with the compound<br>
represented by general formula [3] according to the<br>
scheme 1-a.<br><br>
(15-c)<br>
The compound represented by general formula<br>
[1i] can be produced by reacting the compound<br>
represented by general formula [96] with the compound<br>
represented by general formula [2] according to the<br>
scheme 1-a.<br>
In addition, the compound represented by<br>
general formula [1i] can also be produced by<br>
amidinating the compound represented by general formula<br>
[99] according to the scheme 1-b or scheme 2.<br>
[Scheme 16]<br>
A compound represented by general formula<br>
[1j] can be produced, for example, by the following<br>
scheme:<br><br><br>
wherein each of Ra, R1, R7b, R9, X, G1, G2, Yc, Yc', L, and<br>
W has the same meaning as described above; Rc represents<br>
an amino protecting group; and R4a represents an amino<br>
protecting group that is different from Rc, or an<br>
unsubstituted or substituted alkyl, cycloalkyl or<br>
alkenyl group.<br><br>
(16-a)<br>
The compound represented by general formula<br>
[1ja] can be produced by reacting the compound<br>
represented by general formula [2] with the compound<br>
represented by general formula [4c] in the presence or<br>
absence of a base, and then subjecting the reaction<br>
product to a deprotection reaction for an amino<br>
protecting group.<br>
The compound represented by general formula<br>
[1jb] can be produced by reacting the compound<br>
represented by general formula [2] with the compound<br>
represented by general formula [4d] in the presence or<br>
absence of a base.<br>
These reactions may be carried out according<br>
to the scheme 1-a.<br>
Examples of the compound represented by<br>
general formula [4c] may include: 4-amino-1-benzyl<br>
piperidine, 3-amino-1-benzylpyrrolidine, 2-<br>
(aminomethyl)-1-(tert-butoxycarbonyl)pyrrolidine, and<br>
3-amino-1-benzyl piperidine [the Journal of Medicinal<br>
Chemistry (J. Med. Chem.), vol. 23, pp. 848 to 851,<br>
1980]; 4-(aminomethyl)-1-benzylpiperidine [the same<br>
above publication, vol. 37, pp. 2,721 to 2,734, 1994];<br>
4-(2-aminoethyl)-1-benzylpiperidine, and 2-<br>
(aminomethyl)-1-benzylpiperidine [the same above<br>
publication, vol. 33, pp. 1,880 to 1,887, 1990]; 3-<br>
(aminomethyl)-1-(tert-butoxycarbonyl)pyrrolidine [the<br>
same above publication, vol. 42, pp. 677 to 690, 1999];<br><br>
3-amino-1-benzylhomopiperidine [the same above<br>
publication, vol. 39, pp. 4,704 to 4,716, 1996]; and 4-<br>
amino-1-benzylhomopiperidine [the same above<br>
publication, vol. 44, pp. 1,380 to 1,395, 2001].<br>
(16-b)<br>
The compound represented by general formula<br>
[1j] can be produced by reacting the compounds<br>
represented by general formulas [1ja] and [1jb] with<br>
the compounds represented by general formulas [4f] and<br>
[4e], respectively, in the presence or absence of a<br>
base.<br>
These reactions may be carried out according<br>
to the scheme 1-a.<br>
(16-c)<br>
The compound represented by general formula<br>
[58] can be produced by reacting the compounds<br>
represented by general formulas [56] and [59] with the<br>
compounds represented by general formulas [4f] and<br>
[4e], respectively, in the presence or absence of a<br>
base. The compounds represented by general formulas<br>
[56] and [59] can be produced by reacting the compound<br>
represented by general formula [3] with the compounds<br>
represented by general formulas [4c] and [4d],<br>
respectively.<br>
These reactions may be carried out according<br>
to the scheme 1-a.<br>
(16-d)<br>
The compounds represented by general formulas<br><br>
117<br>
[1j] and [1jb] can be produced by amidinating the<br>
compounds represented by general formulas [58] and<br>
[59], respectively.<br>
Amidination may be carried out according to<br>
the scheme 1-b or scheme 2.<br>
[Scheme 17]<br>
A compound represented by general formula<br>
[1k] can be produced, for example, by the following<br>
scheme:<br><br>
wherein R6b represents an unsubstituted or substituted<br>
alkyl group; and each of R1, R7a, R9, Ra, X, Ya, Yb, G1,<br><br>
G2, and L has the same meaning as described above.<br>
(17-a)<br>
The compound represented by general formula<br>
[1k] can be produced by reacting the compound<br>
represented by general formula [19a] with the compound<br>
represented by general formula [79], or reacting the<br>
compound represented by general formula [2] with the<br>
compound represented by general formula [78], according<br>
to the scheme 6-a.<br>
(17-b)<br>
The compound represented by general formula<br>
[23b] can be produced by reacting the compound<br>
represented by general formula [20a] with the compound<br>
represented by general formula [79], or reacting the<br>
compound represented by general formula [3] with the<br>
compound represented by general formula [78], according<br>
to the scheme 6-a.<br>
The compound represented by general formula<br>
[1k] can be produced by amidinating the compound<br>
represented by general formula [23b] according to the<br>
scheme 1-b or scheme 2.<br>
(17-c)<br>
The compound represented by general formula<br>
[1ea] can be produced by hydrolysis of the compound<br>
represented by general formula [1k] according to the<br>
scheme 4-a.<br>
Salts of the compounds described in the above<br>
schemes 1 to 17 can also be used. Examples of such<br><br>
salts are the same as those described in the compound<br>
represented by general formula [1].<br>
Intermediates of the products obtained by the<br>
above described schemes 1 to 17 can also be used in the<br>
subsequent reactions without being isolated.<br>
Among the compounds obtained by the above<br>
described schemes 1 to 17, with regard to those having<br>
a functional group such as an amino group, cyclic amino<br>
group, hydroxyl group, aldehyde group, or carboxyl<br>
group, their functional groups may previously be<br>
protected with common protecting groups, as necessary,<br>
and these protecting groups may be removed by known<br>
methods after completion of the reaction.<br>
The thus obtained compound represented by<br>
general formula [1] or a salt thereof, is subject to<br>
known reactions such as condensation, addition,<br>
oxidization, reduction, rearrangement, substitution,<br>
halogenation, dehydration, or hydrolysis, or these<br>
reactions are appropriately applied in combination, so<br>
that the above compound or a salt thereof can be<br>
induced to another compound represented by general<br>
formula [1] or a salt thereof.<br>
Moreover, in a case where an isomer (e.g.,<br>
optical isomer, geometric isomer, tautomer, etc.)<br>
exists in the compounds obtained by the above schemes,<br>
these isomers can also be used. Furthermore, a<br>
solvate, a hydrate, and various forms of crystals can<br>
also be used.<br><br>
When the compound of the present invention is<br>
used as a pharmaceutical, generally, pharmaceutical<br>
aids that are used in pharmaceutical preparation, such<br>
as an excipient, carrier, or diluent may be<br>
appropriately mixed with the compound. According to<br>
conventional methods, the thus produced pharmaceutical<br>
can be administered orally or parenterally in the form<br>
of a tablet, capsule, powder, syrup, granule, pill,<br>
suspension, emulsion, liquid, powdered preparation,<br>
suppository, eye drop, nose drop, ear drop, plaster,<br>
ointment, or injection. Moreover, the administration<br>
method, the dosage, and the number of administration<br>
can be selected, as appropriate, depending on the age,<br>
body weight, and symptom of patients. Generally, for<br>
an adult, an amount of 0.01 to 1,000 mg/kg may be<br>
administered orally or parenterally (for example, an<br>
injection, an drop, administration into a rectum site,<br>
etc.) per day, once or dividedly into several times.<br>
Next, pharmacological actions of<br>
representative compounds of the present invention will<br>
be explained below.<br>
Test example 1 Antifungal action<br>
50% growth inhibitory concentration (IC50) was<br>
measured according to the microbroth dilution method,<br>
using, as a reference, the antifungal agent sensitivity<br>
test method proposed by the subcommittee for the<br>
antifungal agent sensitivity test, the Japanese Society<br>
for Medical Mycology (Japanese Journal of Medical<br><br>
Mycology, vol. 36, No. 1, pp. 62 to 64, 1995).<br>
Synthetic amino acid medium, fungal (SAAMF,<br>
manufactured by Nippon Bio-Supp. Center) was used as a<br>
medium for measurement of sensitivity. Candida<br>
albicans TIMM 1623 was cultured at 30Â°C overnight on a<br>
Sabouraud agar plate medium (Eiken Chemical Co., Ltd.),<br>
and the obtained culture was suspended in a sterilized<br>
physiological saline solution. Thereafter, the<br>
suspension was diluted with a measurement medium such<br>
that the number of cells became 1 x 104 cells/ml,<br>
thereby producing an inoculum organism solution. 175<br>
Âµl of a medium, 5 Âµl of a test agent (an agent diluted<br>
solvent in a growth control well), and 20 Âµl of the<br>
inoculum organism solution were added to a 96-well<br>
microplate (flat bottom, manufactured by Sumitomo<br>
Bakelite Co., Ltd.), and the mixture was stirred with a<br>
mixer. Thereafter, using a well Reader SME3400<br>
(Scinics Co., Ltd.), an initial turbidity at a<br>
wavelength of 630 nm was measured. The above mixture<br>
was cultured at 35Â°C, and 36 hours later, a final<br>
turbidity was measure in the same manner. For an<br>
agent-diluted line, values were obtained by subtracting<br>
the initial turbidities from the final turbidities.<br>
For a growth control line also, values were obtained by<br>
subtracting the initial turbidities from the final<br>
turbidities. IC50 was defined as the lowest agent<br>
concentration among the test agent concentrations<br>
having a turbidity equal to or lower than the 50% value<br><br>
(IC50 calculated value) of a value obtained by<br>
subtracting the initial turbidity of a growth control<br>
from the final turbidity thereof. The results<br>
regarding the IC50 value to each cell strain are shown<br>
in Table 14.<br><br>
Test example 2 Therapeutic effect of Candida albicans<br>
on mouse systemic infection<br>
Candida albicans TIMM 1623 was cultured at<br>
30Â°C overnight on a Sabouraud agar plate medium (Eiken<br>
Chemical Co., Ltd.), and the obtained culture was<br>
suspended in a sterilized physiological saline<br>
solution. Thus, a fungal solution for infection,<br>
having a concentration of 1 x 107 cells/ml, was<br>
prepared. This fungal solution was inoculated in a<br>
concentration of 0.2 ml (2 x 106 CFU/mouse) into the<br>
tail vein of each of five ICR male mice (4-week-old,<br>
body weight of 20 Â± 1 g). 2 hours later, 0.2 ml of a<br><br>
solution, which had been prepared by dissolving a test<br>
compound into a sterilized physiological saline<br>
solution and setting the concentration at 0.01 mg/ml,<br>
was administered once into the dorsal subcutis of each<br>
mouse. To mice of a control group, an equal amount of<br>
a sterilized physiological saline solution was<br>
administered.<br>
Viability of the mice was observed until the<br>
14th day after the infection, and the cumulative<br>
survival rate (T/C) of the treatment group to the<br>
control group was calculated, and the obtained value<br>
was used as an index of the life-prolonging effect.<br>
As a result, it was found that, in the case<br>
of the compound in Example 24, T/C was 180 with<br>
administration of 0.1 mg/kg.<br>
Test example 3 Therapeutic effect of Candida albicans<br>
on mouse systemic infection<br>
Candida albicans TIMM 1623 was cultured at<br>
30Â°C overnight on a Sabouraud agar plate medium (Eiken<br>
Chemical Co., Ltd.), and the cultured fumgus was<br>
suspended in a sterilized physiological saline<br>
solution. Thus, a fungal solution for infection,<br>
having a concentration of approximately 107 cells/ml,<br>
was prepared. 0.2 ml of this fungal solution was<br>
inoculated into the tail vein of each of five ICR male<br>
mice (4-week-old, body weight of 20 Â± 1 g). 2 hours<br>
after the infection, 0.2 ml of a solution, which had<br><br>
been prepared by dissolving a test compound into a<br>
sterilized physiological saline solution and adjusting<br>
the concentration at 0.01 mg/ml, was administered once<br>
into the dorsal subcutis of each mouse. From the<br>
following day, the same solution was administered<br>
thereto once a day for 6 days. Thus, the above<br>
solution was administered into the dorsal subcutis of<br>
the mice 7 times in total. To mice of a control group,<br>
an equal amount of a sterilized physiological saline<br>
solution was administered. Viability of the mice was<br>
observed until the 28th day after the infection.<br>
As a result, it was found that the mice of<br>
the control group all died by the 28th day after the<br>
infection, but that the mice of the compound<br>
administration groups in Example 24, Example 40-2, and<br>
Example 56 survived at a ratio of 3/5, 4/5, and 4/5,<br>
respectively.<br>
EXAMPLES<br>
The present invention will be described below<br>
in the following reference examples and examples.<br>
However, these examples are not intended to limit the<br>
scope of the present invention.<br>
It is to be noted that mixing ratios of<br>
eluents all represented volume ratios, and that B.W.<br>
silica gel BW-127ZH (manufactured by Fuji Silysia<br>
Chemical Ltd.) was used as a carrier in column<br>
chromatography, unless otherwise specified.<br><br>
The symbols in each example represent the<br>
following meanings:<br>
d6-DMSO: deuterated dimethyl sulfoxide<br>
Me: methyl<br>
Et: ethyl<br>
Bn: benzyl<br>
Ac: acetyl<br>
Cbz: benzyloxycarbonyl<br>
Boc: tert-butoxycarbonyl<br>
Reference example 1<br><br>
2.78 g of 4-cyanophenol was dissolved in 40<br>
ml of 2-butanone, and then, 3.23 g of potassium<br>
carbonate and 5.00 g of 1,4-dibromo-2-butene were added<br>
thereto at room temperature, followed by stirring at<br>
70Â°C for 4 hours. Insoluble products were removed by<br>
filtration with Celite, and thereafter, the solvent was<br>
removed under reduced pressure. The obtained residue<br>
was then purified by silica gel column chromatography<br>
[eluent; n-hexane : ethyl acetate =5:1] to obtain<br>
2.49 g of a colorless oil product, 4-{[(E)-4-bromo-2-<br>
butenyl]oxy}benzonitrile.<br>
1H-NMR (CDC13) d: 3.99 (2H, dd, J = 7.3, 0.7 Hz), 4.61<br>
(2H, dd, J = 5.1, 0.7 Hz), 5.92-6.02 (1H, m), 6.08 (1H,<br>
dtt, J = 15.4, 7.3 ,0.7 Hz), 6.92-6.98 (2H, m), 7.56-<br><br>
7.62 (2H, m)<br>
Reference example 2<br><br>
0.79 g of 1-(2,4-dimethoxybenzyl)-2,3-<br>
piperazinedione was dissolved in 9.0 ml of N,N-<br>
dimethylformamide, and 0.12 g of 60% sodium hydride was<br>
added thereto while cooled by ice, followed by stirring<br>
at room temperature for 2 hours. While cooled by ice,<br>
6.0 ml of an N,N-dimethylformamide solution containing<br>
0.84 g of 4-(4-bromobutoxy)benzonitrile was added<br>
dropwise thereto, followed by stirring at room<br>
temperature for 75 minutes. 30 ml of water and 30 ml<br>
of chloroform were added to the reaction mixture, so<br>
that the organic layer was separated. The separated<br>
organic layer was washed successively with water, and<br>
with a saturated aqueous solution of sodium chloride,<br>
and then dried over anhydrous magnesium sulfate.<br>
Thereafter, the solvent was removed under reduced<br>
pressure. The obtained residue was then purified by<br>
silica gel column chromatography [eluent; chloroform :<br>
methanol = 20 : 1] to obtain 1.16 g of a white solid,<br>
4-{4-[4-(2,4-dimethoxybenzyl)-2,3-dioxo-1-<br>
piperazinyl]butoxy}benzonitrile.<br>
1H-NMR (CDCl3) d: 1.70-1.90 (4H, m) , 3.42-3.48 (4H, m) ,<br>
3.53 (2H, t, J = 6.8 Hz), 3.80 (3H, s), 3.81 (3H, s),<br><br>
4.03 (2H, t, J = 5.7 Hz), 4.63 (2H, s), 6.42-6.48 (2H,<br>
m), 6.90-6.94 (2H, m) , 7.24-7.28 (1H, m), 7.50-7.59<br>
(2H, m)<br>
Reference example 3<br><br>
1.09 g of 4-{4-[4-(2,4-dimethoxybenzyl)-2,3-<br>
dioxo-1-piperazinyl]butoxy}benzonitrile was suspended<br>
in 2.5 ml of anisole, and 12.5 ml of trifluoroacetic<br>
acid was added thereto at room temperature, followed by<br>
heating to reflux for 2 hours. After completion of the<br>
reaction, the solvent was removed under a reduced<br>
pressure, and the obtained residue was then purified by<br>
silica gel column chromatography [eluent; chloroform :<br>
ethanol = 30 : 1] to obtain 0.30 g of a white solid, 4-<br>
[4-(2,3-dioxo-1-piperazinyl)butoxy]benzonitrile.<br>
1H-NMR (CDCl3) d: 1.76-1.88 (4H, m) , 3.54-3.62 (6H, m) ,<br>
4.05 (2H, t, J = 5.6 Hz), 6.90-6.96 (2H, m), 7.50-7.60<br>
(2H, m), 8.46 (1H, brs)<br>
Reference example 4<br><br>
The following compound was obtained in the<br><br>
same manner as Reference examples 2 and 3.<br>
4-[2-(2, 3-dioxo-1-piperazinyl)ethoxy]benzonitrile<br>
1H-NMR (CDCl3) 8: 3.55-3.60 (2H, m) , 3.75-3.82 (2H, m) ,<br>
3.91 (2H, t, J = 5.0 Hz), 4.27 (2H, t, J = 5.0 Hz),<br>
6.91-6.96 (2H, m), 7.47 (1H, brs), 7.57-7.63 (2H, m)<br>
Reference example 5<br><br>
0.50 g of 4-(4-bromobutoxy)benzonitrile was<br>
dissolved in 5 ml of ethanol. Thereafter, 1.1 g of 6-<br>
aminohexanoic acid methyl ester hydrochloride and 1.4<br>
ml of triethylamine were successively added to the<br>
solution, followed by heating to reflux for 4 hours.<br>
After completion of the reaction, the mixture was<br>
cooled to room temperature, and the solvent was removed<br>
under a reduced pressure. 20 ml of water was added to<br>
the obtained residue, and then, extraction was carried<br>
out with 20 ml of ethyl acetate 5 times. The obtained<br>
organic layer was dried over anhydrous magnesium<br>
sulfate, and the solvent was then removed under reduced<br>
pressure. The obtained residue was purified by silica<br>
gel column chromatography [eluent; chloroform :<br>
methanol = 30 : 1] to obtain 0.65 g of a colorless oil<br>
product, 6-{[4-(4-cyanophenoxy)butyl]amino}hexanoic<br>
acid methyl ester.<br>
1H-NMR (CDCl3) d: 1.35-1.45 (2H, m) , 1.58-1.70 (2H, m),<br>
1.84-2.00 (4H, m), 2.05-2.20 (2H, m), 2.30 (2H, t, J =<br><br>
7.2 Hz), 2.90-3.10 (4H, m), 3.66 (3H, s), 4.02 (2H, t,<br>
J = 5.9 Hz), 6.90-6.96 (2H, m) , 7.55-7.60 (2H, m), 9.41<br>
(1H, brs).<br>
Reference example 6<br><br>
0.80 g of 4-(4-bromobutoxy)benzonitrile was<br>
dissolved in 8.0 ml of dimethyl sulfoxide, and 0.23 g<br>
of sodium azide was added thereto, followed by stirring<br>
at room temperature for 12 hours. 30 ml of water and<br>
20 ml of ethyl acetate were added to the reaction<br>
mixture, so that the organic layer was separated. The<br>
separated organic layer was washed with a saturated<br>
aqueous solution of sodium chloride, and then dried<br>
over anhydrous magnesium sulfate. The solvent was<br>
removed under a reduced pressure to obtain 0.71 g of a<br>
colorless oil product, 4-(4-azidobutoxy)benzonitrile.<br>
IR(neat)cm-1: 2224, 2098, 1606<br>
1H-NMR (CDCl3) d: 1.74-1.96 (4H, m) , 3.38 (2H, t, J =<br>
6.6 Hz), 4.04 (2H, t, J = 6.1 Hz), 6.90-6.98 (2H, m) ,<br>
7.56-7.62 (2H, m)<br>
Reference example 7<br><br>
2.19 g of 4-[3-(2,3-dioxo-1-piperazinyl)-<br><br>
propoxy]-benzonitrile was dissolved in 24.0 ml of N,N-<br>
dimethylformamide, and 0.32 g of 60% sodium hydride was<br>
added thereto, followed by stirring at room temperature<br>
for 1 hour. While cooled by ice, 8.0 ml of N,N-<br>
dimethylformamide solution containing 1.92 g of 4-(3-<br>
bromo-propoxy)-benzonitrile was added dropwise thereto,<br>
followed by stirring at room temperature for 3 hours.<br>
30 ml of water and 30 ml of chloroform were added to<br>
the reaction mixture, and the mixture was adjusted to<br>
pH 1 with 1 mol/L hydrochloric acid. Thereafter, the<br>
organic layer was separated. The obtained organic<br>
layer was washed successively with water and with a<br>
saturated aqueous solution of sodium chloride, and then<br>
dried over anhydrous magnesium sulfate. The solvent<br>
was removed under a reduced pressure to obtain 3.30 g<br>
of a white solid, 4-(3-{4-[3-(4-cyanophenoxy)propyl]-<br>
2,3-dioxo-1-piperazinyl}propoxy)benzonitrile.<br>
IR(KBr)cm-1: 2222, 1660, 1603<br>
1H-NMR (d6-DMSO) d: 1.96-2.03 (4H, m), 3.50 (4H, t, J=<br>
6.8 Hz), 3.55 (4H, s), 4.09 (4H, t, J = 6.1 Hz), 7.07-<br>
7.11 (4H, m), 7.74-7.78 (4H, m)<br>
Reference example 8<br><br>
The following compound was obtained in the<br>
same manner as Reference example 1.<br><br>
4- (3-chloropropoxy)-3-methylbenzonitrile<br>
1H-NMR (CDCl3) d: 2.22 (3H, s), 2.28-2.32 (2H, m), 3.77<br>
(2H, t, J = 6.4 Hz), 4.18 (2H, t, J = 5.9 Hz), 6.87<br>
(1H, d, J = 8.4 Hz), 7.40-7.50 (2H, m)<br>
Reference example 9<br><br>
The following compound was obtained in the<br>
same manner as Reference example 1.<br>
4-(3-bromopropoxy)-3-methoxybenzonitrile<br>
1H-NMR (CDCl3) d: 2.37-2.43 (2H, m) , 3.63 (2H, t, J =<br>
6.3 Hz), 3.88 {3H, s), 4.21 (2H, t, J = 6.0 Hz), 6.93<br>
(1H, d, J = 8.3 Hz), 7.09 (1H, d, J = 1.7 Hz), 7.26-<br>
7.29 (1H, m)<br>
Reference example 10<br><br>
The following compound was obtained in the<br>
same manner as Reference example 1.<br>
4-(3-bromopropoxy)-2-fluorobenzonitrile<br>
1H-NMR (CDCl3) d: 2.32-2.38 (2H, m) , 3.59 (2H, t, J =<br>
6.3 Hz), 4.17 (2H, t, J = 5.9 Hz), 6.72-6.80 (2H, m),<br>
7.53 (1H, d-d, J = 7.6, 8.5 Hz)<br>
Reference example 11<br><br><br>
The following compound was obtained in the<br>
same manner as Reference example 1.<br>
4'-(3-chloropropoxy)[1,1'-biphenyl]-4-carbonitrile<br>
1H-NMR (CDCl3) d: 2.24-2.30 (2H, m) , 3.77 (2H, t, J =<br>
6.4 Hz), 4.17 (2H, t, J = 5.8 Hz), 6.99-7.02 (2H, m) ,<br>
7.51-7.55 (2H, m), 7.62-7.69 (4H, m)<br>
Reference example 12<br><br>
The following compound was obtained in the<br>
same manner as Reference example 1.<br>
4-{ [ (E)-4-chloro-2-butenyl]oxy}benzonitrile<br>
1H-NMR (CDCl3) d: 4.10-4.11 (2H, m) , 4.60-4.61 (2H, m) ,<br>
6.00-6.03 (2H, m), 6.94-6.97 (2H, m), 7.57-7.61 (2H, m)<br>
Reference example 13<br><br>
The following compound was obtained in the<br>
same manner as Reference example 1.<br>
4-(3-chloro-2-methylpropoxy)benzonitrile<br>
1H-NMR (CDCl3) d: 1.16 (3H, d, J = 6.8 Hz), 2.35-2.42<br>
(1H, m), 3.63-3.72 (2H, m), 3.95-4.03 (2H, m), 6.95-<br><br>
6.97 (2H, m), 7.58-7.60 (2H, m)<br>
Reference example 14<br><br>
The following compound was obtained in the<br>
same manner as Reference example 1.<br>
4-[2-(benzyloxy)-3-bromopropoxy]benzonitrile<br>
1H-NMR (CDCl3) 6: 3.56-3.65 (2H, m), 3.97-4.02 (1H, m),<br>
4.14-4.21 (2H, m), 4.66, 4.76 (2H, ABq, J = 12.0 Hz),<br>
6.92-6.96 (2H, m), 7.31-7.37 (5H, m), 7.56-7.60 (2H, m)<br>
Reference example 15<br><br>
9.45 g of 4-aminobenzonitrile was suspended<br>
in 20.3 ml of 1,3-dibromopropane, and 21.0 ml of N,N-<br>
diisopropylethylamine was added thereto, followed by<br>
stirring at 110Â°C for 2 hours. After completion of the<br>
reaction, chloroform, water, and a saturated sodium<br>
bicarbonate solution were added to the reaction<br>
solution. Thereafter, the organic layer was separated.<br>
The separated organic layer was washed with a saturated<br>
aqueous solution of sodium chloride, and then dried<br>
over anhydrous magnesium sulfate. Thereafter, it was<br>
concentrated under a reduced pressure. The obtained<br>
residue was purified by silica gel column<br><br>
chromatography [eluent; n-hexane : ethyl acetate = 5 :<br>
1] to obtain 5.21 g of a pale yellow solid, 4-[(3-<br>
bromopropyl)amino]benzonitrile.<br>
1H-NMR (CDCl3) d: 2.13-2.20 (2H, m) , 3.39 (2H, t, J =<br>
6.6 Hz), 3.50 (2H, t, J = 6.2 Hz), 4.35 (1H, s), 6.57-<br>
6.61 (2H, m), 7.41-7.44 (2H, m)<br>
Reference example 16<br>
Reference example 16-1<br><br>
3.85 g of ethyl 3-fluoro-4-hydroxybenzoate<br>
was dissolved in 46 ml of acetone, and then, 2.89 g of<br>
potassium carbonate and 3.29 g of 1-bromo-3-<br>
chloropropane were added thereto at room temperature,<br>
followed by stirring under heating reflux for 5 hours.<br>
Thereafter, 1.45 g of potassium carbonate and 1.65 g of<br>
1-bromo-3-chloropropane were further added thereto, and<br>
the obtained mixture was stirred at the same<br>
temperature for 4 hours. Thereafter, the temperature<br>
was cooled to room temperature. The reaction mixture<br>
was filtrated with Celite, and the obtained filtrate<br>
was concentrated under a reduced pressure. The<br>
obtained residue was purified by silica gel column<br>
chromatography [eluent; n-hexane : ethyl acetate = 10 :<br>
1] to obtain 4.04 g of a colorless oil product, ethyl<br>
4-(3-chloropropoxy)-3-fluorobenzoate.<br>
1H-NMR (CDCl3) d: 1.38 (3H, t, J = 7.1 Hz), 2.27-2.33<br><br>
(2H, m), 3.78 (2H, t, J = 6.2 Hz), 4.25 (2H, t, J = 5.8<br>
Hz), 4.35 (2H, q, J = 7.1 Hz), 6.70 (1H, t, J = 8.4<br>
Hz), 7.74-7.82 (2H, m)<br>
Reference example 16-2<br><br>
4.00 g of ethyl 4-(3-chloropropoxy)-3-<br>
fluorobenzoate was dissolved in 40 ml of<br>
tetrahydrofuran, and then, while cooled by ice, 0.70 g<br>
of lithium aluminum hydride was added thereto dividedly<br>
3 times. The mixture was stirred at the same<br>
temperature for 1.5 hours. Thereafter, ethyl acetate,<br>
and then water were added thereto. The reaction<br>
mixture was filtrated with Celite, so that the organic<br>
layer was separated. The separated organic layer was<br>
dried over anhydrous magnesium sulfate, and then, the<br>
solvent was removed under a reduced pressure to obtain<br>
3.40 g of a colorless oil product, [4-(3-<br>
chloropropoxy)-3-fluorophenyl] methanol.<br>
1H-NMR (CDCl3) d: 1.60-2.00 (1H, br) , 2.23-2.30 (2H, m) ,<br>
3.78 (2H, t, J = 6.2 Hz), 4.19 (2H, t, J = 5.8 Hz),<br>
4.60-4.63 (2H, m), 6.95-7.14 (3H, m)<br>
Reference example 16-3<br><br><br>
3.30 g of [4-(3-chloropropoxy)-3-<br>
fluorophenyl] methanol was dissolved in 33 ml of<br>
chloroform, and 13.1 g of manganese dioxide was added<br>
thereto at room temperature, followed by stirring at<br>
50Â°C to 60Â°C for 2 hours. After cooling to room<br>
temperature, the reaction mixture was filtrated with<br>
Celite, and the obtained filtrate was concentrated<br>
under a reduced pressure to obtain 3.30 g of a pale<br>
yellow oil product, 4-(3-chloropropoxy)-3-<br>
fluorobenzaldehyde.<br>
IR(neat)cm-1: 1690, 1610, 1515, 1442, 1282<br>
Reference example 16-4<br><br>
3.30 g of 4-(3-chloropropoxy)-3-<br>
fluorobenzaldehyde was dissolved in 40 ml of formic<br>
acid, and 1.11 g of hydroxylamine hydrochloride and<br>
2.07 g of sodium formate were added thereto at room<br>
temperature, followed by stirring at 90Â°C to 100Â°C for :<br>
hours. The reaction mixture was concentrated under a<br>
reduced pressure, so that it became approximately one<br>
third of its amount, and then, water and ethyl acetate<br>
were added thereto. Thereafter, sodium carbonate was<br>
added to the mixture for neutralization. The organic<br>
layer was separated, and the separated organic layer<br>
was dried over anhydrous magnesium sulfate. The<br>
solvent was removed under a reduced pressure, and the<br><br>
obtained residue was purified by silica gel column<br>
chromatography [eluent; n-hexane : ethyl acetate = 8 :<br>
1] to obtain 2.87 g of a colorless oil product, 4-(3-<br>
chloropropoxy)-3-fluorobenzonitrile.<br>
1H-NMR (CDCl3) d 2.28-2.34 (2H, m) , 3.77 (2H, t, J =<br>
6.2 Hz), 4.26 (2H, t, J = 5.8 Hz), 7.02-7.07 (1H, m),<br>
7.35-7.44 (2H, m)<br>
Reference example 17<br>
Reference example 17-1<br><br>
0.70 g of 5-methyl-3-hydroxyisoxazole was<br>
dissolved in 10 ml of pyridine, and 1.1 ml of<br>
triethylamine and 0.90 ml of benzenesulfonyl chloride<br>
were added thereto while cooled by ice, followed by<br>
heating to reflux for 1 hour. After cooling to room<br>
temperature, the solvent was removed under a reduced<br>
pressure. 20 ml of water and 30 ml of ethyl acetate<br>
were added to the obtained residue, so that the organic<br>
layer was separated. The aqueous layer was extracted<br>
twice with 20 ml of ethyl acetate. The obtained<br>
organic layer was combined, and then washed with water,<br>
1 mol/L hydrochloric acid, and a saturated sodium<br>
bicarbonate solution, dried over anhydrous magnesium<br>
sulfate, followed by concnetration under a reduced<br>
pressure. The obtained residue was purified by silica<br>
gel column chromatography [eluent; toluene : ethyl<br><br>
acetate = 20 : 1] to obtain 1.50 g of a colorless oil<br>
product, 5-methyl-3-isoxazolyl benzenesulfonate.<br>
1H-NMR (CDCl3) d: 2.40 (3H, d, J = 0.6 Hz), 6.05 (1H, q,<br>
J = 0.6 Hz), 7.56-7.61 (2H, m), 7.70-7.74 (1H, m),<br>
7.97-7.99 (2H, m)<br>
Reference example 17-2<br><br>
10 ml of benzene was added to 1.00 g of 5-<br>
methyl-3-isoxazolyl benzenesulfonate, and then, 1.10 g<br>
of N-bromosuccinimide and 0.05 g of benzoyl peroxide<br>
were added thereto at room temperature, followed by<br>
heating to reflux for 1 hour. 1 hour later, 0.05 g of<br>
benzoyl peroxide was further added thereto, followed by<br>
heating to reflux for 2 hours. Thereafter, 0.05 g of<br>
2,2'-azobis(isobutyronitrile) was added thereto,<br>
followed by heating to reflux for 3 hours. Thereafter,<br>
0.05 g of 2,2'-azobis(isobutyronitrile) was further<br>
added thereto, followed by heating to reflux for 6<br>
hours. After cooling to room temperature, 30 ml of<br>
toluene and 20 ml of water were added to the reaction<br>
mixture, so that the organic layer was separated. The<br>
aqueous layer was extracted twice with 20 ml of<br>
toluene. The combined organic layer was washed with a<br>
saturated aqueous solution of sodium chloride, and then<br>
dried over anhydrous magnesium sulfate, followed by<br>
concentration under reduced pressure. The obtained<br><br>
residue was purified by silica gel column<br>
chromatography [eluent; n-hexane : benzene =1 : 1] to<br>
obtain 0.65 g of a colorless oil product, 5-<br>
(bromomethyl)-3-isoxazolyl benzenesulfonate.<br>
 1H-NMR (CDCl3) d: 4.37 (2H, s), 6.39 (1H, s) , 7.60-7.63<br>
(2H, m) , 7.73-7.74 (1H, m), 7.97-8.00 (2H, m)<br>
Reference example 18<br><br>
The following compound was obtained in the<br>
same manner as Reference example' 6.<br>
4-(2-azidoethoxy)benzonitrile<br>
1H-NMR (CDCl3) d: 3.63-3.66 (2H, m) , 4.18-4.21 (2H, m) ,<br>
6.97-6.99 (2H, m), 7.58-7.62 (2H, m)<br>
Reference example 19<br><br>
The following compound was obtained in the<br>
 same manner as Reference example 6.<br>
4- [ (3-azidopropyl)amino]benzonitrile<br>
1H-NMR (CDCl3) d: 1.87-1.93 (2H, m) , 3.27-3.32 (2H, m) ,<br>
3.46 (2H, t, J = 6.4 Hz), 4.38 (1H, brs), 6.57 (2H, d,<br>
J = 8.8 Hz), 7.43 (2H, d, J = 8.8 Hz)<br>
3 Reference example 20<br><br><br>
The following compound was obtained in the<br>
same manner as Reference example 6.<br>
4-[(3-azidopropyl)sulfanyl]benzonitrile<br>
1H-NMR (CDCl3) d: 1.92-1.98 (2H, m) , 3.08 (2H, t, J =<br>
7.2 Hz), 3.48 (2H, t, J = 6.2 Hz), 7.31-7.34 (2H, m) ,<br>
7.53-7.56 (2H, m)<br>
Reference example 21<br><br>
1.75 g of 4-(2-azidoethoxy)benzonitrile was<br>
dissolved in 15 ml of acetic acid, and 0.36 g of 5%<br>
palladium-carbon was added thereto at room temperature,<br>
followed by stirring under a hydrogen atmosphere at<br>
room temperature under atmospheric pressure for 7<br>
hours. After completion of the reaction, the catalyst<br>
was removed by filtration, and the filtrate was<br>
concentrated under a reduced pressure. Isopropanol was<br>
added to the obtained residue, and the mixture was<br>
filtrated, so as to obtain 1.64 g of a white solid, 4-<br>
(2-aminoethoxy) benzonitrile hydro chloride "nitrile<br>
hydrochloride".<br>
1H-NMR (d6-DMSO) d: 3.22 (2H, t, J = 5.2 Hz), 4.30 (2H,<br>
t, J = 5.2 Hz), 7.14-7.18 (2H, m), 7.79-7.83 (2H, m),<br>
8.40 (2H, brs)<br><br>
Reference example 22<br><br>
2.00 g of 4-(3-bromopropoxy)benzonitrile was<br>
dissolved in 20 ml of dimethyl sulfoxide, and 0.50 g of<br>
sodium azide was added thereto, followed by stirring at<br>
room temperature for 5 hours. Water and ethyl acetate<br>
were added to the reactoin mixture, so that orgnaic<br>
layers were separated. The separated organic layer was<br>
washed with a saturated aqueous solution of sodium<br>
chloride, and then dried over anhydrous magnesium<br>
sulfate. The solvent was then removed under a reduced<br>
pressure. The obtained residue was dissolved in 20 ml<br>
of ethanol, and 0.20 g of 5% palladium-carbon was added<br>
thereto, followed by stirring under a hydrogen<br>
atmosphere at room temperature under atmospheric<br>
pressure for 5 hours. After completion of the<br>
reaction, the catalyst was removed by filtration, and<br>
the filtrate was concentrated under a reduced pressure.<br>
Ethyl acetate and hydrochloric acid were added to the<br>
obtained residue, and aqueous layer was separated.<br>
Organic layers were extracted with water, and they were<br>
combined with the separated aqueous layer, followed by<br>
concentation under a reduced pressure. Water and<br>
chloroform were added to the obtained residue, and<br>
then, a 5 mol/L sodium hydroxide aqueous solution was<br>
added thereto to adjust pH to 12.5. The organic layer<br><br>
was separated, and the separated organic layer was<br>
dried over anhydrous magnesium sulfate. The solvent<br>
was removed under a reduced pressure to obtain 0.96 g<br>
of a pale yellow oil product, 4-(3-<br>
aminopropoxy)benzonitrile.<br>
1H-NMR (CDCl3) d: 1.20-1.60 (2H, br) , 1.92-1.98 (2H, m) ,<br>
2.92 (2H, t, J = 6.7 Hz), 4.11 (2H, t, J = 6.1 Hz),<br>
6.95 (2H, d, J = 8.9 Hz), 7.58 (2H, d, J = 8.9 Hz).<br>
Reference example 23<br>
Reference example 23-1<br>
The following compound was obtained in the<br>
same manner as Reference example 2.<br><br>
4-({3-[4-(2,4-dimethoxybenzyl)-2,3-dioxo-1-<br>
piperazinyl]propyl}amino)benzonitrile<br>
1H-NMR (CDCl3) d: 1.78-1.84 (2H, m) , 3.20-3.25 (2H, m),<br>
3.39 (4H, s), 3.55 (2H, t, J = 6.1 Hz), 3.81 (3H, s),<br>
4.62 (2H, s), 5.22 (1H, t, J = 6.2 Hz), 6.46-6.48 (2H,<br>
m) , 6.52-6.55 (2H, m), 7.25-7.27 (1H, m) , 7.34-7.36<br>
(2H, m)<br>
Reference example 23-2<br>
The following compound was obtained in the<br>
same manner as Reference example 3.<br><br><br>
4-{[3-(2,3-dioxo-1-<br>
piperazinyl) propyl] amino}benzonitrile<br>
1H-NMR (CDCl3) d: 1.84-1.90 (2H, m) , 3.24 (2H, t, J =<br>
6.0 Hz), 3.53-3.57 (4H, m), 3.62 (2H, t, J = 6.2 Hz),<br>
5.12 (1H, brs), 6.56-6.59 (2H, m), 7.17 (1H, brs) ,<br>
7.40-7.42 (2H, m)<br>
Reference example 24<br>
The following compound was obtained in the<br>
same manner as Reference examples 2 and 3.<br><br>
 3-[3-(2,3-dioxo-1-piperazinyl)propoxy]benzonitrile<br>
1H-NMR (CDCl3) d: 2.13-2.17 (2H, m) , 3.56-3.59 (2H, m) ,<br>
3.62-3.64 (2H, m), 3.71 (2H, t, J = 7.1 Hz), 4.05 (2H,<br>
t, J = 5.8 Hz), 7.05 (1H, s), 7.11-7.13 (2H, m), 7.25-<br>
7.26 (1H, m), 7.37-7.39 (1H, m)<br>
5 Reference example 25<br>
Reference example 25-1<br><br>
1.00 g of 4-(3-chloropropoxy)benzonitrile was<br>
dissolved in 20 ml of dimethylformamide, and then, 0.25<br>
g of 60% sodium hydride was added thereto under cooling<br>
on ice. Thereafter, the reaction mixture was warmed to<br><br>
room temperature. 1.50 g of benzyl 5-oxo-1,4-<br>
diazepane-1-carboxylate was added to the mixture,<br>
followed by stirring at 65Â°C to 75Â°C for 2.5 hours. The<br>
reaction mixture was cooled to room temperature, and<br>
poured into a mixed solution consisting of ice water<br>
and ethyl acetate. The mixture was acidified with<br>
hydrochloric acid, and then, the organic layer was<br>
separated. The separated organic layer was washed with<br>
a saturated aqueous solution of sodium chloride, and<br>
then dried over anhydrous magnesium sulfate. The<br>
solvent was removed under a reduced pressure. The<br>
obtained residue was purified by silica gel column<br>
chromatography [eluent; ethyl acetate] to obtain 0.91 g<br>
of a colorless oil product, benzyl 4â€” [3â€” (4 â€”<br>
cyanophenoxy)propyl]-5-oxo-1,4-diazepane-1-carboxylate.<br>
1H-NMR (CDCl3) d: 2.03-2.05 (2H, m), 2.66 (2H, brs),<br>
3.46-3.50 (2H, m), 3.59 (2H, t, J = 6.8 Hz), 3.67 (4H,<br>
s), 4.02 (2H, t, J = 6.2 Hz), 5.14 (2H, s), 6.92 (2H,<br>
d, J = 8.8 Hz), 7.32-7.38 (5H, m), 7.57 (2H, d, J = 8.8<br>
Hz)<br>
Reference example 25-2<br><br>
0.62 g of benzyl 4-[3-(4-<br>
cyanophenoxy)propyl]-5-oxo-1,4-diazepane-1-carboxylate<br>
was dissolved in a mixed solution consisting of 13.0 ml<br><br>
of ethanol and 4.5 ml of N,N-dimethylformamide, and<br>
then, 0.32 g of 5% palladium-carbon was added thereto,<br>
followed by stirring under a hydrogen atmosphere at<br>
room temperature under atmosphere pressure for 4 hours.<br>
After completion of the reaction, the catalyst was<br>
removed by filtration, and the filtrate was<br>
concentrated under a reduced pressure to obtain 0.44 g<br>
of a yellow oil product, 4-[3-(7-oxo-1,4-diazepan-1-<br>
yl)propoxy]benzonitrile.<br>
1H-NMR (CDCl3) d: 2.00-2.08 (2H, m) , 2.65-2.67 (2H, m) ,<br>
2.93-2.98 (4H, m) , 3.44-3.46 (2H, m) , 3.57 (2H, t, J =<br>
7.2 Hz), 4.04 (2H, t, J = 6.2 Hz), 6.93-6.96 (2H, m) ,<br>
7.57-7.60 (2H, m)<br>
Reference example 26<br><br>
1.70 g of homopiperazine was dissolved in 20<br>
ml of N,N-dimethylformamide, and then, 1.60 g of<br>
potassium carbonate and 1.00 g of 4-(3-<br>
bromopropoxy)benzonitrile were added thereto, followed<br>
by stirring at room temperature for 12 hours. A 1<br>
mol/L sodium hydroxide aqueous solution and chloroform<br>
were added to the reaction mixture, so that organic<br>
layer was separated. The separated organic layer was<br>
dried over anhydrous magnesium sulfate, and then, the<br>
solvent was removed under a reduced pressure. The<br>
obtained oil product was purified by silica gel column<br><br>
chromatography [eluent; chloroform : methanol =5:1]<br>
to obtain 1.00 g of a colorless oil product, 4-[3-(1,4-<br>
diazepan-1-yl)propoxy]benzonitrile.<br>
1H-NMR (CDCl3) d: 1.50-1.70 (1H, m) , 1.73-1.79 (1H, m),<br>
1.93-2.00 (1H, m) , 2.66-2.73 (6H, m), 2.90-2.95 (4H,<br>
m), 4.08 (2H, t, J = 6.4 Hz), 6.94-6.97 (2H, m), 7.56-<br>
7.59 (2H, m)<br>
Reference example 27<br><br>
The following compound was obtained in the<br>
same manner as Reference example 26.<br>
4-[3-(3-oxo-1-piperazinyl)propoxy]benzonitrile<br>
1H-NMR (CDCl3) d: 1.97-2.03 (2H, m) , 2.62 (2H, t, J =<br>
7.0 Hz), 2.67-2.69 (2H, m), 3.16 (2H, s), 3.35-3.39<br>
(2H, m), 4.08 (2H, t, J = 6.4 Hz), 6.65 (1H, brs),<br>
6.93-6.96 (2H, m), 7.56-7.60 (2H, m)<br>
Reference example 28<br>
Reference example 28-1<br><br>
1.44 g of 4-tert-<br>
butoxycarbonylaminopiperidine was dissolved in 14 ml of<br>
N,N-dimethylformamide. Thereafter, 1.99 g of potassium<br>
carbonate and 1.87 g of 4-(3-bromopropoxy)benzonitrile<br><br>
were successively added to the above solution, followed<br>
by stirring at room temperature for 24 hours. Water<br>
and ethyl acetate were added to the reaction mixture,<br>
so that the organic layer was separated. The separated<br>
organic layer was washed with a saturated aqueous<br>
solution of sodium chloride, and then dried over<br>
anhydrous magnesium sulfate. Thereafter, the solvent<br>
was removed under a reduced pressure. The obtained<br>
solid was filtrated with a mixed solution consising of<br>
n-hexane and diisopropyl ether to obtain 2.12 g of<br>
tert-butyl 1- [3-(4-cyanophenoxy)propyl]-4-<br>
piperidinylcarbamate.<br>
1H-NMR (CDCl3) d: 1.38-1.45 (2H, m) , 1.45 (9H, s), 1.92-<br>
2.11 (6H, m), 2.49 (2H, t, J = 7.2 Hz), 2.82-2.85 (2H,<br>
m) , 3.40-3.60 (1H, m), 4.05 (2H, t, J = 6.2 Hz), 4.30-<br>
4.50 (1H, m), 6.92-6.95 (2H, m) , 7.56-7.59 (2H, m)<br>
Reference example 28-2<br><br>
2.12 g of tert-butyl 1- [3-(4-<br>
cyanophenoxy)propyl]-4-piperidinylcarbamate was<br>
dissolved in 20 ml of 6 mol/L hydrochloric acid,<br>
followed by stirring at room temperature for 3 days.<br>
The reaction mixture was concentrated under a reduced<br>
pressure, and then, water and chloroform were added to<br>
the obtained solid. Thereafter, the mixture was<br>
adjusted to pH 13.0 with a 5 mol/L sodium hydroxide<br><br>
aqueous solution. The organic layer was separated, and<br>
then the water layer was extracted with chloroform 4<br>
times. The combined organic layer was dried over<br>
anhydrous magnesium sulfate, and then concentrated<br>
5 under a reduced pressure to obtain 1.64 g of a white<br>
solid, 4-[3-(4-amino-1-<br>
piperidinyl)propoxy]benzonitrile.<br>
1H-NMR (CDCl3) d: 1.00-1.70 (4H, m) , 1.78-1.85 (2H, m) ,<br>
1.95-2.05 (4H, m), 2.49 (2H, t, J = 7.2 Hz), 2.63-2.70<br>
(1H, m) , 2.82-2.90 (2H, m), 4.06 (2H, t, J = 6.3 Hz),<br>
6.93-6.96 (2H, m), 7.56-7.59 (2H, m)<br>
Reference example 29<br>
Reference example 29-1<br><br>
The following compound was obtained in the<br>
same manner as Reference example 28-1.<br>
tert-butyl 1-[3-(4-cyanophenoxy)propyl]-3-<br>
pyrrolidinylcarbamate<br>
1H-NMR (CDCl3) d: 1.44 (9H, s), 1.52-1.65 (2H, m), 1.95-<br>
2.01 (2H, m) , 2.10-2.38 (2H, m) , 2.52-2.64 (1H, m) ,<br>
2.59 (2H, t, J = 6.7 Hz), 2.70-2.90 (1H, m), 4.07 (2H,<br>
t, J = 6.7 Hz), 4.10-4.20 (1H, m), 4.74-4.84 (1H, m),<br>
6.94 (2H, d, J = 8.8 Hz), 7.58 (2H, d, J = 8.8 Hz)<br>
Reference example 29-2<br><br><br>
The following compound was obtained in the<br>
same manner as Reference example 28-2.<br>
4-[3-(3-amino-1-pyrrolidinyl)propoxy]benzonitrile<br>
1H-NMR (CDCl3) d: 1.36-1.75 (3H, m) , 1.96-2.05 (2H, m) ,<br>
2.12-2.24 (1H, m) , 2.32-2.35 (1H, m), 2.44-2.50 (1H,<br>
m), 2.52-2.67 (2H, m), 2.67-2.80 (2H, m), 3.48-3.56<br>
(1H, m), 4.08 (2H, t, J = 6.3 Hz), 6.94 (2H, d, J = 8.8<br>
Hz), 7.57 (2H, d, J = 8.8 Hz)<br>
Reference example 30*******************<br><br>
	The following compound was obtained in the<br>
same manner as Reference example 28.<br>
3-methoxy-4-[3-(1-piperazinyl)propoxy]benzonitrile<br>
hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.10-2.30 (2H, m) , 3.10-3.90 (10H,<br>
 m), 3.82 (3H, s), 4.16 (2H, t, J = 6.0 Hz), 7.14 (1H,<br>
d, J = 9.0 Hz), 7.42-7.44 (2H, m) , 9.40-9.70 (3H, br)<br>
Reference example 31<br>
Reference example 31-1<br><br>
0.75 g of 4-amino-1-benzylpiperidine was<br><br>
dissolved in 6.0 ml of N,N-dimethylformamide, and then,<br>
0.90 g of potassium carbonate and 0.85 g of 4-(3-<br>
bromopropoxy)benzonitrile were added thereto, followed<br>
by stirring at room temperature for 3 days. Water,<br>
chloroform, and potassium carbonate were added to the<br>
reaction mixture, so that the organic layer was<br>
separated. Thereafter, the aqueous layer was extracted<br>
with chloroform. The combined organic layer was dried<br>
over anhydrous magnesium sulfate, and the solvent was<br>
then removed under a reduced pressure. The obtained<br>
oil product was dissolved in 10 ml of chloroform, and<br>
then, 1.0 ml of triethylamine and 0.85 g of di-tert-<br>
butyl dicarbonate were added thereto, followed by<br>
stirring at room temperature for 12 hours. This<br>
reaction mixture was concentrated under a reduced<br>
pressure. The obtained oil product was purified by<br>
silica gel column chromatography [eluent; n-hexane :<br>
ethyl acetate = 1 : 1] to obtain 1.56 g of a colorless<br>
oil product, tert-butyl 1-benzyl-4-piperidinyl[3-(4-<br>
cyanophenoxy)propyl]carbamate.<br>
1H-NMR (CDCl3) d: 1.45 (9H, s), 1.50-1.80 (4H, m) , 1.80-<br>
2.12 (5H, m), 2.90-2.96 (2H, m), 3.29 (2H, brs), 3.49<br>
(2H, s), 4.00 (2H, t, J = 6.1 Hz), 6.90-6.94 (2H, m),<br>
7.20-7.40 (5H, m), 7.54-7.60 (2H, m)<br>
Reference example 31-2<br><br><br>
1.56 g of tert-butyl 1-benzyl-4-<br>
piperidinyl[3-(4-cyanophenoxy)propyl]carbamate was<br>
dissolved in 20 ml of methanol, and then, 0.30 g of 5%<br>
palladium-carbon was added to the solution, followed by<br>
stirring under a hydrogen atmosphere at room<br>
temperature under an atmospheric pressure for 18 hours.<br>
After completion of the reaction, the catalyst was<br>
removed, and the solvent was then removed under a<br>
reduced pressure to obtain 1.05 g of tert-butyl 3-(4-<br>
cyanophenoxy)propyl(4-piperidinyl)carbamate.<br>
1H-NMR (CDCl3) d: 1.44 (9H, s), 1.50-2.30 (8H, m) , 2.82-<br>
2.94 (2H, m), 3.26-3.34 (2H, m), 3.46-3.54 (1H, m) ,<br>
4.01 (2H, t, J = 6.2 Hz), 6.93-7.00 (2H, m) , 7.54-7.60<br>
(2H, m)<br>
Reference example 32<br>
Reference example 32-1<br><br>
4.91 g of tert-butyl 4-(2-bromoethyl)-1-<br>
piperidinecarboxylate was dissolved in 50 ml of 2-<br>
butanone, and then, 2.00 g of 4-cyanophenol and 4.64 g<br>
of potassium carbonate were added thereto, followed by<br>
heating to reflux for 4 hours. After cooling to room<br>
temperature, 50 ml of water and 50 ml of ethyl acetate<br>
were added to the reaction mixture, so that the organic<br>
layer was separated. The separated organic layer was<br>
washed with saturated aqueous solution of sodium<br><br>
chloride dried over anhydrous magnesium sulfate, and<br>
the solvent was then removed under a reduced pressure.<br>
The obtained residue was purified by silica gel column<br>
chromatography [eluent; n-hexane : ethyl acetate = 2 :<br>
1] to obtain 3.61 g of a colorless oil product, tert-<br>
butyl 4-[2-(4-cyanophenoxy)ethyl]-1-<br>
piperidinecarboxylate.<br>
1H-NMR (CDCl3) d: 1.00-1.30 (2H, m) , 1.46 (9H, s), 1.50-<br>
2.04 (5H, m), 2.62-2.76 (2H, m), 4.05 (2H, t, J = 6.2<br>
Hz), 4.00-4.18 (2H, m), 6.93 (2H, d, J = 8.5 Hz), 7.58<br>
(2H, d, J = 8.5 Hz)<br>
Reference example 32-2<br><br>
The following compound was obtained in the<br>
same manner as Reference example 28-2.<br>
4- [2- (4-piperidinyl)ethoxy]benzonitrile<br>
1H-NMR (CDCl3) d: 1.16-1.27 (2H, m) , 1.60-1.78 (5H, m) ,<br>
1.80-2.05 (1H, m), 2.59-2.66 (2H, m) , 3.08-3.11 (2H,<br>
m), 4.05 (2H, t, J = 6.3 Hz), 6.91-6.95 (2H, m), 7.56-<br>
7.59 (2H, m)<br>
Reference example 33<br><br><br>
hydrochloride was suspended in 16 ml of N,N-<br>
dimethylformamide, and then, 3.75 g of triethylamine<br>
and 1.21 g of 4-(2-bromoethoxy)benzonitrile were added<br>
thereto at room temperature, followed by stirring at<br>
50Â°C to 60Â°C for 9 hours. After cooling to room<br>
temperature, water and chloroform were added to the<br>
reaction mixture, and potassium carbonate was then<br>
added thereto, so that the solution was converted into<br>
alkaline. Thereafter, the organic layer was separated.<br>
The separated organic layer was washed with saturated<br>
aqueous solution of sodium chloride, and then dried<br>
over anhydrous magnesium sulfate. The solvent was<br>
removed under a reduced pressure, and the obtained<br>
residue was purified by silica gel column<br>
chromatography [eluent; chloroform : ethanol =10 : 1].<br>
The obtained solid was filtrated with toluene-ethyl<br>
acetate to obtain 0.36 g of a white solid, 4-(2-{[2-(4-<br>
cyanophenoxy)ethyl]amino}ethoxy)benzonitrile.<br>
1H-NMR (CDCl3) d: 3.13 (4H, t, J = 5.1 Hz), 4.15 (4H, t,<br>
J = 5.1 Hz), 6.96 (4H, d, J = 8.6 Hz), 7.58 (4H, d, J =<br>
8.6 Hz)<br>
Reference example 34<br><br>
The following compound was obtained in the<br>
same manner as Reference example 33.<br><br>
4-(3-{ [3-(4-<br>
cyanophenoxy)propyl]amino}propoxy)benzonitrile<br>
1H-NMR (CDCl3) d: 2.10-2.20 (4H, m) , 2.96 (4H, t, J =<br>
7.0 Hz), 4.12 (4H, t, J = 6.2 Hz), 6.92-6.95 (4H, m) ,<br>
7.55-7.58 (4H, m)<br>
Reference example 35<br><br>
The following compound was obtained in the<br>
same manner as Reference example 33.<br>
4-(3-{ [6-(4-<br>
cyanophenoxy)hexyl]amino}propoxy)benzonitrile<br>
1H-NMR (CDCl3) d: 1.38-1.58 (7H, m) , 1.77-1.84 (2H, m) ,<br>
1.97-2.03 (2H, m), 2.64 (2H, t, J = 7.4 Hz), 2.81 (2H,<br>
t, J = 6.8 Hz), 3.99 (2H, t, J = 6.4 Hz), 4.09 (2H, t,<br>
J = 6.2 Hz), 6.91-6.95 (4H, m), 7.56-7.60 (4H, m)<br>
Reference example 36<br><br>
The following compound was obtained in the<br>
same manner as Reference example 7.<br>
4-[ (6-{4-[3-(4-cyanophenoxy)propyl]-2, 3-dioxo-1-<br>
piperazinyl}hexyl)oxy]benzonitrile<br>
1H-NMR (CDCl3) d: 1.30-1.68 (6H, m), 1.74-1.90 (2H, m) ,<br><br>
2.10-2.20 (2H, m), 3.44-3.62 (6H, m), 3.67 (2H, t, J =<br>
7.0 Hz), 3.99 (2H, t, J = 6.2 Hz), 4.07 (2H, t, J = 6.2<br>
Hz), 6.91-6.94 (4H, m), 7.56-7.59 (4H, m)<br>
Reference example 37<br><br>
The following compound was obtained in the<br>
same manner as Reference example 7.<br>
3-(3-{4-[3-(4-cyanophenoxy)propyl]-2, 3-dioxo-1-<br>
piperazinylJpropoxy)benzonitrile<br>
1H-NMR (d6-DMSO) d: 1.94-2.04 (4H, m) , 3.46-3.58 (8H,<br>
m) , 4.02-4.12 (4H, m), 7.09 (2H, d, J = 8.4 Hz), 7.24-<br>
7.54 (4H, m), 7.76 (2H, d, J = 8.4 Hz).<br>
Reference example 38<br><br>
The following compound was obtained in the<br>
same manner as Reference example 7.<br>
4-[(3-{4-[3-(4-cyanophenoxy)propyl]-2,3-dioxo-1-<br>
piperazinyl}propyl)amino]benzonitrile<br>
1H-NMR (d6-DMSO) d: 1.75-1.82 (2H, m), 1.96-2.02 (2H,<br>
m), 3.06-3.11 (2H, m), 3.42 (2H, t, J = 7.2 Hz), 3.49-<br>
3.53 (6H, m), 4.09 (2H, t, J = 6.4 Hz), 6.63 (2H, d, J<br>
= 8.8 Hz), 6.67 (1H, t, J = 5.2 Hz), 7.09 (2H, d, J =<br>
8.8 Hz), 7.44 (2H, d, J = 8.8 Hz), 7.76 (2H, d, J = 8.8<br><br>
Hz)<br>
Reference example 39<br><br>
The following compound was obtained in the<br>
same manner as Reference example 7.<br>
4- [(3-{4-[3-(4-cyanoanilino)propyl]-2,3-dioxo-1-<br>
piperazinyl}propyl)amino]benzonitrile<br>
1H-NMR (d6-DMSO) d: 1.75-1.82 (4H, m) , 3.07-3.11 (4H,<br>
m) , 3.42 (4H, t, J = 7.1 Hz), 3.52 (4H, s), 6.63 (4H,<br>
d, J = 8.8 Hz), 6.67 (2H, t, J = 5.4 Hz), 7.44 (4H, d,<br>
J = 8.8 Hz)<br>
Reference example 40<br><br>
The following compound was obtained in the<br>
same manner as Reference example 7.<br>
4-(3-{4-[3-(4-cyanophenoxy)propyl]-2-oxo-1-<br>
piperazinyl}propoxy)benzonitrile<br>
1H-NMR (CDCl3) d: 1.96-2.13 (4H, m) , 2.59 (2H, t, J =<br>
7.0 Hz), 2.71 (2H, t, J = 5.4 Hz), 3.15 (2H, s), 3.37<br>
(2H, t, J = 5.4 Hz), 3.57 (2H, t, J = 7.0 Hz), 4.04-<br>
4.09 (4H, m), 6.93-6.95 (4H, m), 7.56-7.59 (4H, m)<br>
Reference example 41<br><br><br>
0.15 g of 2,3-piperazinedione was suspended<br>
in 6.5 ml of N,N-dimethylformamide, and then, 0.11 g of<br>
60% sodium hydride was added thereto under cooling on<br>
ice, followed by stirring for 20 minutes. The reaction<br>
mixture was warmed to room temperature, and 0.91 g of<br>
4- [2-(benzyloxy)-3-bromopropoxy]benzonitrile was added<br>
thereto, followed by stirring for 7.5 hours.<br>
Thereafter, 6.5 ml of dimethyl sulfoxide was added to<br>
the reaction mixture, and the mixture was left<br>
overnight. 20 ml of water and 20 ml of ethyl acetate<br>
were added to the reaction mixture, so that the organic<br>
layer was separated. The aqueous layer was extracted<br>
with 20 ml of ethyl acetate 3 times. The organic<br>
layers were combined, and the thus obtained layer was<br>
washed with a saturated aqueous solution of sodium<br>
chloride and then dried over anhydrous magnesium<br>
sulfate. Thereafter, the resultant solution was<br>
concentrated under a reduced pressure. The obtained<br>
residue was purified by silica gel column<br>
chromatography [eluent; n-hexane : ethyl acetate = 1 :<br>
2] to obtain 0.58 g of a white solid, 4-(2-(benzyloxy)-<br>
3-{4-[2-(benzyloxy)-3-(4-cyanophenoxy)propyl]-2,3-<br>
dioxo-1- piperazinyl}propoxy)benzonitrile.<br>
1H-NMR (CDCl3) d: 3.41-3.58 (6H, m) , 3.78-3.86 (2H, m) ,<br>
4.00-4.06 (2H, m), 4.14-4.19 (4H, m), 4.57-4.75 (4H,<br><br>
m) , 6.93-6.95 (4H, m), 7.27-7.33 (10H, m), 7.57-7.59<br>
(4H, m) .<br>
Reference example 42<br><br>
0.97 g of 4- [3-(1,4-diazepan-1-<br>
yl)propoxy]benzonitrile was dissolved in 10 ml of N,N-<br>
dimethylformamide, and then, 1.03 g of potassium<br>
carbonate and 0.97 g of 4-(3-bromopropoxy)benzonitrile<br>
were added thereto, followed by stirring at room<br>
temperature for 12 hours. Water and ethyl acetate were<br>
added to the reaciton mixture, so that the organic<br>
layer was separated. The organic layer was dried over<br>
anhydrous magnesium sulfate, and the solvent was then<br>
removed under a reduced pressure. The obtained oil<br>
product was purified by silica gel column<br>
chromatography [eluent; chloroform : methanol = 30 : 1]<br>
to obtain 1.13 g of a white solid, 4-(3-{4-[3-(4-<br>
cyanophenoxy)propyl]-1,4-diazepan-1-<br>
yl} propoxy)benzonitrile.<br>
1H-NMR (CDCl3) d: 1.70-1.90 (2H, m) , 1.93-2.00 (4H, m) ,<br>
2.66 (4H, t, J = 7.1 Hz), 2.71-2.74 (8H, m), 4.07 (4H,<br>
t, J = 6.3 Hz), 6.92-6.96 (4H, m), 7.56-7.59 (4H, m)<br>
Reference example 43<br><br><br>
The following compound was obtained in the<br>
same manner as Reference example 42.<br>
4-(3-{4-[2-(4-cyanophenoxy)ethyl]-1-<br>
piperazinyl}propoxy)benzonitrile<br>
1H-NMR (CDCl3) d: 1.97-2.03 (2H, m) , 2.52-2.62 (10H, m) ,<br>
2.84 (2H, t, J = 5.6 Hz), 4.07 (4H, t, J = 6.2 Hz),<br>
4.15 (2H, t, J = 5.6 Hz), 6.93-6.96 (4H, m) , 7.56-7.59<br>
(4H, m)<br>
Reference example 4 4<br><br>
The following compound was obtained in the<br>
same manner as Reference example 42.<br>
4'-(3-{4-[3-(4-cyanophenoxy)propyl]-1-<br>
piperazinyl}propoxy)[1,1'-biphenyl]-4-<br>
carbonitrile hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.10-2.30 (4H, m) , 3.20-4.00 (12H,<br>
m) , 4.16 (2H, t, J = 6.4 Hz), 4.20 (2H, t, J = 6.2 Hz),<br>
7.08-7.14 (4H, m), 7.72-7.91 (8H, m)<br>
Reference example 45<br><br><br>
The following compound was obtained in the<br>
same manner as Reference example 42.<br>
4-{3-[4-(4-cyanobenzyl)-1-<br>
piperazinyl]propoxy}benzonitrile<br>
1H-NMR (CDCl3) d: 1.94-2.02 (2H, m) , 2.30-2.70 (10H, m) ,<br>
3.55 (2H, s), 4.06 (2H, t, J = 6.4 Hz), 6.92-6.96 (2H,<br>
m) , 7.45 (2H, d, J = 8.3 Hz), 7.55-7.62 (4H, m)<br>
Reference example 46<br><br>
The following compound was obtained in the<br>
same manner as Reference example 42.<br>
4-{4-[3-(4-cyanophenoxy)propyl]-1-<br>
piperazinyl}benzonitrile<br>
1H-NMR (CDCl3) d: 1.99-2.06 (2H, m) , 2.56-2.62 (6H, m) ,<br>
3.32-3.35 (4H, m), 4.10 (2H, t, J = 6.2 Hz), 6.84-6.88<br>
(2H, m), 6.93-6.98 (2H, m), 7.48-7.53 (2H, m), 7.56-<br>
7.60 (2H, m)<br>
Reference example 47<br><br>
The following compound was obtained in the<br>
same manner as Reference example 42.<br>
4-{4-[5-(4-cyanophenoxy)pentyl]-1-<br><br>
piperazinyl}benzonitrile<br>
1H-NMR (CDCl3) d: 1.48-1.65 (4H, m) , 1.81-1.88 (2H, m) ,<br>
2.41-2.45 (2H, m) , 2.57-2.60 (4H, m), 3.33-3.35 (4H,<br>
m), 4.01 (2H, t, J = 6.4 Hz), 6.83-6.88 (2H, m), 6.90-<br>
6.95 (2H, m), 7.47-7.52 (2H, m), 7.56-7.60 (2H, m)<br>
Reference example 48<br><br>
The following compound was obtained in the<br>
same manner as Reference example 42.<br>
4-(3-{4-[3-(4-cyano-2-methoxyphenoxy)propyl]-1-<br>
piperazinyl}propoxy)-3-methoxybenzonitrile<br>
1H-NMR (CDCl3) d: 2.00-2.07 (4H, m) , 2.30-2.70 (8H, m) ,<br>
2.52 (4H, t, J = 7.1 Hz), 3.88 (6H, s), 4.13 (4H, t, J<br>
= 6.6 Hz), 6.92 (2H, d, J = 8.3 Hz), 7.07 (2H, d, J =<br>
2.0 Hz), 7.25 (2H, dd, J = 2.0, 8.3 Hz)<br>
Reference example 4 9<br><br>
The following compound was obtained in the<br>
same manner as Reference example 42.<br>
4-(3-{4-[3-(4-cyanophenoxy)propyl]-7-oxo-1,4-diazepan-<br>
1-yl}propoxy)benzonitrile<br>
1H-NMR (CDCl3) d: 1.76-2.08 (4H, m), 2.58-2.68 (8H, m) ,<br><br>
3.46-3.48 (2H, m), 3.54-3.58 (2H, m), 4.03 (2H, t, J =<br>
6.2 Hz), 4.06 (2H, t, J = 6.0 Hz), 6.92-6.95 (4H, m),<br>
7.56-7.60 (4H, m)<br>
Reference example 50<br><br>
	The following compound was obtained in the<br>
same manner as Reference example 42.<br>
tert-butyl 1-(4-cyanobenzyl)-4-piperidinyl [3-(4-<br>
cyanophenoxy)propyl]carbamate<br>
1H-NMR (CDCl3) d: 1.46 (9H, s), 1.60-1.80 (4H, m) , 1.90-<br>
2.20 (4H, m), 2.80-2.90 (2H, m) , 3.08-3.40 (2H, m),<br>
3.40-3.60 (1H, m), 3.53 (2H, s), 4.02 (2H, t, J = 6.1<br>
Hz), 6.91-6.95 (2H, m), 7.44 (2H, d, J = 8.7 Hz), 7.57-<br>
7.62 (4H, m)<br>
Reference example 51<br><br>
The following compound was obtained in the<br>
same manner as Reference example 42.<br>
tert-butyl 3-(4-cyanophenoxy)propyl{1-[3-(4-<br>
cyanophenoxy)propyl]-4-piperidinyl}carbamate<br>
1H-NMR (CDCl3) d: 1.46 (9H, s), 1.65-1.80 (4H, m) , 1.96-<br>
2.10 (6H, m), 2.50 (2H, t, J = 7.3 Hz), 2.80-3.00 (3H,<br>
m) , 3.20-3.40 (2H, m), 4.01 (2H, t, J = 5.9 Hz), 4.05<br><br>
(2H, t, J = 6.1 Hz), 6.91-6.95 (4H, m), 7.58 (4H, d, J<br>
= 8.8 Hz).<br>
Reference example 52<br><br>
The following compound was obtained in the<br>
same manner as Reference example 42.<br>
4-(2-{1-[3-(4-cyanophenoxy)propyl]-4-<br>
piperidinyl}ethoxy)benzonitrile<br>
1H-NMR (CDCl3) d: 1.20-1.40 (2H, m), 1.50-1.60 (1H, m),<br>
1.70-1.78 (4H, m), 1.93-2.03 (4H, m) , 2.47-2.51 (2H,<br>
m) , 2.91-2.94 (2H, m), 4.05 (2H, t, J = 6.1 Hz), 4.06<br>
(2H, t, J = 6.1 Hz), 6.93 (2H, d, J = 8.5 Hz), 6.94<br>
(2H, d, J = 8.5 Hz), 7.57 (2H, d, J = 8.5 Hz), 7.58<br>
(2H, d, J = 8.5 Hz)<br>
Reference example 53<br><br>
The following compound was obtained in the<br>
same manner as Reference example 42.<br>
4-[3-(4- { [3-(4-cyanophenoxy)propyl]amino}-1-<br>
piperidinyl)propoxy]benzonitrile<br>
1H-NMR (CDCl3) d: 1.34-1.44 (2H, m) , 1.45-1.70 (1H, br) ,<br>
1.85-2.06 (8H, m), 2.40-2.60 (1H, m), 2.50 (2H, t, J =<br>
7.2 Hz), 2.82 (2H, t, J = 6.8 Hz), 2.85-2.95 (2H, m) ,<br><br>
4.06 (2H, t, J = 6.3 Hz), 4.10 (2H, t, J = 6.1 Hz),<br>
6.93-6.95 (4H, m), 7.55-7.59 (4H, m)<br>
Reference example 54<br><br>
The following compound was obtained in the<br>
same manner as Reference example 42.<br>
4-[3-(3-{[3-(4-cyanophenoxy)propyl]amino}-1-<br>
pyrrolidinyl)propoxy]benzonitrile<br>
1H-NMR (CDCl3) d: 1.60-2.22 (7H, m) , 2.50-2.90 (8H, m) ,<br>
3.30-3.50 (1H, m), 4.08 (2H, t, J = 6.3 Hz), 4.10 (2H,<br>
t, J = 6.3 Hz), 6.94 (4H, d, J = 8.8 Hz), 7.57 (4H, d,<br>
J = 8.8 Hz).<br>
Reference example 55<br><br>
2.98 g of piperazine was dissolved in 14 ml<br>
of dimethyl sulfoxide, and then, 24 ml of N,N-<br>
diisopropylethylamine and 13.5 g of 4-(3-<br>
chloropropoxy)benzonitrile were added thereto at room<br>
temperature, followed by stirring at 110Â°C for 3 hours.<br>
After cooling to room temperature, a precipitate was<br>
filtrated with a mixed solvent consisting of rnethylene<br>
chloride and diisopropyl ether to obtain 6.65 g of a<br>
solid, 4-(3-{4-[3-(4-cyanophenoxy)propyl]-1-<br><br>
piperazinyl} propoxy)benzonitrile.<br>
1H-NMR (CDCl3) d: 1.96-2.03 (4H, m) , 2.50-2.54 (12H, m),<br>
4.07 (4H, t, J = 6.2 Hz), 6.93-6.96 (4H, m), 7.55-7.58<br>
(4H, m)<br>
Reference example 56<br><br>
The following compound was obtained in the<br>
same manner as Reference example 55.<br>
4-(3-{4-[3-(4-cyano-2-methylphenoxy)propyl]-1-<br>
piperazinyl}propoxy)-3-methylbenzonitrile<br>
1H-NMR (CDCl3) d: 1.99-2.05 (4H, m) , 2.21 (6H, s) , 2.40-<br>
2.56 (12H, m), 4.07 (4H, t, J = 6.3 Hz), 6.85 (2H, d, J<br>
= 8.4 Hz), 7.40 (2H, brs), 7.47 (2H, dd, J = 1.4, 8.4<br>
Hz)<br>
Reference example 57<br><br>
The following compound was obtained in the<br>
same manner as Reference example 55.<br>
4-(3-{4-[3-(4-cyano-3-fluorophenoxy)propyl]-<br>
1-piperazinyl}propoxy)-2-fluorobenzonitrile<br>
1H-NMR (CDCl3) 6: 1.95-2.02 (4H, m) , 2.30-2.70 (12H, m) ,<br>
4.07 (4H, t, J = 6.3 Hz), 6.71-6.77 (4H, m), 7.50 (2H,<br>
dd, J = 7.7, 8.7 Hz)<br><br>
Reference example 58<br><br>
The following compound was obtained in the<br>
same manner as Reference example 55.<br>
4-(3-{4-[3-(4-cyano-2-fluorophenoxy)propyl]-1-<br>
piperazinyljpropoxy)-3-fluorobenzonitrile hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.20-2.40 (4H, m) , 3.10-4.00 (12H,<br>
m), 4.29 (4H, t, J = 6.0 Hz), 7.35-7.39 (2H, m), 7.70-<br>
7.72 (2H, m), 7.86-7.89 (2H, m)<br>
Reference example 59<br><br>
The following compound was obtained in the<br>
same manner as Reference example 55.<br>
4-(2-{4-[2-(4-cyanophenoxy)ethyl]-1-<br>
piperazinyl}ethoxy)benzonitrile<br>
1H-NMR (CDCl3) d: 2.50-2.70 (8H, m), 2.84 (4H, t, J =<br>
5.7 Hz), 4.14 (4H, t, J = 5.7 Hz), 6.93-6.97 (4H, m) ,<br>
7.57-7.60 (4H, m).<br>
Reference example 60<br><br><br>
The following compound was obtained in the<br>
same manner as Reference example 55.<br>
4-[((E)-4-{4-[(E)-4-(4-cyanophenoxy)-2-butenyl]-1-<br>
piperazinyl}-2-butenyl)oxy]benzonitrile<br>
1H-NMR (CDCl3) d: 2.30-2.70 (8H, m) , 3.05 (4H, d, J =<br>
5.6 Hz), 4.57 (4H, d, J = 4.8 Hz), 5.81-5.94 (4H, m),<br>
6.93-6.95 (4H, m), 7.56-7.59 (4H, m)<br>
Reference example 61<br><br>
The following compound was obtained in the<br>
same manner as Reference example 55.<br>
4- (3-{4-[3-(4-cyanophenoxy)-2-methylpropyl]-1-<br>
piperazinyl}-2-methylpropoxy)benzonitrile hydrochloride<br>
1H-NMR(CD3OD) d: 1.22 (6H, d, J = 6.8 Hz), 2.50-2.70<br>
(2H, m) , 3.00-3.80 (12H, m), 4.05-4.15 (4H, m) , 7.10-<br>
7.15 (4H, m), 7.66-7.70 (4H, m)<br>
Reference example 62<br><br>
The following compound was obtained in the<br>
same manner as Reference example 55.<br>
4-(2-(benzyloxy)-3-{4-[2-(benzyloxy)-3-(4-<br>
cyanophenoxy)propyl]-1-piperazinyl}propoxy)benzonitrile<br><br>
1H-NMR (CDCl3) d: 2.40-2.63 (12H, m) , 3.85-3.95 (2H, m) ,<br>
4.07-4.21 (4H, m), 4.71 (4H, s), 6.94-6.98 (4H, m),<br>
7.27-7.35 (10H, m), 7.55-7.59 (4H, m)<br>
Reference example 63<br><br>
The following compound was obtained in the<br>
same manner as Reference example 55.<br>
4- (3-{4- [3-(4-cyanophenoxy)propyl]-2-methyl-1-<br>
piperazinyl}propoxy)benzonitrile hydrochloride<br>
1H-NMR (d6-DMSO) d: 1.30-1.50 (3H, m) , 2.00-2.40 (4H,<br>
m) , 3.10-4.00 (11H, m), 4.10-4.30 (4H, m) , 7.11-7.15<br>
(4H, m) , 7.79 (4H, d, J = 8.4 Hz)<br>
Reference example 64<br><br>
The following compound was obtained in the<br>
same manner as Reference example 55.<br>
ethyl 1,4-bis[3-(4-cyanophenoxy)propyl]-2-<br>
piperazinecarboxylate<br>
1H-NMR (CDCl3) d: 1.22 (3H, t, J = 7.1 Hz), 1.92-2.00<br>
(4H, m) , 2.36-2.80 (8H, m), 2.83-2.90 (1H, m), 3.10-<br>
3.15 (1H, m), 3.24-3.30 (1H, m), 4.03-4.20 (6H, m),<br><br>
6.92-6.96 (4H, m), 7.56-7.59 (4H, m)<br>
Reference example 65<br><br>
The following compound was obtained in the<br>
same manner as Reference example 55.<br>
4-{3-[{2-[[3-(4-<br>
cyanophenoxy)propyl](methyl)amino]ethyl}(methyl)amino]<br>
propoxy}benzonitrile hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.23-2.29 (4H, m), 2.85 (6H, s) ,<br>
3.28-3.70 (8H, m), 4.19 (4H, t, J = 6.0 Hz), 7.13 (4H,<br>
d, J = 8.6 Hz), 7.79 (4H, d, J = 8.6 Hz), 11.57 (2H,<br>
brs)<br>
Reference example 66<br><br>
0.40 g of 3-[4-(3-hydroxypropyl)-1-<br>
piperazinyl]-1-propanol was suspended in 4.0 ml of N,N-<br>
dimethylformamide, and then, 0.16 g of 60% sodium<br>
hydride was added thereto, followed by stirring for 1<br>
hour. Thereafter, 0.57 g of 2-chloro-5-cyanopyridine<br>
was added thereto, and the mixture was stirred at room<br>
temperature for 4 hours. Thereafter, 5 ml of<br>
diisopropyl ether and 5 ml of water were added to the<br><br>
reaction solution, and a precipitate was then filtrated<br>
to obtain 0.50 g of a solid, 6-[3-(4-{3-[(5-cyano-2-<br>
pyridinyl)oxylpropyl}-1-<br>
piperazinyl)propoxy]nicotinonitrile.<br>
1H-NMR (CDCl3 + CD3OD) d: 1.90-2.10 (4H, m) , 2.50-2.62<br>
(12H, m), 4.42 (4H, t, J = 6.4 Hz), 6.85 (2H, dd, J =<br>
0.6, 8.8 Hz), 7.83 (2H, dd, J = 2.4, 8.8 Hz), 8.48 (2H,<br>
dd, J = 0.6, 2.4 Hz)<br>
Reference example 67<br>
Reference example 67-1<br><br>
1.00 g of 4-(3-bromopropoxy)benzonitrile was<br>
dissolved in 10 ml of N,N-dimethylformamide. 0.73 ml<br>
of 4-aminobutyl alcohol and 1.06 g of potassium<br>
carbonate were successively added to the obtained<br>
solution, and the mixture was stirred at room<br>
temperature for 12 hours. Thereafter, a 1 mol/L sodium<br>
hydroxide aqueous solution and chloroform were added to<br>
the reaction mixture, so that the organic layer was<br>
separated. Thereafter, the aqueous layer was extracted<br>
twice with chloroform. The separated organic layer was<br>
combined, dried over anhydrous magnesium sulfate. The<br>
solvent was removed under a reduced pressure. The<br>
obtained oil product was dissolved in 10 ml of<br>
chloroform, and then, 1.08 ml of triethylamine and 1.68<br><br>
g of di-tert-butyl dicarbonate were added to the<br>
solution, followed by stirring at room temperature for<br>
4 days. The solvent was removed under a reduced<br>
pressure. Thereafter, ethyl acetate and water were<br>
added to the residue, so that the organic layer was<br>
separated. The separated organic layer was washed<br>
successively with water and with a saturated aqueous<br>
solution of sodium chloride, and then dried over<br>
anhydrous magnesium sulfate. Thereafter, the solvent<br>
was removed under a reduced pressure. The obtained oil<br>
product was purified by silica gel column<br>
chromatography [eluent; n-hexane : ethyl acetate = 1 :<br>
1] to obtain 0.63 g of a colorless oil product, tert-<br>
butyl 3-(4-cyanophenoxy)propyl(4-<br>
hydroxybutyl)carbamate.<br>
1H-NMR (CDCl3)d: 1.43 (9H, s), 1.53-1.80 (5H, m) , 2.00-<br>
2.10 (2H, m), 3.10-3.30 (2H, m), 3.38 (2H, t, J = 6.8<br>
Hz), 3.60-3.80 (2H, m), 4.02 (2H, t, J = 6.1 Hz), 6.90-<br>
6.95 (2H, m), 7.55-7.60 (2H, m)<br>
Reference example 67-2<br><br>
A mixed solution consisting of 0.32 ml of<br>
oxalyl chloride and 14 ml of tetrahydrofuran was cooled<br>
to -60Â°C, and 0.35 ml of dimethyl sulfoxide was then<br>
added dropwise to the solution. The mixed solution was<br><br>
stirred at -60Â°C for 5 minutes, and thereafter, 6 ml of<br>
a tetrahydrofuran solution containing 0.63 g of tert-<br>
butyl 3-(4-cyanophenoxy)propyl(4-hydroxybutyl)carbamate<br>
was added dropwise thereto over 5 minutes. The<br>
obtained mixed solution was stirred at -60Â°C for 2<br>
hours, and thereafter, 1.77 ml of triethylamine was<br>
added dropwise thereto. After the reaction mixture was<br>
warmed to room temperature, water and chloroform were<br>
added thereto, so that the organic layer was separated.<br>
The separated organic layer was washed with a saturated<br>
aqueous solution of sodium chloride, and then dried<br>
over anhydrous magnesium sulfate. Thereafter, the<br>
solvent was removed under a reduced pressure. The<br>
obtained oil product was purified by silica gel column<br>
chromatography [eluent; n-hexane : ethyl acetate = 1 :<br>
1] to obtain 0.65 g of a colorless oil product, tert-<br>
butyl 3-(4-cyanophenoxy)propyl(4-oxobutyl)carbamate.<br>
1H-NMR (CDCl3) d: 1.56 (9H, s), 1.83-1.90 (2H, m) , 1.90-<br>
2.10 (2H, m), 2.47 (2H, t, J = 6.9 Hz), 3.23 (2H, t, J<br>
= 6.9 Hz), 3.37 (2H, t, J = 6.9 Hz), 4.02 (2H, t, J =<br>
6.1 Hz), 6.91-6.95 (2H, m) , 7.55-7.60 (2H, m), 9.78<br>
(1H, s) .<br>
Reference example 67-3<br><br><br>
0.65 g of tert-butyl 3-(4-<br>
cyanophenoxy)propyl(4-oxobutyl)carbamate was dissolved<br>
in 10 ml of methylene chloride. While cooled by ice,<br>
15 ml of a methylene chloride solution containing 0.50<br>
g of 4-(3-aminopropoxy)benzonitrile was added to the<br>
solution, and thereafter, 0.60 g of triacetoxy sodium<br>
borohydride was added thereto. After this reaction<br>
mixture was warmed to room temperature, the mixture was<br>
stirred for 19.5 hours. The reaction mixture was<br>
slowly added to a mixture consisting of a 10% potassium<br>
carbonate aqueous solution and chloroform, and the<br>
organic layer was separated. The separated organic<br>
layer was washed with a saturated aqueous solution of<br>
sodium chloride, and then dried over anhydrous<br>
magnesium sulfate. The solvent was then removed under<br>
a reduced pressure. The obtained oil product was<br>
dissolved in 10 ml of chloroform, and then, 0.39 ml of<br>
triethylamine and 0.62 g of di-tert-butyl dicarbonate<br>
were added to the solution, followed by stirring at<br>
room temperature for 3 days. The solvent was removed<br>
under a reduced pressure, and the residue was purified<br>
by silica gel column chromatography [eluent; n-hexane :<br>
ethyl acetate =2 : 1] to obtain 0.90 g of a colorless<br>
oil product, tert-butyl 4-{(tert-butoxycarbonyl)[3-(4-<br>
cyanophenoxy)propyl]amino}butyl[3-(4-<br>
cyanophenoxy)propyl]carbamate.<br>
1H-NMR (CDCl3) d: 1.42 (18H, s), 1.45-1.55 (4H, m) ,<br>
1.90-2.10 (4H, m) , 3.10-3.30 (4H, in), 3.30-3.50 (4H,<br><br>
m), 4.01 (4H, t, J = 6.0 Hz), 6.90-6.95 (4H, m) , 7.58<br>
(4H, d, J = 8.8 Hz)<br>
Reference example 68<br><br>
0.50 g of 4-[3-(4-{ [3-(4-<br>
cyanophenoxy)propyl]amino}-1-<br>
piperidinyl)propoxy]benzonitrile was dissolved in 5.0<br>
ml of N,N-dimethylformamide, and then, 0.21 ml of ethyl<br>
6-bromohexanoate and 0.49 g of potassium carbonate were<br>
successively added to the solution, followed by<br>
srirring at room temperature for 7 days. Ethyl acetate<br>
and water were added to the reaction mixture, so that<br>
the organic layer was separated. The obtained organic<br>
layer was washed with a saturated saline solution, and<br>
then dried over anhydrous magnesium sulfate. The<br>
resultant solution was then concentrated under a<br>
reduced pressure. The obtained oil product was<br>
purified by silica gel column chromatography [eluent;<br>
chloroform : methanol =40 : 1] to obtain 0.40 g of a<br>
colorless oil product, ethyl 6-([3-(4-<br>
cyanophenoxy)propyl]{1-[3-(4-cyanophenoxy)propyl]-4-<br>
piperidinyl}amino)hexanoate .<br>
1H-NMR (CDCl3) d: 1.25 (3H, t, J = 7.1 Hz), 1.20-1.66<br>
(10H, m) , 1.85-1.99 (6H, m), 2.25 (2H, t, J = 7.6 Hz),<br>
2.42-2.49 (5H, m), 2.61 (2H, t, J = 6.6 Hz), 2.90-3.10<br><br>
(2H, m), 4.05 (2H, t, J = 6.2 Hz), 4.05 (2H, t, J = 6.0<br>
Hz), 4.12 (2H, q, J = 7.1 Hz), 6.91-6.96 (4H, m), 7.55-<br>
7.60 (4H, m)<br>
Reference example 69<br>
Reference example 69-1<br><br>
1.85 g of 4-[3-(l-<br>
piperazinyl)propoxy]benzonitrile was dissolved in 10 ml<br>
of N,N-dimethylformamide, and then, 1.77 g of potassium<br>
carbonate and 1.79 g of tert-butyl 6-<br>
bromohexylcarbamate were successively added thereto,<br>
followed by stirring at room temperature for 22 hours.<br>
Thereafter, a 1 mol/L sodium hydroxide aqueous solution<br>
and chloroform were added to the reaction mixture, so<br>
that the organic layer was separated. Thereafter, the<br>
aqueous layer was extracted with chloroform. The<br>
organic layers were combined, and dried over anhydrous<br>
magnesium sulfate. The solvent was then removed under<br>
a reduced pressure. The obtained oil product was<br>
purified by silica gel column chromatography [eluent;<br>
chloroform : methanol = 10 : 1] to obtain 3.46 g of a<br>
colorless oil product, tert-butyl 6-{4-[3-(4-<br>
cyanophenoxy)propyl]-1-piperazinyl}hexylcarbamate.<br>
1H-NMR (CDCl3) d: 1.20-1.80 (8H, m), 1.44 (9H, s), 1.96-<br>
2.02 (2H, m), 2.32-2.54 (12H, m), 3.00-3.20 (2H, m) ,<br>
4.06 (2H, t, J = 6.3 Hz), 4.50 (1H, brs), 6.92-6.96<br><br>
(2H, m), 7.55-7.59 (2H, m)<br>
Reference example 69-2<br><br>
3.46 g of tert-butyl 6-{4-[3-(4-<br>
cyanophenoxy)propyl]-1-piperazinylJhexylcarbamate was<br>
dissolved in 30 ml of 6 mol/L hydrochloric acid, and<br>
the obtained solution was stirred at room temperature<br>
for 12 hours. Thereafter, the solvent was removed<br>
under a reduced pressure. The obtained residue was<br>
filtrated with ethyl acetate-ethanol to obtain 2.51 g<br>
of a solid, 4-{3-[4-(6-aminohexyl)-1-<br>
piperazinyl]propoxy}benzonitrile hydrochloride.<br>
1H-NMR (d6-DMSO) d: 1.20-1.80 (8H, m) , 2.10-2.30 (2H,<br>
m) , 2.74-2.79 (2H, m), 3.00-3.90 (14H, m), 4.19 (2H, t,<br>
J = 6.0 Hz), 7.12 (2H, d, J = 8.8 Hz), 7.79 (2H, d, J =<br>
8.8 Hz), 7.91 (3H, brs)<br>
Reference example 69-3<br><br>
Water and chloroform were added to 0.70 g of<br>
4-{3-[4-(6-aminohexyl)-1-<br>
piperazinyl]propoxy}benzonitrile hydrochloride, and the<br>
mixture was then adjusted to pH 12.5 with a 5 mol/L<br>
sodium hydroxide aqueous solution. The organic layer<br>
was separated, and the aqueous layer was then extracted<br><br>
with chloroform 4 times. The organic layers were<br>
combined, and dried over anhydrous magnesium sulfate.<br>
The solvent was then removed under a reduced pressure.<br>
The obtained oil product was dissolved in 10 ml of<br>
tetrahydrofuran. Thereafter, 0.21 ml of triethylamine,<br>
0.15 ml of acetic anhydride, and 0.01 g of 4-<br>
(dimethylamino) pyridine were successively added to the<br>
solution, followed by stirring at room temperature for<br>
16 hours. Water, chloroform, and potassium carbonate<br>
were added to the reaction mixture, so that the organic<br>
layer was separated. The organic layer was dried over<br>
anhydrous magnesium sulfate, and then concentrated<br>
under a reduced pressure. The obtained residue was<br>
purified by silica gel column chromatography feluent;<br>
chloroform : methanol = 10 : 1] to obtain 0.75 g of a<br>
white solid, N-(6-{4-[3-(4-cyanophenoxy)propyl]-1-<br>
piperazinyl}hexyl)acetamide.<br>
1H-NMR (CDCl3) d: 1.20-1.80 (8H, m) , 1.97 (3H, s) , 1.90-<br>
2.10 (2H, m), 2.31-2.60 (12H, m), 3.21-3.26 (2H, m) ,<br>
4.06 (2H, t, J = 6.2 Hz), 5.42 (1H, brs), 6.94 (2H, d,<br>
J = 9.0 Hz), 7.57 (2H, d, J = 9.0 Hz)<br>
Reference example 70<br>
Reference example 70-1<br><br>
The following compound was obtained in the<br><br>
same manner as Reference example 7.<br>
tert-butyl 4â€”(4â€”{4â€”[3â€”(4-cyanophenoxy)propyl]-2,3-<br>
dioxo-1-piperazinyl}butyl)-1-piperidinecarboxylate<br>
1H-NMR (CDCl3) d: 1.00-1.11 (2H, m) , 1.22-1.64 (9H, m) ,<br>
1.45 (9H, s), 2.14 (2H, quint, J=6.4 Hz), 2.50-2.60<br>
(2H, m), 3.47 (2H, t, J = 11.6 Hz), 3.50-3.59 (4H, m) ,<br>
3.67 (2H, t, J = 6.8 Hz), 4.00-4.15 (2H, m), 4.07 (2H,<br>
t, J = 6.4 Hz), 6.93 (2H, d, J = 9.2 Hz), 7.59 (2H, d,<br>
J = 9.2 Hz)<br>
Reference example 70-2<br><br>
0.42 g of tert-butyl 4-(4-{4-[3-(4-<br>
cyanophenoxy)propyl]-2, 3-dioxo-1-piperazinyl}butyl)-1-<br>
piperidinecarboxylate was dissolved in 8.2 ml of<br>
methylene chloride, and then 3.1 ml of trifluoroacetic<br>
acid was added thereto under cooling on ice, followed<br>
by stirring at room temperature for 2 hours. The<br>
reaction mixture was concentrated under a reduced<br>
pressure. The obtained residue was purified by silica<br>
gel column chromatography [eluent; chloroform : ethanol<br>
= 5 : 1] to obtain 0.42 g of a pale yellow amorphous<br>
solid, 4-(3-{2,3-dioxo-4-[4-(4-piperidinyl)butyl]-1-<br>
piperazinyl}propoxy)benzonitrile trifluoroacetate.<br>
1H-NMR (CDCl3) d: 1.20-1.90 (11H, m) , 2.13 (2H, quint,<br>
J = 6.4 Hz), 2.77-2.88 (2H, m;, 3.35-3.68 (10H, m),<br><br>
4.07 (2H,	t, J = 6.0 Hz), 6.94 (2H, d, J = 9.0 Hz),<br>
7.58 (2H,	d, J = 9.0 Hz), 8.90-9.20 (1H, br), 9.30-9.50<br>
(1H, br)<br>
Reference	example 71<br><br>
The following compound was obtained in the<br>
same manner as Reference example 42.<br>
tert-butyl 4-(4-{4-[3-(4-cyanophenoxy)propyl]-1-<br>
piperazinyl}butyl)-1-piperidinecarboxylate<br>
1H-NMR (CDCl3) d: 1.00-1.11 (2H, m), 1.20-1.80 (9H, m) ,<br>
1.45 (9H, s), 1.94-2.02 (2H, m) , 2.28-2.78 (14H, m),<br>
3.96-4.14 (2H, m), 4.06 (2H, t, J = 6.3 Hz), 6.90-6.98<br>
(2H, m), 7.56-7.60 (2H, m)<br>
Reference example 72<br>
Reference example 72-1<br><br>
0.80 g of lithium aluminum hydride was<br>
suspended in 14 ml of tetrahydrofuran. Thereafter, 28<br>
ml of a tetrahydrofuran solution containing 3.00 g of<br>
ethyl 4-(1-methyl-4-piperidinyl)butyrate was added<br>
dropwise to the suspension at 10Â°C over 45 minutes. The<br>
mixture was stirred at the same temperature for 30<br>
minutes, and the reaction mixture was warmed to room<br><br>
temperature, followed by further stirring for 1 hour.<br>
Thereafter, 20 ml of a 1 mol/L sodium hydroxide aqueous<br>
solution was added to the reaction solution under<br>
cooling on ice, and the reaction mixture was filtrated<br>
with Celite. The filtrate was concentrated under<br>
reduced pressure, and 1 mol/L hydrochloric acid was<br>
then added to the obtained residue, so that the residue<br>
was adjusted to pH 2. Thereafter, it was washed twice<br>
with 20 ml of chloroform. The aqueous layer was<br>
adjusted to pH 10.5 with a 1 mol/L sodium hydroxide<br>
aqueous solution, and then extracted twice with 40 ml<br>
of chloroform. The combined organic layer was dried<br>
over anhydrous magnesium sulfate. The solvent was then<br>
removed under a reduced pressure to obtain 1.31 g of a<br>
colorless oil product, 4-(1-methyl-4-piperidinyl)-1-<br>
butanol.<br>
1H-NMR (CDCl3) d: 1.20-1.28 (5H, m) , 1.33-1.41 (2H, m) ,<br>
1.52-1.59 (2H, m) , 1.66-1.69 (2H, m), 1.88 (2H, t, J =<br>
11.6 Hz), 1.99 (1H, brs), 2.24 (3H, s), 2.78-2.86 (2H,<br>
m), 3.63 (2H, t, J = 6.6 Hz)<br>
Reference example 72-2<br><br>
0.38 g of 4-(l-methyl-4-piperidinyl)-1-<br>
butanol was dissolved in 16 ml of tetrahydrofuran, and<br>
then, 0.57 g of triphenylphosphine and 0.73 g of carbon<br><br>
tetrabromide were successively added thereto under<br>
cooling on ice. The mixture was left at room<br>
temperature overnight. Thereafter, a precipitate was<br>
filtrated, and the filtrate was concentrated under a<br>
reduced pressure. 20 ml of diethyl ether and 20 ml of<br>
water were added to the obtained residue, and the<br>
mixture was adjusted to pH 1 with 1 mol/L hydrochloric<br>
acid. Then, aqueous layer was separated. The obtained<br>
aqueous layer was adjusted to pH 10.5 with 1 mol/L<br>
sodium hydroxide, and then extracted with 20 ml of<br>
ethyl acetate. The ethyl acetate layer was dried over<br>
anhydrous magnesium sulfate, and then concentrated<br>
under a reduced pressure to obtain 0.30 g of a yellow<br>
oil product, 4-(4-bromobutyl)-1-methylpiperidine.<br>
1H-NMR (CDCl3) d: 1.21-1.29 (5H, m) , 1-41-1.48 (2H, m) ,<br>
1.66-1.68 (2H, m), 1.78-1.91 (4H, m), 2.25 (3H, s),<br>
2.83 (2H, d, J = 12-0 Hz), 3.41 (2H, t, J = 6-4 Hz)<br>
Reference example 72-3<br><br>
The following compound was obtained in the<br>
same manner as Reference example 42.<br>
4- (3-{4-[4-(1-methyl-4-piperidinyl)butyl]-1-<br>
piperazinyl}propoxy)benzonitrile<br>
1H-NMR (CDCl3) d: 1.20-1.34 (6H, m) , 1.43-1.51 (2H, m) ,<br>
1.51-1.70 (5H, m), 1.85-1.90 (2H, m&gt;, 1.95-2.02 (2H,<br><br>
m), 2.25 (3H, s), 2.30-2.35 (2H, m), 2.40-2.50 (8H, m) ,<br>
2.83 (2H, d, J = 11.6 Hz), 4.06 (2H, t, J = 6.4 Hz),<br>
6.94 (2H, d, J = 9.2 Hz), 7.57 (2H, d, J = 9.2 Hz)<br>
Reference example 73<br>
Reference example 73-1<br><br>
3.00 g of 1-tert-butoxycarbonylpiperazine was<br>
dissolved in 30 ml of N,N-dimethylformamide.<br>
Thereafter, 6.68 g of potassium carbonate and 2.86 g of<br>
ethyl 6-bromohexanoate were successively added to the<br>
solution, and the mixture was stirred at room<br>
temperature for 16 hours. The reaction mixture was<br>
added to a mixed solvent of 30 ml of ethyl acetate and<br>
120 ml of water, so that the organic layer was<br>
separated. The separated organic layer was washed with<br>
a saturated aqueous solution of sodium chloride, and<br>
then dried over anhydrous magnesium sulfate. The<br>
resultant product was concentrated under reduced<br>
pressure to obtain 5.68 g of tert-butyl 4-(6-ethoxy-6-<br>
oxyhexyl)-1-piperazinecarboxylate.<br>
5.68 g of tert-butyl 4-(6-ethoxy-6-oxyhexyl)-<br>
1-piperazinecarboxylate was dissolved in<br>
tetrahydrofuran. Thereafter, while cooled by ice, 52<br>
ml of a tetrahydrofuran solution containing a 1 mol/L<br><br>
borane-tetrahydrofuran complex was added to the above<br>
solution, followed by stirring at room temperature for<br>
24 hours. Thereafter, 11.5 ml of acetone was added<br>
dropwise to the reaction mixture under cooling on ice,<br>
and 52 ml of 2 mol/L hydrochloric acid was then added<br>
thereto. The solvent was removed, until the<br>
temperature of the reaction mixture became 80Â°C or<br>
higher. Thereafter, the mixture was heated to reflux<br>
for 4 hours. After cooling to room temperature,<br>
chloroform and water were added to the reaction<br>
mixture. The obtained mixture was then adjusted to pH<br>
11.0 with a 5 mol/L sodium hydroxide aqueous solution.<br>
The organic layer was separated, and then, the aqueous<br>
layer was extracted with chloroform 20 times. The<br>
obtained organic layer was dried over anhydrous<br>
magnesium sulfate, and then concentrated under a<br>
reduced pressure. The obtained residue was dissolved<br>
in 35 ml of chloroform, and 4.42 g of di-tert-butyl<br>
dicarbonate was then added thereto under cooling on<br>
ice. The mixture was stirred at room temperature for<br>
15 hours. Thereafter, chloroform, water, and potassium<br>
carbonate were added to the reaction mixture, so that<br>
the organic layer was separated. The aqueous layer was<br>
then extracted with chloroform. The obtained organic<br>
layer was combined, and then dried over anhydrous<br>
magnesium sulfate. The solvent was removed under<br>
reduced pressure. 7.88 g of the obtained oil product<br>
was purified by silica gel column chromatography<br><br>
[eluent; chloroform : methanol = 10 : 1] to obtain 3.55<br>
g of a colorless oil product, tert-butyl 4-(6-<br>
hydroxyhexyl)-1-piperazinecarbonxylate.<br>
1H-NMR (CDCl3) d: 1.28-1.70 (9H, m), 1.46 (9H, s), 2.26-<br>
2.42 (6H, m), 3.38-3.48 (4H, m), 3.65 (2H, t, J = 6.6<br>
Hz)<br>
Reference example 73-2<br><br>
A mixed solution of 1.85 ml of oxalyl<br>
chloride and 70 ml of chloroform was cooled to -60Â°C,<br>
and 2.03 ml of dimethyl sulfoxide was added dropwise<br>
thereto. The mixture was stirred at -60Â°C for 5<br>
minutes, and then, 20 ml of chloroform solution<br>
containing 3.05 g of tert-butyl 4-(6-hydroxyhexyl)-1-<br>
piperazinecarboxylate was added dropwise thereto over 5<br>
minutes. The obtained mixture was stirred at a<br>
temerature ranging from -60Â°C to -40Â°C for 2 hours, and<br>
then, 10.3 ml of triethylamine was added dropwise<br>
thereto. The reaction mixture was warmed to room<br>
temperature. Thereafter, water and potassium carbonate<br>
were added thereto, so that the organic layer was<br>
separated. The separated organic layer was washed with<br>
saturated aqueous solution of sodium chloride, and then<br>
dried over anhydrous magnesium sulfate. The solvent<br>
was then removed under a reduced pressure. The<br><br>
obtained oil product was purified by silica gel column<br>
chromatography feluent; chloroform : methanol = 20 : 1]<br>
to obtain 3.07 g of a colorless oil product, tert-butyl<br>
4-(6-oxohexyl)-1-piperazinecarboxylate.<br>
1H-NMR (CDCl3) d: 1.25-1.70 (6H, m) , 1.46 (9H, s), 2.25-<br>
2.50 (6H, m), 2.45 (2H, dt, J = 1.7, 7.3 Hz), 3.35-3.50<br>
(4H, m), 9.77 (1H, t, J = 1.7 Hz)<br>
Reference example 73-3<br><br>
0.80 g of tert-butyl 4-(6-oxohexyl)-1-<br>
piperazinecarboxylate was dissolved in 10 ml of<br>
methylene chloride. While cooled by ice, 20 ml of a<br>
methylene chloride solution containing 2.12 g of 4-[3-<br>
(1-piperazinyl)propoxy]benzonitrile was added to the<br>
solution. Thereafter, 0.89 g of triacetoxy sodium<br>
borohydride was added thereto. The reaction mixture<br>
was warmed to room temperature, and the mixture was<br>
then stirred for 18 hours. The reaction mixure was<br>
slowly added to a mixture of 10% potassium carbonate<br>
aqueous soltuion and chloroform, so that the organic<br>
layer was separated. The separated organic layer was<br>
dried over anhydrous magnesium sulfate, and the solvent<br>
was then removed under a reduced pressure. Thereafter,<br>
the residue was purified by silica gel column<br>
chromatography [eluent; n-hexane : ethyl acetate = 2 :<br><br>
1] to obtain 1.41 g of a colorless oil product, tert-<br>
butyl 4-(6-{4-[3-(4-cyanophenoxy)propyl]-1-<br>
piperazinyl}hexyl)-1-piperazinecarboxylate.<br>
1H-NMR (CDCl3) d: 1.25-1.70 (8H, m) , 1.46 (9H, s), 1.92-<br>
2.04 (2H, m), 2.20-2.70 (18H, m), 3.35-3.50 (4H, m),<br>
4.06 (2H, t, J = 6.3 Hz), 6.90-6.98 (4H, m) , 7.54-7.62<br>
(4H, m)<br>
Example 1<br><br>
0.65 g of 6-{[4-(4-<br>
cyanophenoxy)butyl]amino}hexanoic acid methyl ester was<br>
dissolved in 7.0 ml of ethanol. While cooled by ice,<br>
hydrogen chloride gas was blown into the solution,<br>
followed by stirring at room temperature for 2 days.<br>
After completion of the reaction, the solvent was<br>
removed under a reduced pressure. The obtained residue<br>
was dissolved in 7.0 ml of ethanol, and 0.38 g of<br>
ammonium acetate was added thereto, followed by heating<br>
to reflux for 2 hours. After completion of the<br>
reaction, the reaction mixture was cooled to room<br>
temperature. The solvent was removed under a reduced<br>
pressure, and then, 10 ml of ethyl acetate was added to<br>
the obtained residue to obtain a solid by filtration.<br>
The obtained solid was dissolved in 6 ml of water, and<br>
2 ml of 6 mol/L hydrochloric acid was added thereto,<br><br>
followed by heating to reflux for 1 hour. After<br>
completion of the reaction, the reaction product was<br>
cooled to room temperature, and the solvent was removed<br>
under a reduced pressure. Isopropanol was added to the<br>
obtained residue, and filtration was carried out to<br>
obtain 0.34 g of a colorless solid, 6â€” [ (4 â€” {4 â€”<br>
[amino(imino)methyl]phenoxy}butyl)amino]hexanoic acid<br>
hydrochloride.<br>
IR(KBr)cm-1: 3320, 1677, 1611<br>
1H-NMR (d6-DMSO) d: 1.25-1.40 (2H, m) , 1.45-1.58 (2H,<br>
m), 1.58-1.69 (2H, m) , 1.72-1.90 (4H, m), 2.22 (2H, t,<br>
J = 7.2 Hz), 2.80-2.99 (4H, m) , 4.08-4.25 (2H, m), 7.16<br>
(2H, d, J = 8.3 Hz), 7.86 (2H, d, J = 8.3 Hz), 8.91<br>
(2H, brs), 9.00 (2H, brs), 9.24 (2H, brs)<br>
Example 2<br><br>
The following compound was obtained in the<br>
same manner as Reference example 5 and Example 1.<br>
4-[3-(methylamino)propoxy]benzamidine hydrochloride<br>
IR(KBr)cm-1: 3308, 3164, 2797, 1676, 1610<br>
1H-NMR (d5-DMSO) d: 2.13-2.21 (2H, m), 2.55 (3H, s),<br>
3.01-3.08 (2H, m), 4.23 (2H, t, J = 6.2 Hz), 7.17 (2H,<br>
d, J = 8.8 Hz), 7.96 (2H, d, J = 8.8 Hz), 9.21 (2H,<br>
brs), 9.46 (4H, brs)<br>
Example 3<br>
Example 3-1<br><br><br>
2.3 g of 6-aminohexanoic acid methyl ester<br>
hydrochloride was dissolved in 8.4 ml of N,N-<br>
dimethylformamide. Thereafter, 1.7 ml of triethylamine<br>
and 0.20 g of 4-(3-bromopropoxy)benzonitrile were added<br>
to the solution, followed by stirring at 70Â°C to 80Â°C<br>
for 1.2 hours. Thereafter, 0.80 g of 4-(3-<br>
bromopropoxy)benzonitrile was added to the reaction<br>
solution, followed by stirring at 70Â°C to 80Â°C for 6<br>
hours. After cooling to room temperature, 20 ml of<br>
water and 20 ml of ethyl acetate were added to the<br>
reaction solution, so that the organic layer was<br>
separated. The aqueous layer was adjusted to pH 9 with<br>
a sodium hydroxide aqueous solution. Thereafter,<br>
sodium chloride was added thereto until the solution<br>
became saturated. Thereafter, it was extracted with 20<br>
ml of ethyl acetate 5 times. The obtained organic<br>
layer was combined, and the thus obtained layers were<br>
dried over anhydrous magnesium sulfate. The solvent<br>
was then removed under a reduced pressure. The<br>
 obtained residue was purified by silica gel column<br>
chromatography [eluent; chloroform : ethanol =20 : 1],<br>
and then, 20 ml of methylene chloride and 20 ml of<br>
water were added thereto. Thereafter, 1.00 g of sodium<br>
carbonate and 1.1 ml of di-tert-butyl dicarbonate were<br><br>
added to the mixed solution, followed by stirring for 1<br>
hour. After completion of the reaction, the organic<br>
layer was separated, and the aqueous layer was<br>
extracted twice with 30 ml of chloroform. The obtained<br>
organic layer was combined, and 10 ml of water was<br>
added thereto. The mixture was then adjusted to pH 2<br>
with 1 mol/L hydrochloric acid. The organic layer was<br>
separated, washed with 0.5 mol/L hydrochloric acid and<br>
with water, and then dried over anhydrous magnesium<br>
sulfate. The solvent was removed under a reduced<br>
pressure to obtain 0.96 g of a yellow oil product,<br>
methyl 6-{(tert-butoxycarbonyl)[3-(4-<br>
cyanophenoxy)propyl]amino}hexanoate.<br>
1H-NMR (CDCl3) d: 1.24-1.47 (4H, m) , 1.53 (9H, s) , 1.60-<br>
1.72 (2H, m), 1.96-2.09 (2H, m) , 2.27-2.37 (2H, m),<br>
3.12-3.40 (4H, m), 3.67 (3H, s), 3.98-4.05 (2H, m),<br>
6.90-6.96 (2H, m), 7.54-7.62 (2H, m)<br>
Example 3-2<br><br>
The following compound was obtained in the<br>
same manner as Example 1.<br>
6-[(3-{4-<br>
[araino(imino)methyl]phenoxy}propyl)amino]hexanoic acid<br>
hydrochloride<br>
IR(KBr)cm-1: 3122, 1700, 1676, 1608<br><br>
1H-NMR (d6-DMSO) d: 1.25-1.40 (2H, m), 1.45-1.60 (2H,<br>
m) , 1.60-1.72 (2H, m), 2.12-2.26 (4H, m), 2.86 (2H,<br>
brs), 3.02 (2H, brs), 4.22 (2H, t, J = 6.1 Hz), 7.16<br>
(2H, d, J = 8.9 Hz), 7.91 (2H, d, J = 8.9 Hz), 9.1-9.4<br>
(6H, m) , 12.1 (1H, brs)<br>
Example 4<br><br>
0.70 g of 4-(4-azidobutoxy)benzonitrile was<br>
dissolved in 7.0 ml of ethanol, and while cooling on<br>
ice, hydrogen chloride gas was blown into the solution.<br>
The solution was stirred at room temperature for 12<br>
hours, and the solvent was then removed under a reduced<br>
pressure. The obtained residue was suspended in 7.0 ml<br>
of ethanol, and 0.57 g of ammonium acetate was added<br>
thereto, followed by heating to reflux for 3 hours.<br>
Thereafter, the reaction solution was cooled to room<br>
temperature, and the solvent was then removed under a<br>
reduced pressure. 10 ml of ethyl acetate was added to<br>
the obtained residue, and filtration was carried out to<br>
obtain 0.95 g of a white solid, 4-(4-<br>
azidobutoxy)benzamidine acetate.<br>
IR(KBr)cm-1: 3252, 2957, 2096, 1700, 1612<br>
1H-NMR (d5-DMSO) d: 1.60-1.90 (7H, m), 3.42 (2H, t, J=<br>
6.7 Hz), 4.12 (2H, t, J = 6.2 Hz), 7.15 (2H, d, J = 8.8<br>
Hz), 7.3 (3H, brs), 7.84 (2H, d, J = 8.8 Hz)<br><br>
Example 5<br><br>
0.48 g of 4-(4-azidobutoxy)benzamidine was<br>
dissolved in 5.0 ml of methanol, and 0.08 g of 5%<br>
palladium-carbon was then added thereto, followed by<br>
stirring under a hydrogen atmosphere at ambient<br>
temperature under atmospheric pressure for 7.5 hours.<br>
After completion of the reaction, the catalyst was<br>
removed by filtration, and the solvent was removed<br>
under a reduced pressure. The obtained residue was<br>
dissolved in 10 ml of ethanol, and a 10mol/L hydrogen<br>
chloride ethanol solution was then added to the<br>
solution. The solvent was then removed under a reduced<br>
pressure. The obtained residue was recrystallized with<br>
isopropanol to obtain 0.20 g of 4-(4-<br>
aminobutoxy) benzamidine hydrochloride.<br>
IR(KBr)cm-1: 3043, 1668, 1608<br>
1H-NMR (d6-DMSO) d: 1.65-1.86 (4H, m) , 2.84 (2H, t, J =<br>
7.3 Hz), 4.11 (2H, t, J = 6.1 Hz), 7.16 (2H, d, J = 9.0<br>
Hz), 7.8 (3H, brs), 7.87 (2H, d, J = 9.0 Hz), 9.0 (1H,<br>
brs), 9.3 (2H, brs)<br>
Example 6<br><br><br>
The following compound was obtained in the<br>
same manner as Reference example 6 and Examples 4 and<br>
5.<br>
4-(2-aminoethoxy)benzamidine hydrochloride<br>
IR(KBr)cm"1:3121, 1669, 1611,<br>
1H-NMR (d6-DMSO) d: 3.23 (2H, t, J = 5.1 Hz), 4.32 (2H,<br>
t, J = 5.1 Hz), 7.17-7.23 (2H, m), 7.46 (7H, brs),<br>
7.85-7.92 (2H, m)<br>
Example 7<br><br>
The following compound was obtained in the<br>
same manner as Reference example 6 and Examples 4 and<br>
5.<br>
4-[(5-aminopentyl)oxy]benzamidine hydrochloride<br>
IR(KBr)cm-1: 3353, 1676, 1610<br>
1H-NMR (d6-DMSO) d: 1.41-1.52 (2H, m), 1.59-1.69 (2H,<br>
m) , 1.69-1.80 (2H, m), 2.78 (2H, brs), 4.09 (2H, t, J =<br>
6.3 Hz), 7.15 (2H, d, J = 9.1 Hz), 7.86 (2H, d, J = 9.1<br>
Hz), 7.98 (2H, brs), 8.99 (2H, brs), 9.23 (2H, brs)<br>
Example 8<br><br><br>
The following compound was obtained in the<br>
same manner as Reference example 6 and Examples 4 and<br>
5.<br>
4-[(6-aminohexyl)oxy]benzamidine hydrochloride<br>
IR(KBr)cm-1: 3039, 1677, 1609<br>
1H-NMR (d6-DMSO) d: 1.41 (4H, brs), 1.58-1.66 (2H, m) ,<br>
1.69-1.78 (2H, m), 2.73-2.81 (2H, m), 4.10 (2H, t, J=<br>
5.6 Hz), 7.15 (2H, d, J = 8.4 Hz), 7.94 (2H, d, J = 8.4<br>
Hz), 8.24 (2H, brs), 9.00-9.30 (3H, brm), 9.43 (2H,<br>
brs)<br>
Example 9<br>
Example 9-1<br><br>
Benzyl [4-(3-<br>
azidopropoxy)phenyl](imino)methylcarbamate was obtained<br>
from benzyl [4-(3-bromo<br>
propoxy)phenyl](imino)methylcarbamate in the same<br>
manner as Reference example 6.<br>
1H-NMR (CDCl3) d: 2.00-2.10 (2H, m) , 3.52 (2H, t, J =<br><br>
6.4 Hz), 4.09 (2H, t, J = 6.0 Hz), 4.50-4.90 (1H, br) ,<br>
5.21 (2H, s), 6.44 (1H, brs), 6.90-6.95 (2H, m), 7.25-<br>
7.50 (5H, m), 7.80-7.90 (2H, m)<br>
Example 9-2<br><br>
0.51 g of benzyl [4-(3-<br>
azidopropoxy)phenyl](imino)methylcarbamate was<br>
dissolved in 16 ml of N,N-dimethylformamide.<br>
Thereafter, 0.26 g of 5% palladium-carbon suspended in<br>
12 ml of N,N-dimethylformamide was added to the above<br>
solution, and the obtained mixture was stirred under a<br>
hydrogen atmosphere at room temperature under<br>
atmospheric pressure for 3.5 hours. 3.5 hours later,<br>
0.4 ml of 6 mol/L hydrochloric acid was added to the<br>
reaction mixture, and the mixture was stirred under a<br>
hydrogen atmosphere at room temperature for 1.8 hours,<br>
and then at 40Â°C to 45Â°C for 1.8 hours. After<br>
completion of the reaction, the catalyst was removed by<br>
filtration, and the solvent was removed under a reduced<br>
pressure. 6 mol/L hydrochloric acid was added to the<br>
obtained residue, and the solvent was then removed<br>
under a reduced pressure. Isopropanol was added to the<br>
obtained residue, and thereafter, a precipitate was<br>
filtrated to obtain 0.12 g of 4-(3-<br>
aminopropoxy)benzamidine hydrochloride.<br><br>
IR (KBr) cm-1: 3346, 3100, 1668, 1609<br>
1H-NMR (d6-DMSO) d: 2.04-2.12 (2H, m) , 2.90-3.00 (2H,<br>
brm), 4.21 (2H, t, J = 6.2 Hz), 7.17 (2H, d, J = 8.9<br>
Hz), 7.89 (2H, d, J = 8.9 Hz), 8.24 (3H, brs), 9.11<br>
(2H, brs), 9.31 (2H, brs)<br>
Example 10<br><br>
0.20 g of 4-[3-(2,3-dioxo-l-<br>
piperazinyl)propoxy]benzamidine acetate was dissolved<br>
in 5.0 ml of 6 mol/L hydrochloric acid, followed by<br>
heating to reflux for 1 hour. The solvent was then<br>
removed under a reduced pressure. The obtained residue<br>
was filtrated with ethanol to obtain 0.14 g of a<br>
colorless solid, 4-{3-[(2-<br>
aminoethyl)amino]propoxy}benzamidine hydrochloride.<br>
IR(KBr)cm-1: 3368, 2716, 1674, 1608<br>
1H-NMR (d6-DMSO) 5: 2.10-2.21 (2H, m) , 3.12 (2H, t, J =<br>
6.8 Hz), 3.25 (4H, s) , 4.25 (2H, t, J = 6.0 Hz), 7.18<br>
(2H, d, J = 8.8 Hz), 7.91 (2H, d, J = 8.8 Hz), 8.63<br>
(2H, brs), 9.18 (2H, brs), 9.36 (2H, brs), 9.98 (2H,<br>
brs)<br>
Example 11<br><br><br>
0.30 g of tert-butyl {4-[3-(2,3-dioxo-1-<br>
piperazinyl)propoxy]phenyl}(imino)methylcarbamate was<br>
dissolved in 3.9 ml of N,N-dimethylformamide, and while<br>
cooled by ice, 31 nag of 60% sodium hydride was added to<br>
the solution, followed by stirring at room temperature<br>
for 30 minutes. Subsequently, 0.12 ml of 6-<br>
bromohexanoic acid ethyl ester was added dropwise to<br>
the reaction mixture, followed by stirring at room<br>
temperature for 2 hours. 20 ml of ice and 20 ml of<br>
ethyl acetate were added to the reaction mixture. The<br>
mixture was adjusted to pH 5 with 1 mol/L hydrochloric<br>
acid, and the aqueous layer was separated. The<br>
obtained aqueous layer was adjusted to pH 10.5 with a 1<br>
mol/L sodium hydroxide aqueous solution, and then<br>
extracted with 50 ml of ethyl acetate. The obtained<br>
organic layer was washed with a saturated aqueous<br>
solution of sodium chloride, and then dried over<br>
anhydrous magnesium sulfate. The solvent was removed<br>
under a reduced pressure. Toluene and diisopropyl<br>
ether were added to the obtained residue, and<br>
filtration was carried out to obtain 0.10 g of a white<br>
solid, 6-[4-(3-{4-[ [(tert-<br>
butoxycarbonyl)amino](imino)methyl]phenoxy}propyl)-2,3-<br>
dioxo-1-piperazinyl]hexanoic acid ethyl ester.<br>
IR(KBr)cm-1: 3374, 1734, 1692, 1616<br>
1H-NMR (CDCl3) d: 1.25 (3H, t, J = 7.1 Hz), 1.30-1.40<br>
(2H, m), 1.55 (9H, s), 1.55-1.70 (4H, m) , 2.10-2.20<br><br>
(2H, m), 2.29 (2H, t, J = 7.4 Hz), 3.40-3.60 (6H, m),<br>
3.67 (2H, t, J = 6.9 Hz), 4.06 (2H, t, J = 6.0 Hz),<br>
4.11 (2H, q, J = 7.1 Hz), 6.90 (2H, d, J = 8.8 Hz),<br>
7.84 (2H, d, J = 8.8 Hz)<br>
Example 12<br><br>
95 mg of 6-[4-(3-{4-[[(tert-<br>
butoxycarbonyl)amino](imino)methyl]phenoxy}propyl)-2,3-<br>
dioxo-1-piperazinyl]hexanoic acid ethyl ester was<br>
dissolved in 1.8 ml of 6 mol/L hydrochloric acid,<br>
followed by heating to reflux for 5 hours. After<br>
completion of the reaction, 6 mol/L hydrochloric acid<br>
was removed under a reduced pressure. Ethanol was<br>
added to the obtained residue, and filtration was<br>
carried out to obtain 73 mg of a white solid, 6-({2-<br>
[(3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)amino]ethyl}amino)he<br>
xanoic acid hydrochloride.<br>
IR(KBr)cm-1: 3369, 2749, 1718, 1670, 1610<br>
1H-NMR(D2O) d: 1.2-1.3 (2H, m) , 1.4-1.7 (4H, m), 2.0-2.3<br>
(4H, m) , 2.9-3.1 (2H, m), 3.1-3.4 (6H, m) , 4.0-4.2 (2H,<br>
m), 6.9-7.1 (2H, m), 7.6-7.7 (2H, m)<br>
Example 13<br><br><br>
The following compound was obtained in the<br>
same manner as Examples 11 and 12.<br>
4- (3-{[2-(hexylamino)ethyl]amino}propoxy)benzamidine<br>
hydrochloride<br>
IR(KBr)cm"1: 2772, 1676, 1610<br>
1H-NMR (d6-DMSO) 5: 0.88 (3H, t, J = 6.6 Hz), 1.2-1.4<br>
(6H, m) , 1.6-1.7 (2H, m) , 2.1-2.2 (2H, m), 2.8-3.0 (2H,<br>
m) , 3.0-3.2 (2H, m), 3.2-3.4 (4H, m), 3.5 (2H, brs),<br>
4.2-4.3 (2H, m), 7.17 (2H, d, J = 7.8 Hz), 7.87 (2H, d,<br>
J = 7.8 Hz), 9.16 (2H, brs), 9.25 (2H, brs)<br>
Example 14<br>
Example 14-1<br><br>
1.74 g of methyl 3-[4-(3-{4-<br>
[{[(benzyloxy)carbonyl]amino}(imino)methyl]phenoxy}prop<br>
yl)-2,3-dioxo-l-piperazinyl]propanoate was dissolved in<br>
10 ml of N,N-dimethylformamide. Thereafter, 0.52 g of<br>
5% palladium-carbon suspended in 7.4 ml of N,N-<br>
dimethylformamide and 0.85 ml of 6 mol/L hydrochloric<br>
acid were added to the solution, followed by stirring<br><br>
under a hydrogen atmosphere at room temperature under<br>
atmospheric pressure for 2 hours. After completion of<br>
the reaction, the catalyst was removed by filtration,<br>
and the residue was washed with 20 ml of N,N-<br>
dimethylformamide. The filtrate was then concentrated<br>
under a reduced pressure. 20 ml of xylene was added to<br>
the obtained residue, and the mixture was further<br>
concentrated under a reduced pressure to obtain 1.37 g<br>
of methyl 3-[4-(3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)-2,3-dioxo-l-<br>
piperazinyl]propanoate hydrochloride.<br>
1H-NMR (d6-DMSO) d: 1.95-2.05 (2H, m), 2.61 (2H, t, J=<br>
6.8 Hz), 3.50-3.58 (8H, m), 3.60 (3H, s), 4.12 (2H, t,<br>
J = 6.0 Hz), 7.14 (2H, d, J = 8.8 Hz), 7.88 (2H, d, J =<br>
8.8 Hz), 9.14 (2H, brs), 9.31 (2H, brs)<br>
Example 14-2<br>
The following compound was obtained in the<br>
same manner as Example 12.<br><br>
N-{2-[(3-{4-<br>
[amino (imino) methyl] phenoxy }propyl) amino] ethyl} -/?-<br>
alanine hydrochloride<br>
IR(KBr)cm"1: 3377, 3237, 2763, 1724, 1684, 1609<br>
XH-NMR (d6-DMSO) 5: 2.10-2.20 (2H, m) , 2.71 (2H, t, J =<br><br>
7.2 Hz), 3.09-3.18 (4H, m), 3.29 (4H, brs), 3.30-3.60<br>
(4H, m), 4.22 (2H, t, J = 6.0 Hz), 7.17 (2H, d, J = 8.8<br>
Hz), 7.85 (2H, d, J = 8.8 Hz), 8.90 (2H, brs), 9.21<br>
(2H, brs)<br>
Example 15<br>
Example 15-1<br><br>
1.80 g of 4-[3-(2,3-dioxo-l-<br>
piperazinyl)propoxy]benzonitrile was dissolved in 33 ml<br>
of N,N-dimethylformamide, and while cooled by ice, 0.26<br>
g of 60% sodium hydride was added to the solution,<br>
followed by stirring for 1 hour. Subsequently, 0.41 ml<br>
of methyl iodide was added to the reaction mixture, and<br>
then, 1.5 hours later, 0.41 ml of methyl iodide was<br>
further added thereto, followed by stirring at room<br>
temperature. After completion of the reaction, the<br>
reaction mixture was added to a mixed solution of ice<br>
water and chloroform, and the obtained mixture was then<br>
adjusted to pH 7.2 with hydrochloric acid. Thereafter,<br>
the organic layer was separated. The aqueous layer was<br>
extracted twice with 20 ml of chloroform, and the<br>
obtained organic layer was combined. The thus obtained<br>
layer was washed with a saturated aqueous solution of<br>
sodium chloride, and then dried over anhydrous<br>
magnesium sulfate. The obtained solution was then<br><br>
concentrated under a reduced pressure- The obtained<br>
residue was purified by silica gel column<br>
chromatography [eluent; chloroform : methanol =20 : 1]<br>
to obtain 1.48 g of a white solid, 4-[3-(4-methyl-2,3-<br>
dioxo-1-piperazinyl)propoxy]benzonitrile.<br>
1H-NMR (CDCl3) d: 2.10-2.18 (2H, m), 3.09 (3H, s) , 3.56-<br>
3.63 (4H, m), 3.67 (2H, t, J = 6.8 Hz), 4.07 (2H, t, J<br>
= 6.4 Hz), 6.92-6.96 (2H, m), 7.56-7.60 (2H, m)<br>
Example 15-2<br><br>
10 ml of ethanol and 2.5 ml of methylene<br>
chloride were added to 1.44 g of 4-[3-(4-methyl-2,3-<br>
dioxo-l-pipera2inyl)propoxy]benzonitrile. While cooled<br>
by ice, hydrogen chloride gas was introduced into the<br>
mixture until it became saturated. It was left at rest<br>
at room temperature for 22.5 hours. After completion<br>
of the reaction, the solvent was removed under a<br>
reduced pressure. 10 ml of ethanol and 2.5 ml of<br>
methylene chloride were added to the obtained residue,<br>
and 0.97 g of ammonium acetate was then added thereto,<br>
followed by heating to reflux. After completion of the<br>
reaction, the temperature was cooled to room<br>
temperature, and the reaction solution was then<br>
concentrated under a reduced pressure. The obtained<br>
residue was filtrated with ethanol to obtain a white<br>
solid. 10 ml of 6 mol/L hydrochloric acid was added to<br>
the obtained white solid, and the mixture was subject<br>
to heating to reflux for 6 hours. The reaction mixture<br>
was concentrated under a reduced pressure, and the<br><br>
obtained white solid was filtrated with ethanol to<br>
obtain 1.26 g of 4-(3-{[2-<br>
(methylamino)ethyl]amino}propoxy)benzamidine<br>
hydrochloride.<br>
IR(KBr)cm-1: 2722, 1669, 1610<br>
1H-NMR (d6-DMSO + D2O) d: 2.14-2.21 (2H, m) , 2.68 (3H,<br>
s), 3.22 (2H, t, J = 7.6 Hz), 3.30-3.37 (4H, m), 4.19-<br>
4.23 (2H, m), 7.19 (2H, d, J = 8.8 Hz), 7.82 (2H, d, J<br>
= 8.8 Hz)<br>
Example 16<br><br>
The following compound was obtained in the<br>
same manner as Example 15.<br>
4-(3-{[2-(propylamino)ethyl]amino}propoxy)benzamidine<br>
hydrochloride<br>
IR(KBr)cm-1: 3318, 2771, 1673, 1609<br>
1H-NMR (d6-DMSO) d: 0.94 (3H, t, J = 7.0 Hz), 1.6-1.8<br>
(2H, m), 2.18 (2H, brs), 2.90 (2H, brs), 3.13 (2H,<br>
brs), 3.34 (4H, brs), 4.25 (2H, brs), 7.1-7.7 (2H, m) ,<br>
7.18	(2H, d, J = 6.8 Hz), 7.89 (2H, d, J = 6.8 Hz),<br>
9.18	(2H, brs), 9.30 (2H, brs)<br>
Example 17<br><br><br>
The following compound was obtained in the<br>
same manner as Example 15.<br>
4- ( {2-[ (3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)amino]ethyl}amino)bu<br>
tyric acid hydrochloride<br>
IR(KBr)cm-1: 3418, 2770, 1718, 1670, 1609<br>
1H-NMR (d6-DMSO-D2O) d: 1.8-1.9 (2H, m) , 2.1-2.2 (2H, m) ,<br>
2.39 (2H, t, J = 7.4 Hz), 3.00 (2H, t, J = 7.6 Hz),<br>
3.17 (2H, t, J = 7.6 Hz), 3.30 (4H, s), 4.21 (2H, t, J<br>
= 5.8 Hz), 7.17 (2H, d, J = 9.0 Hz), 7.83 (2H, d, J =<br>
9.0 Hz)<br>
Example 18<br><br>
2.16 g of 4-(3-{4-[3-(4-cyanophenoxy)propyl]-<br>
2,3-dioxo-l-piperazinyl}propoxy)benzonitrile was<br>
suspended in 50.0 ml of ethanol. While cooled by ice,<br>
hydrogen chloride gas was blown into the suspension,<br>
followed by stirring at room temperature for 12 hours.<br>
After completion of the reaction, the solvent was<br>
removed under a reduced pressure to obtain 2.95 g of a<br>
pale yellow solid, ethyl 4-{3-[4-(3-{4-<br>
[ethoxy(imino)methyl]phenoxy}propyl)-2,3-dioxo-l-<br><br>
piperazinyl]propoxy}benzenecarboximidoate<br>
hydrochloride.<br>
IR(KBr)cm-1: 3393, 2875, 1684, 1608<br>
1H-NMR (d6-DMSO) d: 1.47 (6H, t, J = 7.0 Hz), 1.95-2.05<br>
(4H, m) , 3.46-3.62 (8H, m), 4.15 (4H, t, J = 6.0 Hz),<br>
4.61 (4H ,q, J = 7.0 Hz), 7.16 (4H, d, J = 9.0 Hz),<br>
8.16 (4H, d, J = 9.0 Hz), 11.22 (1H, brs), 11.96 (1H,<br>
brs)<br>
Example 19<br><br>
2.69 g of ethyl 4-{3-[4-(3-{4-<br>
[ethoxy(imino)methyl]phenoxy}propyl)-2,3-dioxo-1-<br>
piperazinyl]propoxy}benzenecarboximidoate hydrochloride<br>
was suspended in 45.0 ml of ethanol, and then, 1.60 g<br>
of ammonium acetate was added to the suspension. The<br>
mixture was subject to heating to reflux for 3 hours.<br>
The reaction mixture was cooled to room temperature,<br>
and a precipitate was filtrated to obtain 2.51 g of a<br>
colorless solid, 4-{3-[4-(3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)-2,3-dioxo-1-<br>
piperazinyl]propoxy}benzamidine acetate.<br>
IR(KBr) cm-1: 3117, 167 0, 160 9<br>
1H-NMR(CD3OD) d: 1.90 (3H, s), 2.10-2.20 (4H, m) , 3.64-<br>
3.76 (8H, m), 4.16 (4H, t, J = 5.9 Hz), 7.10-7.20 (4H,<br>
m) , 7.75-7.80 (4H, m)<br><br>
Example 20<br><br>
The following compound was obtained in the<br>
same manner as Reference example 7 and Examples 18 and<br>
19.<br>
4-{2-[4-(2-{4-[amino(imino)methyl]phenoxy}ethyl)-2,3-<br>
dioxo-1-piperazinyl]ethoxy}benzamidine acetate<br>
IR(KBr)cm-1: 3203, 1674, 1612<br>
1H-NMR (d6-DMSO) d: 1.89 (6H, s), 3.67 (4H, s), 3.76<br>
(4H, t, J = 4.8 Hz), 4.26 (4H, t, J = 4.8 Hz), 7.16<br>
(4H, d, J = 8.8 Hz), 7.81 (4H, d, J = 8.8 Hz)<br>
Example 21<br><br>
The following compound was obtained in the<br>
same manner as Reference example 7 and Examples 18 and<br>
19.<br>
4-{4-[4-(4-{4-[amino(imino)methyl]phenoxy}butyl)-2,3-<br>
dioxo-l-piperazinyl]butoxy}benzamidine acetate<br><br>
IR(KBr) cm-1: 3134, 3049, 1654, 1610<br>
1H-NMR(CD3OD) d: 1.80-1.86 (8H, m) , 1.90 (6H, s), 3.56<br>
(4H, t, J = 6.6 Hz), 3.65 (4H, s), 4.14 (4H, t, J = 5.5<br>
Hz), 7.10-7.14 (4H, m), 7.75-7.80 (4H, m)<br>
Example 22<br><br>
The following compound was obtained in the<br>
same manner as Reference example 7 and Examples 18 and<br>
19.<br>
4-{3-[4-(2-{4-[amino(imino)methyl]phenoxy}ethyl)-2,3-<br>
dioxo-1-piperazinyl]propoxy}benzamidine acetate<br>
IR(KBr)cm-1: 3346, 3128, 1670, 1608<br>
1H-NMR (d6-DMSO) d: 1.97-2.04 (2H, m) , 2.08 (6H, s),<br>
3.53 (2H, t, J = 6.8 Hz), 3.55-3.60 (2H, m) , 3.67-3.71<br>
(2H, m), 3.77 (2H, t, J = 5.4 Hz), 4.11 (2H, t, J = 6.0<br>
Hz), 4.27 (2H, t, J = 5.4 Hz), 7.12 (2H, d, J = 8.8<br>
Hz), 7.18 (2H, d, J = 9.0 Hz), 7.86 (2H, d, J = 8.8<br>
Hz), 7.90 (2H, d, J = 9.0 Hz), 9.22 (8H, brs)<br>
Example 23<br><br><br>
The following compound was obtained in the<br>
same manner as Reference example 7 and Examples 18 and<br>
19.<br>
4-({(E)-4-[4-(3-{4-[amino(imino)methyl]phenoxy}propyl)-<br>
2,3-dioxo-1-piperazinyl]-2-butenyl}oxy)benzamidine<br>
acetate<br>
IR(KBr)cm-1: 3164, 1669, 1610<br>
1H-NMR(D2O) d: 1.96 (6H, s), 2.10-2.20 (2H, m) , 3.58-<br>
3.74 (6H, m), 4.10 (2H, d, J = 5.4 Hz), 4.21 (2H, t, J<br>
= 5.4 Hz), 4.75 (2H, d, J = 4.9 Hz), 5.86 (1H, dt, J =<br>
15.6, 5.4 Hz), 5.93 (1H, dt, J = 15.6,4.9 Hz), 7.04<br>
(2H, d, J = 8.8 Hz), 7.10-7.20 (2H, m), 7.70-7.82 (4H,<br>
m)<br>
Example 2 4<br><br>
1.76 g of 4-{3-[4-(3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)-2,3-dioxo-1-<br>
piperazinyl]propoxy}benzamidine acetate was dissolved<br>
in 30.0 ml of 6 mol/L hydrochloric acid, and the<br>
obtained solution was subject to heating to reflux for<br>
5 hours. After completion of the reaction, 6 mol/L<br>
hydrochloric acid was removed under a reduced pressure.<br>
Ethanol was added to the obtained residue, and<br>
filtration was carried out to obtain 1.29 g of a<br>
colorless solid, 4-[3-({2-[(3-{4-<br><br>
[amino(imino)methyl]phenoxy}propyl)amino]ethyl}amino)pr<br>
opoxy]benzamidine hydrochloride.<br>
IR(KBr)cm-1: 3306, 3162, 2714, 1674, 1609<br>
1H-NMR (d6-DMSO) d: 2.14-2.22 (4H, m) , 3.14 (4H, brs),<br>
3.38 (4H, s), 4.24 (4H, t, J = 6.1 Hz), 7.18 (4H, d, J<br>
= 8.8 Hz), 7.87 (4H, d, J = 8.8 Hz), 9.03 (4H, brs),<br>
9.27 (4H, brs), 9.82 (4H, brs)<br>
Example 2 5<br><br>
The following compound was obtained in the<br>
same manner as Example 24.<br>
4-[2-({2-[(2-{4-<br>
[amino(imino)methyl]phenoxy}ethyl)amino]ethyl}amino)eth<br>
oxy]benzamidine hydrochloride<br>
IR(KBr)cm-1: 3312, 3097, 1662, 1609<br>
1H-NMR (d6-DMSO) d: 3.20-3.80 (10H, m), 4.44 (4H, brs),<br>
7.24 (4H, d, J = 8.4 Hz), 7.90 (2H, d, J = 8.4 Hz),<br>
9.11 (4H, brs), 9.32 (4H, brs), 9.98 (2H, brs)<br>
Example 2 6<br><br>
The following compound was obtained in the<br>
same manner as Example 24.<br>
4-[4-({2-[(4-{4-<br><br>
[amino(imino)methyl]phenoxy}butyl)amino]ethyl}amino)but<br>
oxy]benzamidine hydrochloride<br>
IR(KBr)cm-1: 3320, 3164, 2717, 1676, 1609<br>
1H-NMR (d6-DMSO) d: 1.84 (8H, brs), 3.02 (4H, brs),<br>
3.30-3.40 (4H, m), 4.13 (4H, brs), 7.17 (4H, d, J = 8.5<br>
Hz), 7.87 (4H, d, J = 8.5 Hz), 9.04 (4H, brs), 9.27<br>
(4H, brs), 9.68 (3H, brs)<br>
Example 2 7<br><br>
The following compound was obtained in the<br>
same manner as Example 24.<br>
4-[3-({2-[(2-{4-<br>
[amino(imino)methyl]phenoxy}ethyl)amino]ethyl}amino)pro<br>
poxy]benzamidine hydrochloride<br>
IR(KBr)cm-1: 3335, 3124, 2772, 1671, 1609<br>
1H-NMR (d6-DMSO) d: 2.20 (2H, brs), 3.14 (2H, brs),<br>
3.30-3.60 (6H, brm), 4.26 (2H, brs), 4.46 (2H, brs),<br>
7.17 (2H, d, J = 7.8 Hz), 7.25 (4H, d, J = 7.1 Hz),<br>
7.80-8.00 (4H, brm), 9.19 (4H, brs), 9.30-9.50 (4H,<br>
brm), 10.05 (4H, brs)<br>
Example 2 8<br><br>
The following compound was obtained in the<br><br>
same manner as Examples 4 and 5.<br>
4-[(3-aminopropyl)amino]benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 1.84-1.91 (2H, m) , 2.84-2.91 (2H,<br>
m) , 3.50-4.00 (2H, br) , 6.72 (2H, d, J = 8.8 Hz), 7.74<br>
5 (2H, d, J = 8.8 Hz), 8.28 (3H, s), 8.78 (2H, s), 8.98<br>
(2H, s)<br>
Example 2 9<br><br>
The following compound was obtained in the<br>
same manner as Example 4.<br>
4- [ (3-azidopropyl)sulfanyl]benzamidine<br>
1H-NMR (d6-DMSO) d: 1.79-1.86 (2H, m), 3.07 (2H, t, J=<br>
7.4 Hz), 3.33 (1H, s), 3.47 (2H, t, J = 6.6 Hz), 6.73<br>
(2H, s), 7.35 (2H, d, J = 8.4 Hz), 7.72 (2H, d, J = 8.4<br>
Hz) .<br>
 Example 30<br><br>
0.24 g of 4-[(3-<br>
azidopropyl)sulfanyl]benzamidine was dissolved in 4.0<br>
mi of methanol. Thereafter, 0.18 g of 1,3-<br>
propanedithiol and 0.56 ml of triethylamine were added<br>
 to the solution at room temperature, followed by<br><br>
stirring for 1 day. Thereafter, 2.16 g of 1,3-<br>
propanedithiol was further added thereto at room<br>
temperature, followed by stirring for 5 hours.<br>
Thereafter, 20 ml of water and 20 ml of ethyl acetate<br>
were added to the reaction mixture, and the aqueous<br>
layer was separated. Organic layer was extracted with<br>
10 ml of water, and the obtained water layer was<br>
combined. 20 ml of 6mol/L hydrochloric acid was added<br>
to the aqueous layer. The mixture was washed with<br>
chloroform 3 times, and then concentrated under a<br>
reduced pressure. The obtained residue was purified by<br>
silica gel column chromatography [eluent; chloroform :<br>
methanol : trifluoroacetic acid = 2000 : 1000 : 1] to<br>
obtain 0.10 g of a pale yellow solid, 4-[(3-<br>
aminopropyl)sulfanyl]benzamidine trifluoroacetate.<br>
1H-NMR (d6-DMSO) d: 1.88-1.96 (2H, m) , 2.80-3.00 (2H,<br>
m), 3.17 (1H, s), 3.21 (2H, t, J = 7.0 Hz), 7.54 (2H,<br>
d, J = 8.8 Hz), 7.80 (2H, d, J = 8.8 Hz), 8.10 (3H, s),<br>
9.11 (2H, s), 9.37 (2H, s) .<br>
Example 31<br><br>
0.60 g of 4-(2-{ [2- (4-<br>
cyanophenoxy)ethyl]aminojethoxy)benzonitrile was<br>
dissolved in 20 ml of ethanol. Thereafter, while<br>
cooled by ice, hydrogen chloride gas was introduced<br><br>
into the solution, until it became saturated. The<br>
solution was left at rest at room temperature for 12<br>
hours. After completion of the reaction, the reaction<br>
solution was concentrated under a reduced pressure.<br>
The obtained residue was dissolved in 30 ml of ethanol,<br>
and 1.20 g of ammonium acetate was then added thereto<br>
at room temperature. The mixture was stirred for 5.5<br>
hours while being heated to reflux. After cooling to<br>
room temperature, the solvent was removed under a<br>
reduced pressure. Hydrochloric acid was added to the<br>
residue, and the solvent was removed again.<br>
Thereafter, the obtained solid was filtrated with a<br>
mixed solution of isopropanol and ethanol to obtain<br>
0.31 g of a pale brown solid, 4-{2-[(2-{4-<br>
[amino(imino)methyl]phenoxy}ethyl)amino]ethoxy}benzamid<br>
ine hydrochloride.<br>
1H-NMR (d6-DMSO) d: 3.35-3.55 (4H, m), 4.50 (4H, t, J =<br>
5.0 Hz), 7.22 (4H, d, J = 9.0 Hz), 7.93 (4H, d, J = 9.0<br>
Hz), 9.21 (3H, s), 9.40 (4H, s), 9.88 (2H, brs)<br>
Example 32<br><br>
The following compound was obtained in the<br>
same manner as Example 31.<br>
4-{3-[(3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)amino]propoxy}benzam<br><br>
idine hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.15-2.22 (4H, m), 3.00-3.20 (4H,<br>
m), 4.22 (4H, t, J = 6.1 Hz), 7.16 (4H, d, J = 9.0 Hz),<br>
7.87 (4H, d, J = 9.3 Hz), 9.00 (4H, s), 9.29 (6H, s)<br>
Example 33<br><br>
The following compound was obtained in the<br>
same manner as Example 31.<br>
4-{3-[(6-{4-<br>
[amino(imino)methyl]phenoxy}hexyl)amino]propoxy}benzami<br>
dine acetate<br>
1H-NMR(D2O) d: 1.40-1.60 (4H, m) , 1.74-1.87 (4H, m) ,<br>
1.94 (6H, s), 2.23-2.30 (2H, m), 3.11-3.15 (2H, m),<br>
3.31 (2H, t, J = 7.4 Hz), 4.18 (2H, t, J = 6.2 Hz),<br>
4.30 (2H, t, J = 5.6 Hz), 7.16-7.21 (4H, m), 7.78-7.82<br>
(4H, m)<br>
Example 34<br><br>
The following compound was obtained in the<br>
same manner as Examples 18 and 19.<br>
4-{3-[4-(6-{4-[amino(imino)methyl]phenoxy}hexyl)-2,3-<br><br>
dioxo-1-piperazinyl]propoxy}benzamidine acetate<br>
1H-NMR (d6-DMSO + D2O) d: 1.26-1.36 (2H, m) , 1.40-1.60<br>
(4H, m) , 1.70-1.80 (8H, m), 1.90-2.20 (2H, m), 3.30-<br>
3.45 (2H, m), 3.50-3.62 (6H, m), 4.07-4.14 (4H, m),<br>
7.11-7.14 (4H, m), 7.76-7.79 (4H, m)<br>
Example 35<br><br>
The following compound was obtained in the<br>
same manner as Examples 18 and 19.<br>
3-{3-[4-(3-{4-[amino(imino)methyl]phenoxy}propyl)-2,3-<br>
dioxo-1-piperazinyl]propoxy}benzamidine<br>
1H-NMR (d6-DMSO) d: 1.90-2.00 (4H, m) , 3.51-3.57 (8H,<br>
m) , 4.07-4.13 (4H, m), 7.12 (2H, d, J = 8.8 Hz), 7.23-<br>
7.26 (1H, m), 7.36-7.38 (2H, m), 7.49 (1H, t, J = 8.2<br>
Hz), 7.81 (2H, d, J = 8.8 Hz), 9.10-9.60 (6H, m).<br>
Example 3 6<br><br>
The following compound was obtained in the<br>
same manner as Examples 18 and 19.<br>
4-[3-{4-[3-{4-[amino(imino)methyl]phenoxy}-2-<br>
(benzyloxy)propyl]-2,3-dioxo-1-piperazinyl}-2-<br>
(benzyloxy)propoxy]benzamidine<br>
1H-NMR (d6-DMSO) d: 3.48-3.72 (6H, m) , 4.00-4.08 (2H,<br><br>
m), 4.16-4.19 (2H, m), 4.24-4.28 (2H, m), 4.37 (2H, t,<br>
J = 5.1 Hz), 4.59-4.70 (4H, m), 7.17 (4H, d, J = 9.0<br>
Hz), 7.23-7.30 (10H, m), 7.86 (4H, d, J = 9.0 Hz),<br>
8.80-9.40 (6H, m).<br>
Example 37<br><br>
The following compound was obtained in the<br>
same manner as Examples 18 and 19.<br>
4- ({3-[4-(3-{4-[amino(imino)methyl]anilino}propyl)-2,3-<br>
dioxo-1-piperazinyl]propyl}amino)benzamidine<br>
1H-NMR (d6-DMSO) d: 1.70-1.90 (4H, m) , 3.11-3.16 (4H,<br>
m) , 3.20-3.50 (4H, m), 3.55 (4H, s), 6.69 (4H, d, J =<br>
8.9 Hz), 6.93 (2H, t, J = 5.4 Hz), 7.70 (4H, d, J = 8.9<br>
Hz), 8.10-8.90 (6H, br)<br>
Example 38<br><br>
The following compound was obtained in the<br>
same manner as Examples 18 and 19.<br>
4-{3-[4-(3-{4-[amino(imino)methyl]phenoxy}propyl)-2-<br>
oxo-1-piperazinyl]propoxy}benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 1.97-2.03 (2H, m), 2.20-2.40 (2H,<br>
 m) , 3.30-4.00 (10H, m), 4.15-4.23 (4H, m) , 7.15-7.20<br>
(4H, m) , 7.90-7.94 (4H, m) , 9.18-9.20 (4H, s), 9.38-<br><br>
9.40 (4H, m), 12.38 (1H, brs)<br>
Example 39<br><br>
The following compound was obtained in the<br>
same manner as Examples 18 and 19.<br>
4-{3-[4-(3-{4-[amino(imino)methyl]phenoxy}propyl)-7-<br>
oxo-1,4-diazepan-l-yl]propoxy}benzamidine acetate<br>
1H-NMR(D2O) d: 1.94 (6H, s), 2.01-2.11 (4H, m) , 2.67-<br>
2.82 (8H, m) , 3.58-3.68 (4H, m), 4.18 (4H, t, J = 5.6<br>
Hz), 7.14-7.20 (4H, m), 7.80 (4H, d, J = 8.4 Hz)<br>
Example 4 0<br>
Example 40-1<br><br>
4.00 g of 4-(3-{4-[3-(4-cyanophenoxy)propyl]-<br>
1-piperazinyl}propoxy)benzonitrile was dissolved in 280<br>
ml of ethanol. While cooled by ice, hydrogen chloride<br>
gas was blown into the solution, followed by stirring<br>
at room temperature for 2 days. After completion of<br>
the reaction, the solvent was removed under a reduced<br>
pressure. The obtained residue was suspended in 200 ml<br>
of ethanol, and 7.62 g of ammonium acetate was then<br>
added to the suspension at room temperature, followed<br><br>
by heating to reflux for 6 hours. After cooling to<br>
room temperature, the solvent was removed under a<br>
reduced pressure. 200 ml of water and 100 ml of<br>
chloroform were added to the obtained residue, and the<br>
mixture was then adjusted to pH 13 by addition of a<br>
5.0mol/L sodium hydroxide aqueous solution. A<br>
precipitate was filtrated, and the precipitate was<br>
washed with water, until the filtrate became neutral to<br>
obtain 4.04 g of a white solid, 4-{3-[4-(3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)-1-<br>
piperazinyl]propoxy}benzamidine.<br>
1H-NMR (d6-DMSO) d: 1.70-2.00 (4H, m), 2.10-2.70 (12H,<br>
m) , 4.03 (4H, t, J = 6.2 Hz), 6.00-6.80 (6H, brs), 6.92<br>
(4H, t, J = 8.7 Hz), 7.71 (4H, t, J = 8.7 Hz)<br>
Example 40-2<br><br>
0.25 g of 4-{3-[4-(3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)-1-<br>
piperazinyl]propoxy}benzamidine was suspended in 5.0 ml<br>
of ethanol. 1.5 ml of a 2.0mol/L hydrogen chloride<br>
ethanol solution was added to the suspension.<br>
Thereafter, 3.0 ml of water was added for dissolution.<br>
The solvent was then removed under a reduced pressure.<br>
Thereafter, the residue was filtrated with ethanol to<br>
obtain 0.25 g of 4-{3- [4-(3-{4-<br>
[amino(imino)methyl]phenoxyJpropyl)-1-<br><br>
piperazinyl]propoxy}benzamidine hydrochloride.<br>
1H-NMR (d6-DMSO) d: 2.10-2.30 (4H, m), 3.10-3.90 (14H,<br>
m) , 4.10-4.30 (4H, m) , 7.17 (4H, d, J = 8.8 Hz), 7.86<br>
(4H, d, J = 8.8 Hz), 8.99 (4H, s), 9.24 (4H, s)<br>
Example 41<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4-{3-[4-(3-{4-[amino(imino)methyl]-2-<br>
methylphenoxy}propyl)-1-piperazinyl]propoxy}-3-<br>
methylbenzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.10-2.40 (10H, m), 3.00-4.00 (12H,<br>
m) , 4.22 (4H, t, J = 5.6 Hz), 7.17 (2H, d, J = 8.3 Hz),<br>
7.70-7.80 (4H, m), 9.06 (4H, s), 9.24 (4H, s), 12.10-<br>
12.80 (2H, br)<br>
Example 42<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4-{3-[4-(3-{4-[amino(imino)methyl]-3-<br>
fluorophenoxyJpropyl)-1-piperazinyl]propoxy}-2-<br>
fluorobenzamidine hydrochloride<br>
1H-NMR (d6-DMSO + D2O) d: 2.16-2.30 (4H, m) , 3.35 (4H, t,<br><br>
J = 7.7 Hz), 3.58 (8H, brs), 4.00-4.40 (4H, m), 6.99-<br>
7.09 (4H, m), 7.66 (2H, t, J = 8.5 Hz)<br>
Example 43<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4-{3-[4-(3-{4-[amino(imino)methyl]-2-<br>
fluorophenoxyJpropyl)-1-piperazinyl]propoxy}-3-<br>
fluorobenzamidine hydrochloride<br>
1H-NMR(D2O) d: 2.41-2.47 (4H, m) , 3.63 (4H, t, J = 7.4<br>
Hz), 3.65-4.00 (8H, m), 4.40 (4H, t, J = 5.4 Hz), 7.32-<br>
7.36 (2H, m), 7.65-7.68 (4H, m)<br>
Example 4 4<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4-{3-[4-(3-{4-[amino(imino)methyl]-2-<br>
methoxyphenoxy}propyl)-1-piperazinyl]propoxy}-3-<br>
methoxybenzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.10-2.40 (4H, m) , 3.10-4.00 (14H,<br>
m.) , 3.88 (6H, s), 4.20 (4H, t, J = 5.9 Hz), 7.20 (2H,<br>
d, J = 8.3 Hz), 7.51 (2H, s), 7.51-7.53 (2H, m), 9.01<br><br>
(4H, s), 9.29 (4H, s).<br>
Example 45<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4'-{3-[4-(3-{4-[amino(imino)methyl]phenoxy}propyl)-1-<br>
piperazinyl]propoxy}[1,1'-biphenyl]-4-amidine<br>
hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.20-2.30 (4H, m) , 3.20-3.90 (14H,<br>
m) , 4.17 (2H, t, J = 5.8 Hz), 4.23 (2H, t, J = 5.8 Hz),<br>
7.11 (2H, d, J = 8.8 Hz), 7.18 (2H, d, J = 9.2 Hz),<br>
7.77 (2H, d, J = 8.8 Hz), 7.89-7.97 (6H, m), 9.16 (2H,<br>
s), 9.31-9.33 (4H, m), 9.49 (2H, s)<br>
Example 4 6<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4-{3-[4-(3-{4-[amino(imino)methyl]phenoxy}-2-<br>
methylpropyl)-1-piperazinyl]-2-<br>
methylpropoxy}benzamidine hydrochloride<br>
1H-NMR(D2O) d: 1.20 (6H, d, J = 6.8 Hz), 2.66-2.70 (2H,<br><br>
m), 3.31-3.36 (2H, m) , 3.47-3.52 
(8H, m), 4.09-4.13 {2H, m) , 4.21-4.25 (2H, m} , 7.19<br>
(4H, d, J = 8.8 Hz), 7.81 (4H, J=8 . 8 Hz)<br>
Example 47<br><br>
70 ml of ethanol was added to 1.00 g of 4-(2-<br>
(benzyloxy)-3-{4-[2-(benzyloxy)-3-
cyanophenoxy)propyl]-l-<br>
piperazinyl}propoxy)benzonitrile. While cooled by ice,<br>
hydrogen chloride gas was introduced into the mixture,<br>
until it became saturated, followed by stirring at room<br>
temperature for 18 hours. Thereafter, 20 ml of ethanol<br>
was further added to the reaction mixture. While<br>
cooled by ice, hydrogen chloride gas was introduced<br>
into the mixture again, until it became saturated,<br>
followed by stirring at room temperature for 20 hours.<br>
The reaction mixture was concentrated under a reduced<br>
pressure to obtain 1.35 g of a pale yellow solid. 1.24<br>
g of the obtained solid was suspended in 120 ml of<br>
ethanol, and 2.20 g of ammonium acetate was then added<br>
thereto at room temperature, followed by stirring for 4<br>
hours under heated to reflux. The reaction mixture was<br>
cooled to room temperature, and it was then<br>
concentrated under a reduced pressure. The obtained<br>
residue was dissolved in methanol, and a 2 mol/L<br><br>
hydrogen chloride ethanol solution was then added to<br>
the solution. The solvent was removed under a reduced<br>
pressure, and the obtained yellow solid was purified by<br>
silica gel chromatography [YMC-GEL,ODS-AM 120-S50,<br>
eluent; a 10% acetonitrile aqueous solution] to obtain<br>
a colorless oil product. 15 ml of 6 mol/L hydrochloric<br>
acid was added to the obtained oil product, followed by<br>
stirring at 85Â°C to 90Â°C for 7 hours. The reaction<br>
mixture was concentrated under a reduced pressure. The<br>
obtained solid was filtrated with isopropanol to obtain<br>
0.42 g of a white solid, 4-{3-[4-(3-{4-<br>
[amino(imino)methyl]phenoxy}-2-hydroxypropyl)-1-<br>
piperazinyl]-2-hydroxypropoxy}benzamidine<br>
hydrochloride.<br>
1H-NMR(D2O) d: 3.50-3.70 (4H, m) , 3.80-4.00 (8H, m) ,<br>
4.21-4.31 (4H, m), 4.55-4.65 (2H, m), 7.10-7.30 (4H,<br>
m) , 7.70-7.90 (4H, m)<br>
Example 4 8<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4-{3-[4-(2-{4-[amino(imino)methyl]phenoxy}ethyl)-1-<br>
piperazinyl]propoxy}benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.20-2.30 (2H, brm), 3.20-3.90 (14H,<br>
m), 4.22 (2H, t, J = 6.0 Hz), 4.53 (2H, brs), 7.16-7.25<br>
(4H, m) , 7.87-7.92 (4H, m), 9.10 (2H, s), 9.13 (2H, s),<br><br>
9.30 (2H, s), 9.32 (2H, s)<br>
Example 4 9<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4-{2-[4-(2-{4-[amino(imino)methyl]phenoxy}ethyl)-1-<br>
piperazinyl]ethoxy}benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 3.20-3.90 (14H, m), 4.40-4.60 (4H,<br>
m) , 7.23 (4H, d, J = 8.8 Hz), 7.89 (4H, d, J = 8.8 Hz),<br>
9.06 (4H, s), 9.29 (4H, s)<br>
Example 50<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4-({(E)-4-[4-((E)-4-{4-[amino(imino)methyl]phenoxy}-2-<br>
butenyl)-1-piperazinyl]-2-butenyl}oxy)benzamidine<br>
hydrochloride<br>
1H-NMR (d6-DMSO) : 3.10-4.00 (14H, m) , 4.76 (4H, d, J =<br>
4.4 Hz), 5.94-6.03 (2H, m) , 6.10-6.30 (2H, m), 7.19<br>
(4H, d, J = 9.0 Hz), 7.87 (4H, d, J = 9.0 Hz), 9.04<br>
(4H, s), 9.27 (4H, s)<br>
Example 51<br><br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4- [3-(4-{4-[amino(imino)methyl]benzyl}-1-<br>
piperazinyl)propoxy]benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.10-2.30 (2H, m) , 3.10-4.90 (16H,<br>
m) , 7.46 (2H, d, J = 8.8 Hz), 7.91 (2H, d, J = 8.8 Hz),<br>
7.90-8.10 (4H, m), 9.14 (2H, s), 9.33 (2H, s), 9.42<br>
(2H, s), 9.58 (2H, s).<br>
Example 52<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4-[4-{3-{4-[amino(imino)methyl]phenoxy}propyl)-1-<br>
piperazinyl]benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.20-2.40 (2H, m), 3.00-3.50 (8H,<br>
m) , 3.50-3.70 (2H, m), 4.10-4.20 (2H, m), 4.22 (2H, t,<br>
J - 6.6 Hz), 7.16-7.20 (4H, m) , 7.82 (2H, d, J = 8.9<br>
Hz), 7.86 (2H, d, J = 8.9 Hz), 8.77 (2H, s), 8.93 (2H,<br>
s), 9.09 (2H, s), 9.22 (2H, s).<br>
Example 53<br><br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4-[4-(5-{4-[amino(imino)methyl]phenoxy}pentyl)-1-<br>
piperazinyl]benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 1.42-1.54 (2H, m) , 1.74-1.90 (4H,<br>
m) , 3.00-3.20 (4H, m) , 3.20-3.50 (4H, m) , 3.50-3.70<br>
(2H, m) , 4.06-4.16 (4H, m), 7.16 (2H, d, J = 9.1 Hz),<br>
7.17 (2H, d, J = 9.1 Hz), 7.82 (2H, d, J = 9.1 Hz),<br>
7.85 (2H, d, J = 9.1 Hz), 8.85 (2H, s), 8.99 (2H, s),<br>
9.11 (2H, s), 9.24 (2H, s)<br>
Example 54<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4-{3-[4-(3-{4-[amino(imino)methyl]phenoxy}propyl)-2-<br>
methyl-1-piperazinyl]propoxy}benzamidine hydrochloride<br>
1H-NMR(D2O) d: 2.20-2.50 (4H, m), 3.33-3.60 (5H, m),<br>
3.72-4.04 (6H, m), 4.20-4.40 (4H, m), 7.17-7.20 (4H,<br>
m) , 7.86 (4H, d, J = 8.4 Hz)<br>
Example 55<br><br>
The following compound was obtained in the<br><br>
same manner as Example 40.<br>
4-{3-[4-(3-{4-[amino(imino)methyl]phenoxy}propyl)-1,4-<br>
diazepan-1-yl]propoxy}benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.10-2.40 (6H, m) , 3.20-4.00 (14H,<br>
m), 4.21 (4H, t, J = 5.9 Hz), 7.17 (4H, d, J = 8.8 Hz),<br>
7.86 (4H, d, J = 8.8 Hz), 8.96 (4H, s), 9.23 (4H, s)<br>
Example 5 6<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4-{2-[1-(3-{4-[amino(imino)methyl]phenoxy}propyl)-4-<br>
piperidinyl]ethoxy}benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 1.60-1.80 (3H, m) , 1.80-2.00 (2H,<br>
m), 2.10-2.30 (2H, m), 2.80-3.00 (2H, m) , 3.10-3.40<br>
(5H, m) , 3.40-3.60 (2H, m), 4.10-4.21 (4H, m), 7.16<br>
(4H, d, J = 8.8 Hz), 7.85 (2H, d, J = 8.8 Hz), 7.86<br>
(2H, d, J = 8.8 Hz), 8.99-9.00 (4H, m), 9.24-9.25 (4H,<br>
m)<br>
Example 57<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4-(3-{3-[(3-{4-<br><br>
[amino(imino)methyl]phenoxy}propyl)amino]-1-<br>
pyrrolidinyl}propoxy)benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.10-2.70 (6H, m) , 3.00-4.10 (10H,<br>
m), 4.21-4.26 (4H, m), 7.18 (4H, d, J = 8.8 Hz), 7.86<br>
(4H, d, J = 8.8 Hz), 8.96 (4H, brs), 9.24 (4H, brs),<br>
9.80-10.02 (2H, br)<br>
Example 58<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4- (3-{ [1-(3-{4-[amino(imino)methyl]phenoxy}propyl)-4-<br>
piperidinyl]amino}propoxy)benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.00-2.40 (8H, m) , 2.90-3.70 (10H,<br>
m) , 4.10-4.30 (4H, m), 7.16 (2H, d, J = 8.8 Hz), 7.17<br>
(2H, d, J = 8.8 Hz), 7.88 (4H, d, J = 8.8 Hz), 9.05<br>
(4H, s), 9.28 (4H, s), 9.60-9.80 (2H, m)<br>
Example 59<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4-{3-[(1-{4-[amino(imino)methyl]benzyl}-4-<br>
piperidinyl)amino]propoxy}benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.00-2.40 (6H, m), 2.90-3.70 (7H,<br><br>
m), 4.22 (2H, t, J = 6.1 Hz), 4.30-4.50 (2H, m), 7.16<br>
(2H, d, J = 8.7 Hz), 7.80-8.00 (1H, m), 7.87 (2H, d, J<br>
= 8.7 Hz), 7.90 (2H, d, J = 8.7 Hz), 7.95 (2H, d, J =<br>
8.7 Hz), 9.03 (2H, s), 9.20-9.40 (4H, m), 9.40-9.80<br>
(4H, m)<br>
Example 60<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4-{3-[{2-[(3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)(methyl)amino]ethyl}<br>
(methyl)amino]propoxy}benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.10-2.30 (4H, m), 2.85 (6H, s),<br>
3.20-3.90 (8H, m), 4.22 (4H, t, J = 6.0 Hz), 7.17 (4H,<br>
d, J = 9.0 Hz), 7.91 (4H, d, J = 9.0 Hz), 9.17 (4H, s),<br>
9.37 (4H, s), 11.7 (2H, brs)<br>
Example 61<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
4-[3-({4-[(3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)amino]butyl}amino)pr<br>
opoxy]benzamidine hydrochloride<br><br>
1H-NMR (d6-DMSO) d: 1.60-1.80 (4H, m), 2.10-2.30 (4H,<br>
m), 2.80-3.20 (8H, m), 4.22 (4H, t, J = 6.1 Hz), 7.17<br>
(4H, d, J = 9.0 Hz), 7.86 (4H, d, J = 9.0 Hz), 8.97<br>
(4H, s), 9.00-9.60 (2H, br), 9.25 (6H, s).<br>
Example 62<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
Ethyl 6-{(3-{4-[amino(imino)methyl]phenoxy}propyl)[1-<br>
(3-{4-[amino(imino)methyl]phenoxy}propyl)-4-<br>
piperidinyl]amino}hexanoate hydrochloride<br>
1H-NMR (d6-DMSO) d: 1.18 (3H, t, J = 7.1 Hz), 1.25-1.40<br>
(2H, m) , 1.45-1.65 (2H, m), 1.70-1.90 (2H, m), 2.10-<br>
2.40 (10H, m), 3.00-3.90 (11H, m), 4.06 (2H, q, J=7.1<br>
Hz), 4.10-4.30 (4H, m), 7.16-7.21 (4H, m), 7.86 (4H, d,<br>
J = 8.8 Hz), 8.94 (4H, s), 9,23 (4H, s), 11.05 (1H, s),<br>
11.20 (1H, s).<br>
Example 63<br><br>
The following compound was obtained in the<br>
same manner as Example 40.<br>
N-{6-[4-(3-{4-[amino(imino)methyl]phenoxyJpropyl)-1-<br>
piperazinyl]hexyl}acetamide<br><br>
1H-NMR (CDCl3) d: 1.25-1.42 (4H, m) , 1.44-1.54 (4H, m),<br>
1.90-2.10 (2H, m), 1.97 (3H, s), 2.10-2.80 (15H, m) ,<br>
3.21-3.26 (2H, m), 4.05 (2H, t, J = 6.3 Hz), 5.30-5.50<br>
(1H, brs), 6.92 (2H, d, J = 8.7 Hz), 7.55 (2H, d, J =<br>
8.7 Hz)<br>
Example 64<br><br>
0.81 g of 4-(3-{4-[3-(4-cyanophenoxy)propyl]-<br>
1-piperazinyl}propoxy)benzonitrile was dissolved in 20<br>
ml of chloroform, and 180 ml of ethanol was then added<br>
thereto. While cooled by ice, hydrogen chloride gas<br>
was blown into the solution. The solution was reacted<br>
at room temperature for 24 hours. Thereafter, the<br>
solvent was removed under a reduced pressure. The<br>
obtained residue and 0.84 g of methoxyamine<br>
hydrochloride were suspended in 30 ml of ethanol.<br>
While cooled by ice, 4.2 ml of triethylamine was added<br>
to the suspension, followed by stirring for 5 hours.<br>
The solvent was removed under a reduced pressure. 30<br>
ml of chloroform and 30 ml of a 1mol/L sodium hydroxide<br>
aqueous solution were added to the obtained residue, so<br>
that the organic layer was separated. The separated<br>
organic layer was dried over anhydrous sodium sulfate<br>
and then concentrated under a reduced pressure. The<br><br>
obtained residue was purified by silica gel column<br>
chromatography [eluent; chloroform : methanol = 20 : 1]<br>
to obtain 0.59 g of a pale brown solid. 0.50 g of the<br>
obtained solid was dissolved in 10 ml of chloroform,<br>
and 2 ml of a 2mol/L hydrogen chloride ethanol solution<br>
was added thereto. The solvent was removed under a<br>
reduced pressure, and the obtained residue was<br>
filtrated with ethanol to obtain 0.51 g of a white<br>
solid, 4-{3-[4-(3-{4-<br>
[amino(methoxyimino)methyl]phenoxy}propyl)-1-<br>
piperazinyl]propoxy}-N'-methoxybenzamidine<br>
hydrochloride.<br>
1H-NMR (d6-DMSO) d: 2.20-2.40 (4H, m) , 3.25-4.00 (14H,<br>
m) , 3.86 (6H, s), 4.21 (4H, t, J = 6.0 Hz), 7.15 (4H,<br>
d, J = 9.0 Hz), 7.82 (4H, d, J = 9.0 Hz), 8.75-9.50<br>
(4H, br), 12.00-13.00 (2H, br)<br>
Example 65<br><br>
The following compound was obtained in the<br>
same manner as Example 64.<br>
4-{3-[4-(3-{4-<br>
[imino(methylamino)methyl]phenoxy}propyl)-1-<br>
piperazinyl]propoxy}-N-methylbenzamidine hydrochloride<br>
1H-NMR (d6-DMSO + D2O) d: 2.20-2.30 (4H, m) , 3.00 (6H,<br><br>
s), 3.30-3.40 (4H, m) , 3.90-4.00 (8H, m), 4.19 (4H, t,<br>
J = 6.0 Hz), 7.16 (4H, d, J = 9.2 Hz), 7.75 (4H, d, J =<br>
9.2 Hz)<br>
Example 66<br><br>
The following compound was obtained in the<br>
same manner as Example 64.<br>
N-allyl-4-{3-[4-(3-{4-<br>
[ (allylamino) (imino)methyl]phenoxy}propyl)-1-<br>
piperazinyl]propoxy}benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.20-2.30 (4H, m) , 3.30-4.00 (14H,<br>
m) , 4.00-4.30 (8H, m) , 5.23-5.33 (4H, m), 5.89-5.98<br>
(2H, m), 7.16 (4H, d, J = 8.2 Hz), 7.85 (4H, d, J = 8.2<br>
Hz), 9.07 (2H, s), 9.55 (2H, s), 10.05 (2H, s)<br>
Example 67<br><br>
5.9 ml of water and 23.7 ml of ethanol were<br>
added to 2.06 g of hydroxylamine hydrochloride and 0.60<br>
g of 4-(3-{4-[3-(4-cyanophenoxy)propyl]-1-<br>
piperazinyl}propoxy)benzonitrile. Then, 4.14 ml of<br>
triethylamine was added thereto, and the mixture was<br>
subject to heating to reflux for 1 hour. After cooling<br><br>
to room temperature, a precipitate was filtrated, and 2<br>
mol/L hydrochloric acid and ethanol were added thereto<br>
and dissolved therein. The solvent was removed under<br>
reduced pressure. The obtained residue was purified by<br>
silica gel chromatography [YMC-GEL, ODS-AM 120-S50,<br>
eluent; water] to obtain 0.44 g of a white solid, 4-{3-<br>
[4-(3-{4-[amino(hydroxyimino)methyl]phenoxyJpropyl)-1-<br>
piperazinyl]propoxy}-N'-hydroxybenzamidine<br>
hydrochloride.<br>
1H-NMR (d6-DMSO + D2O) d: 2.20-2.30 (4H, m) , 3.30-3.50<br>
(4H, m) , 3.50-3.90 (8H, m), 4.20 (4H, t, J = 5.6 Hz),<br>
7.18 (4H, d, J = 9.2 Hz), 7.71 (4H, d, J = 9.2 Hz).<br>
Example 68<br><br>
0.54 g of 4-{3-[4- (3-{4-<br>
[amino(hydroxyimino)methyl]phenoxy}propyl)-1-<br>
piperazinyl]propoxy}- N'-hydroxybenzamidine<br>
hydrochloride was dissolved in 20 ml of water, and the<br>
solution was then adjusted to pH 12 with a 5 mol/L<br>
sodium hydroxide aqueous solution. A precipitate was<br>
filtrated, and it was washed with water and ethanol to<br>
obtain 0.42 g of a white solid, 4-{3-[4-(3-{4-<br>
[amino(hydroxyimino)methyl]phenoxy}propyl)-1-<br>
piperazinyl]propoxy}- N'-hydroxybenzamidine.<br>
1H-NMR (d6-DMSO) d: 1.80-2.00 (4H, m) , 2.20-2.80 (12H,<br>
m), 4.02 (4H, t, J = 6.3 Hz), 5.71 (4H, s), 6.91 (4H,<br><br>
d, J = 8.7 Hz), 7.59 (4H, d, J = 8.7 Hz), 9.45 (2H, s) .<br>
Example 69<br><br>
0.12 g of 4-{3-[4- (3-{4-<br>
[amino(hydroxyimino)methyl]phenoxy}propyl)-1-<br>
piperazinyl]propoxy}- N'-hydroxybenzamidine was<br>
dissolved in 2.0 ml of acetic acid, and 0.08 ml of<br>
acetic anhydride was then added to the solution at room<br>
temperature, followed by stirring for 1 hour. 1 hour<br>
later, 0.08 g of 5% palladium-carbon was added to the<br>
reaction mixture, and the mixture was stirred under a<br>
hydrogen atmosphere at room temperature under<br>
atmospheric pressure for 1.5 hours. After completion<br>
of the reaction, the catalyst was removed by<br>
filtration, and the solvent was removed under a reduced<br>
pressure. The obtained residue was dissolved in<br>
methanol, and 3 ml of a 2.6 mol/L hydrogen chloride<br>
ethanol solution was added thereto. Thereafter, the<br>
solvent was removed under a reduced pressure.<br>
Isopropanol was added to the obtained residue, and a<br>
precipitate was filtrated to obtain 0.11 g of a pale<br>
brown solid, 4-{3- [4-(3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)-1-<br>
piperazinyl]propoxy}benzamidine hydrochloride.<br>
Data of physicochemical properties of this<br>
compound was consistent with data of the compound<br><br>
obtained in Example 40-2.<br>
Example 7 0<br><br>
0.30 g of 6-[3-(4-{3-[(5-cyano-2-<br>
pyridinyl)oxy]propyl}-1-<br>
piperazinyl)propoxy]nicotinonitrile was suspended in<br>
7.4 ml of ethanol. 0.21 ml of triethylamine and 0.10 g<br>
of hydroxylamine hydrochloride were successively added<br>
to the suspension, followed by heating to reflux for 2<br>
hours. Thereafter, 0.01 g of hydroxylamine<br>
hydrochloride and 0.02 ml of triethylamine were<br>
successively added to the reaction solution, followed<br>
by heating to reflux for 3.5 hours. After cooling, a<br>
solid was filtrated, and it was then washed with 10 ml<br>
of ethanol to obtain 0.25 g of a pale brown solid.<br>
0.20 g of the obtained pale brown solid was dissolved<br>
in 2.0 ml of trifluoroacetic acid, and 0.15 ml of<br>
trifluoroacetic anhydride was added to the solution,<br>
followed by stirring for 0.7 hour. 0.15 ml of<br>
trifluoroacetic anhydride was further added to the<br>
reaction solution, and the mixture was stirred for 1.3<br>
hours. 0.29 ml of triethylamine and 1.5 ml of<br>
trifluoroacetic anhydride were added to the reaction<br>
solution, followed by stirring for 62.5 hours. The<br><br>
solvent was removed under a reduced pressure. 10 ml of<br>
water, 10 ml of a saturated sodium bicarbonate<br>
solution, and 20 ml of ethyl acetate were added to the<br>
obtained residue, so that the organic layer was<br>
i separated. The separated organic layer was washed<br>
twice with 10 ml of a saturated sodium bicarbonate<br>
solution, and then dried over anhydrous magnesium<br>
sulfate. The solvent was then removed under a reduced<br>
pressure. The obtained residue was purified by silica<br>
gel column chromatography [eluent; n-hexane : ethyl<br>
acetate = 1 : 1] to obtain 0.14 g of a white solid, (6-<br>
{3-[4-(3-{[5-(amino{[ (2,2,2-<br>
trifluoroacetyl)oxy]imino}methyl)-2-<br>
pyridinyl]oxy}propyl)-1-piperazinyl]propoxy}-3-<br>
pyridinyl) { [ (2,2,2-<br>
trifluoroacetyl)oxy]imino}methylamine.<br>
IR(KBr) cm-1: 1610<br>
Example 71<br><br>
0.13 g of (6-{3-[4-(3-{ [5-(amino{[(2,2,2-<br>
trifluoroacetyl)oxy]imino}methyl)-2-<br>
pyridinyl]oxy}propyl)-1-piperazinyl]propoxy}-3-<br>
pyridinyl) { [ (2,2,2-<br>
trifluoroacetyl)oxy]imino}methylamine was dissolved in<br>
5.0 ml of methanol, 2.0 ml of ethyl acetate, and<br>
0.12 ml of trifluoroacetic acid. 26 mg of 5%<br><br>
palladium-carbon was added to the solution, and the<br>
mixture was stirred under a hydrogen atmosphere at room<br>
temperature under atmospheric pressure for 7.5 hours.<br>
50 ml of methanol was added to the reaction solution<br>
followed by filtration, and the filtrate was then<br>
concentrated under a reduced pressure. 5 ml of a<br>
2mol/L hydrogen chloride methanol solution was added to<br>
the obtained residue, and the mixture was concentrated<br>
under a reduced pressure. Thereafter, 5 ml of ethanol<br>
was added thereto, and the solvent was removed under a<br>
reduced pressure. Ethanol was added to the obtained<br>
residue, and the mixture was filtrated to obtain 0.12 g<br>
of a white solid, 6-(3-{4-[3-({5-[amino(imino)methyl]-<br>
2-pyridinyl}oxy)propyl]-1-piperazinyl}propoxy)-3-<br>
pyridinecarboximidamide hydrochloride.<br>
1H-NMR (d6-DMSO) d: 2.20-2.30 (4H, m) , 3.20-3.60 (8H,<br>
m) , 3.70-3.91 (4H, br), 4.45 (4H, t, J = 6.0 Hz), 7.06<br>
(2H, d, J = 8.8 Hz), 8.19 (2H, dd, J = 2.6, 8.8 Hz),<br>
8.73 (2H, d, J = 2.6 Hz), 9.22 (4H, s), 9.50 (4H, s),<br>
11.80-12.60 (2H, br)<br>
Example 72<br><br>
The following compound was obtained in the<br>
same manner as Example 11.<br>
5-{[4-(3-{4-[[(tert-<br><br>
butoxycarbonyl)amino](imino)methyl]phenoxy}propyl)-2,3-<br>
dioxo-1-piperazinyl]methyl}-3-isoxazolyl<br>
benzenesulfonate<br>
1H-NMR (CDCl3) d: 1.57 (11H, s), 2.10-2.20 (2H, m) ,<br>
3.50-3.70 (6H, m), 4.07 (2H, t, J = 5.7 Hz), 4.69 (2H,<br>
s), 6.30 (1H, s), 6.88 (2H, d, J = 8.8 Hz), 7.50-7.70<br>
(2H, m) , 7.70-7.80 (1H, m), 7.83 (2H, d, J = 8.8 Hz),<br>
7.90-8.00 (2H, m)<br>
Example 7 3<br><br>
The following compound was obtained in the<br>
same manner as Example 24.<br>
4-[3-({2-[(6-{4-<br>
[amino(imino)methyl]phenoxy}hexyl)amino]ethyl}amino)pro<br>
poxy]benzamidine hydrochloride<br>
1H-NMR (d5-DMSO) d: 1.35-1.50 (4H, m) , 1.64-1.80 (4H,<br>
m), 2.10-2.30 (2H, m) , 2.87-2.90 (2H, m), 3.07-3.20<br>
(2H, m) , 3.27-3.50 (4H, m), 4.10 (2H, t, J = 5.6 Hz),<br>
4.20-4.30 (2H, m), 7.13-7.21 (4H, m), 7.83-7.93 (4H,<br>
m) , 9.00-9.20 (4H, m) , 9.20-9.40 (4H, m), 9.50-10.00<br>
(4H, m)<br>
Example 74<br><br><br>
The following compound was obtained in the<br>
same manner as Example 24.<br>
3-[3-({2-[(3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)amino]ethyl}amino)pr<br>
opoxy]benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 2.10-2.30 (4H, m) , 3.10-3.20 (4H,<br>
m), 3.30-3.50 (4H, m), 4.20-4.30 (4H, m), 7.18 (2H, d,<br>
J = 8.2 Hz), 7.32 (1H, d, J = 7.6 Hz), 7.45 (1H, d, J =<br>
7.6 Hz), 7.49 (1H, s), 7.54 (1H, t, J = 7.6 Hz), 7.89<br>
(2H, d, J = 8.2 Hz), 9.12 (2H, s), 9.32 (4H, s), 9.50<br>
(2H, s), 9.60-10.20 (4H, m)<br>
Example 75<br><br>
The following compound was obtained in the<br>
same manner as Example 24.<br>
4-{[3-({2-[(3-{4-<br>
[amino(imino)methyl]anilino}propyl)amino]ethyl}amino)pr<br>
opyl]amino}benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 1.90-2.00 (4H, m) , 3.00-3.10 (4H,<br>
m), 3.27 (4H, t, J = 6.8 Hz), 3.34 (4H, brs), 3.50-3.90<br>
(2H, br), 6.72 (4H, d, J = 8.9 Hz), 6.80-7.20 (2H, br),<br>
7.69 (4H, d, J = 8.9 Hz), 8.62 (4H, s), 8.89 (4H, s),<br>
9.75 (4H, brs) .<br>
Example 76<br><br><br>
The following compound was obtained in the<br>
same manner as Example 24.<br>
4-[3-({2-[(3-{4-[amino(imino)methyl]phenoxy}-2-<br>
hydroxypropyl)amino]ethyl}amino)-2-<br>
hydroxypropoxy]benzamidine hydrochloride<br>
1H-NMR (d6-DMSO + D2O) d: 3.00-3.20 (2H, m) , 3.20-3.40<br>
(2H, m), 3.40-3.50 (4H, m), 4.00-4.20 (4H, m), 4.20-<br>
4.40 (2H, m), 7.10-7.30 (4H, m), 7.80-8.00 (4H, m)<br>
Example 77<br><br>
The following compound was obtained in the<br>
same manner as Examples 18 and 24.<br>
4-{[3-({2-[(3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)amino]ethyl}amino)pr<br>
opyl]amino}benzamidine hydrochloride<br>
1H-NMR (d6-DMSO + D2O) d: 1.90-2.00 (2H, m) , 2.10-2.30<br>
(2H, m), 3.00-3.20 (4H, m), 3.24-3.30 (2H, m), 3.36<br>
(4H, s), 4.25 (2H, t, J = 6.0 Hz), 6.73 (2H, d, J = 8.4<br>
Hz), 7.18 (2H, d, J = 8.8 Hz), 7.71 (2H, d, J = 8.4<br>
Hz), 7.89 (2H, d, J = 8.8 Hz)<br>
Example 78<br><br><br>
The following compound was obtained in the<br>
same manner as Example 24.<br>
N-(3-{4-[amino(imino)methyl]phenoxy}propyl)-N-{2-[(3-<br>
{ 4- [amino (imino) methyl] phenoxy}propyl) amino] ethyl} -ÃŸ-<br>
alanine hydrochloride<br>
1H-NMR(D2O) d: 2.30-2.47 (4H, m) , 3.04-3.12 (2H, m) ,<br>
3.43-3.52 (2H, m), 3.59-3.87 (8H, m), 4.25-4.35 (4H,<br>
m), 7.15-7.23 (4H, m) , 7.74-7.81 (4H, m)<br>
Example 7 9<br><br>
The following compound was obtained in the<br>
same manner as Example 24.<br>
6-{ (3-{4-[amino(imino)methyl]phenoxy}propyl) [l-(3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)-4-<br>
piperidinyl]amino}hexanoic acid hydrochloride<br>
1H-NMR (d6-DMSO) d: 1.20-1.40 (2H, m), 1.45-1.70 (2H,<br>
m), 1.70-1.90 (2H, m), 2.10-2.40 (10H, m), 3.00-3.80<br>
(13H, m) , 4.10-4.30 (4H, m), 7.10-7.30 (4H, m), 7.85<br>
(4H, d, J = 8.8 Hz), 8.89 (4H, s), 9,2.1 (4H, s).<br>
Example 8 0<br><br><br>
0.54 g of ethyl 1,4-bis[3-(4-<br>
cyanophenoxy)propyl]-2-piperazinecarboxylate was<br>
suspended in 11.3 ml of ethanol. While cooled by ice,<br>
hydrogen chloride gas was blown into the suspension.<br>
The suspension was reacted at room temperature for 13.5<br>
hours, and thereafter, the solvent was removed under a<br>
reduced pressure. The obtained residue was dissolved<br>
in 11.3 ml of ethanol, and 0.78 g of ammonium acetate<br>
was added to the solution, followed by heating to<br>
reflux for 2 hours. After cooling to room temperature,<br>
insoluble products were removed by filtration, and the<br>
filtrate was then concentrated under a reduced<br>
pressure. The obtained residue was dissolved in 22.6<br>
ml of 2 mol/L hydrochloric acid, followed by heating to<br>
reflux for 4 hours. Thereafter, 11.3 ml of 6 mol/L<br>
hydrochloric acid was further added thereto, followed<br>
by heating to reflux for 2 hours. Thereafter, the<br>
reaction mixture was cooled to room temperature, and<br>
the solvent was then removed under a reduced pressure.<br>
The obtained residue was purified by silica gel<br>
chromatography [YMC-GEL, ODS-AM 120-S50, eluent; water]<br>
to obtain 0.29 g of a white solid, 1,4-bis(3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)-2-piperazine<br>
carboxylic acid hydrochloride.<br>
1H-NMR(D2O) d: 2.19-2.30 (4H, m), 3.10-3.30 (6H, m),<br>
3.37-3.50 (2H, m), 3.50-3.85 (3H, m), 4.26 (4H, t, J=<br><br>
5.6 Hz), 7.15-7.18 (4H, m), 7.76-7.80 (4H, m).<br>
Example 81<br><br>
0.59 g of N-{6-[4- (3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)-1-<br>
piperazinyl]hexyl}acetamide was dissolved in 20 ml of 6<br>
mol/L hydrochloric acid, followed by heating to reflux<br>
for 5 hours. After cooling to room temperature, the<br>
solvent was removed under a reduced pressure. The<br>
obtained solid was purified by silica gel<br>
chromatography [YMC-GEL, ODS-AM 120-S50, eluent; water]<br>
to obtain 0.33 g of a white solid, 4-{3-[4-(6-<br>
aminohexyl)-1-piperazinyl]propoxy}benzamidine<br>
hydrochloride.<br>
1H-NMR (d6-DMSO + D2O) d: 1.20-1.40 (4H, m) , 1.50-1.80<br>
(4H, m), 2.10-2.30 (2H, m), 2.70-2.90 (2H, m), 3.00-<br>
3.90 (12H, m), 4.20 (2H, t, J = 5.9 Hz), 7.17 (2H, d, J<br>
= 8.3 Hz), 7.84 (2H, d, J = 8.3 Hz)<br>
Example 82<br><br>
5.6 ml of 6 mol/L hydrochloric acid was added<br>
to 0.14 g of 5-{[4-(3-{4-[[(tert-<br>
butoxycarbonyl) amino](imino)methyl]phenoxy}propyl)-2,3-<br><br>
dioxo-1-piperazinyl]methyl}-3-isoxazolyl<br>
benzenesulfonate, and the mixture was subject to<br>
heating to reflux for 50 minutes. After cooling to<br>
room temperature, the solvent was removed under a<br>
reduced pressure. Ethanol was added to the obtained<br>
residue, and a precipitate was filtrated to obtain 0.06<br>
g of a white solid, 4-{3-[(2-{[(3-hydroxy-5-<br>
isoxazolyl)methyl]amino}ethyl)amino]propoxy}benzamidine<br>
hydrochloride.<br>
1H-NMR (d6-DMSO + CF3CO2D) d: 2.05-2.20 (2H, m) , 3.15<br>
(2H, t, J = 7.2 Hz), 3.36 (4H, s), 4.22 (2H, t, J = 6.0<br>
Hz), 4.38 (2H, s), 6.34 (1H, s), 7.17 (2H, d, J = 9.0<br>
Hz), 7.84 (2H, d, J = 9.0 Hz)<br>
Example 83<br><br>
0.55 g of 4-[3-({2-[ (3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)amino]ethyl}amino)pr<br>
opoxy]benzamidine hydrochloride was suspended in 10 ml<br>
of dimethyl sulfoxide, and then, 0.66 g of<br>
triethylamine and 0.22 g of acetic anhydride were added<br>
to the suspension at room temperature. The mixture was<br>
stirred at the same above temperature for 5.5 hours.<br>
Water and chloroform were added to the reaction<br>
solution, and then, a sodium hydroxide aqueous solution<br>
was added thereto, so that the mixture was converted<br><br>
into alkaline. The aqueous layer was then separated.<br>
The aqueous layer was converted into acidic by adding a<br>
hydrogen chloride ethanol solution, and they were then<br>
concentrated under a reduced pressure. The obtained<br>
residue was purified by silica gel chromatography [YMC-<br>
GEL, ODS-AM 120-S50, eluent; 5% acetonitrile aqueous<br>
solution] to obtain 0.30 g of a colorless amorphous<br>
solid, N-{2-[acetyl(3-{4-<br>
â€¢ [amino(imino)methyl]phenoxy}propyl)amino]ethyl}-N-(3-<br>
{4-[amino(imino)methyl]phenoxy}propyl)acetamide<br>
hydrochloride.<br>
1H-NMR (d6-DMSO) d: 1.90-2.10 (10H, m), 3.30-3.50 (8H,<br>
m) , 4.00-4.20 (4H, m), 7.12-7.18 (4H, m) , 7.84-7.87<br>
(4H, m), 9.02 (4H, s), 9.25 (4H, s)<br>
Example 84<br><br>
0.31 g of 4-{3-[4-(3-{4-<br>
[amino(imino)methyl]phenoxy}propy1)-1-<br>
piperazinyl]propoxy}benzamidine was suspended in 2.0 ml<br>
of dimethyl sulfoxide, and then, 0.26 ml of acetic<br>
anhydride was added to the suspension at room<br>
temperature, followed by stirring for 4 hours. A<br>
precipitate was filtrated, and it was then washed with<br>
dimethyl sulfoxide and with ethanol to obtain 0.21 g of<br>
a white solid, N-[(4-{3-[4-(3-{4-<br><br>
[(acetylamino)(imino)methyl]phenoxy}propyl)-1-<br>
piperazinyl]propoxy}phenyl)(imino)methyl] acetamide<br>
acetate.<br>
1H-NMR (d6-DMSO + D2O) d: 1.80-2.00 (4H, m) , 2.07 (12H,<br>
s), 2.30-2.50 (12H, m), 4.07 (4H, t, J = 6.3 Hz), 7.02<br>
(4H, d, J = 8.8 Hz), 7.71 (4H, d, J = 8.8 Hz)<br>
Example 85<br>
Example 85-1<br><br>
5.99 g of N-benzyloxycarbonyl-(S)-<br>
phenylalanine and 3.34 g of 4-nitrophenol were<br>
dissolved in 50 ml of chloroform. 10 ml of a<br>
chloroform solution containing 4.54 g of N,N'-<br>
dicyclohexylcarbodiimide was added dropwise to the<br>
solution at a temperature of 25Â°C or lower, and the<br>
mixture was stirred at room temperature for 4 hours. A<br>
precipitate was removed by filtration, and the filtrate<br>
was concentrated under a reduced pressure. 50 ml of<br>
ethyl acetate was added to the obtained residue, and<br>
insoluble products were removed by filtration.<br>
Thereafter, the filtrate was washed with a 1 mol/L<br>
sodium hydroxide aqueous solution 3 times, and then<br>
with a saturated aqueous solution of sodium chloride<br>
once. Organic layer was dried over anhydrous magnesium<br>
sulfate, and then concentrated under a reduced<br><br>
pressure. Isopropanol was added to the obtained<br>
residue, and a precipitate was filtrated to obtain 3.69<br>
g of a pale yellow solid, N-benzyloxycarbonyl-(S)-<br>
phenylalanine 4-nitrophenyl ester.<br>
1H-NMR (CDCl3) d: 3.20-3.30 (2H, m) , 4.86-4.91 (1H, m),<br>
5.13 (2H, s), 5.27 (1H, d, J = 7.6 Hz), 7.10-7.38 (12H,<br>
m), 8.24 (2H, d, J = 8.8 Hz)<br>
Example 85-2<br><br>
16.0 ml of a 30% hydrogen bromide-acetic acid<br>
solution was added to 3.36 g of N-benzyloxycarbonyl-<br>
(S)-phenylalanine 4-nitrophenyl ester at room<br>
temperature, and the mixture was stirred for 4 hours.<br>
40 ml of diethyl ether was added to the reaction<br>
solution, and a precipitate was filtrated to obtain<br>
2.72 g of a white solid, N-(S)-phenylalanine = 4-<br>
nitrophenyl ester hydrobromide. 1.47 g of N-(S)-<br>
phenylalanine 4-nitrophenyl ester hydrobromide was<br>
dissolved in 5.0 ml of N,N-dimethylformamide. While<br>
cooled by ice, 0.40 ml of acetic anhydride and 0.62 ml<br>
of triethylamine were successively added dropwise to<br>
the solution, and then the mixture was stirred at room<br>
temperature for 0.5 hour. 30 ml of chloroform and 2<br>
mol/L hydrochloric acid were added to the reaction<br><br>
solution, so that the organic layer was separated. The<br>
separated organic layer was washed with a saturated<br>
sodium bicarbonate solution and with a saturated<br>
aqueous solution of sodium chloride, and then dried<br>
over anhydrous magnesium sulfate. The obtained<br>
solution was concentrated under reduced pressure.<br>
Thus, 1.23 g of a white solid, N-acetyl-(S)-<br>
phenylalanine 4-nitrophenyl ester was obtained.<br>
1H-NMR (CDCl3) d: 2.05 (3H, s), 3.23 (1H, dd, J = 6.6,<br>
14.0 Hz), 3.29 (1H, dd, J = 6.6, 14.0 Hz), 5.07 (1H,<br>
dt, J = 7.3, 6.6 Hz), 5.95 (1H, d, J = 7.3 Hz), 7.13-<br>
7.23 (4H, m) , 7.32-7.40 (3H, m) , 8.23-8.27 (2H, m)<br>
Example 85-3<br><br>
0.35 g of 4-{3-[4-(3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)-1-<br>
piperazinyl]propoxy}benzamidine was suspended in 4.0 ml<br>
of N,N-dimethylformamide, and 0.58 g of N-acetyl-(S)-<br>
phenylalanine 4-nitrophenyl ester was added to the<br>
suspension at room temperature, followed by stirring<br>
for 12 hours. Ethyl acetate and water were added to<br>
the reaction mixture, and the obtained mixture was then<br>
adjusted to pH 12 with 5 mol/L sodium hydroxide aqueous<br>
solution. Thereafter, the organic layer was separated.<br>
The separated organic layer was washed with a 5 mol/L<br><br>
sodium hydroxide aqueous solution and with a saturated<br>
saline solution, and then concentrated under a reduced<br>
pressure. The obtained residue was dissolved in 10 ml<br>
of isopropanol, and carbon dioxide gas was blown into<br>
the solution. A precipitate was filtrated to obtain<br>
0.30 g of a pale yellow solid. 0.25 g of the obtained<br>
solid was dissolved in 5 ml of ethanol, and 0.50 ml of<br>
a 2.5 mol/L hydrogen chloride ethanol solution was<br>
added to the solution at room temperature. Thereafter,<br>
the mixture was concentrated under a reduced pressure<br>
to obtain 0.27 g of a pale yellow solid, (2S)-2-<br>
(acetylamino)-N-[(4-{3-[4-(3-{4-[{[(2S) -2-<br>
(acetylamino)-3-<br>
phenylpropanoyl]amino}(imino)methyl]phenoxy}propyl)-1-<br>
piperazinyl]propoxy}phenyl)(imino)methyl]-3-<br>
phenylpropanamide hydrochloride.<br>
1H-NMR (d6-DMSO) d: 1.85 (6H, s) , 2.20-2.30 (4H, m) ,<br>
2.95 (2H, dd, J = 9.6,13.7 Hz), 3.20 (2H, dd, J = 5.5,<br>
13.7 Hz), 3.25-3.90 (12H, m), 4.20-4.30 (4H, m), 4.80-<br>
5.00 (2H, m), 7.18-7.40 (14H, m), 7.23 (4H, d, J = 8.5<br>
Hz), 8.68 (2H, d, J = 5.4 Hz), 10.87 (2H, brs), 11.30-<br>
11.70 (2H, br), 12.00-12.80 (2H, br)<br>
Example 8 6<br><br>
The following compond was obtained in the<br><br>
same manner as Examples 18 and 19.<br>
4-(3-{2,3-dioxo-4-[4-(4-piperidinyl)butyl]-1-<br>
piperazinyl}propoxy)benzamidine acetate<br>
1H-NMR (d6-DMSO) d: 1.05-1.13 (2H,m) , 1.15-1.44 (5H,<br>
m), 1.35 (1H, brs), 1.44-1.51 (2H, m), 1.60-1.70 {2H,<br>
m) , 1.79 (3H, s), 1.96-2.04 (2H, m) , 2.50-2.60 (2H, m),<br>
2.95-3.70 (15H, m), 4.10 (2H, t, J = 6.0 Hz), 7.12 (2H,<br>
d, J = 8.8 Hz), 7.80 (2H, d, J = 8.8 Hz)<br>
Example 8 7<br><br>
The following compond was obtained in the<br>
same manner as Example 40.<br>
4-(3-{4-[4-(4-piperidinyl)butyl 3-1-<br>
piperazinyl}propoxy)benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 1.20-1.40 (6H, m), 1.51 (1H, brs),<br>
1.64-1.84 (4H, m) , 2.20-2.30 (2H, m) , 2.72-2.88 (2H,<br>
m), 3.00-3.90 (16H, m), 4.18-4.23 (2H, m), 7.17 (2H, d,<br>
J = 8.7 Hz), 7.88 (2H, d, J = 8.7 Hz), 8.81 (1H, s),<br>
8.96-9.14 (3H, m), 9.29 (2H, s)<br>
Example 88<br><br>
The following compond was obtained in the<br>
same manner as Example 40.<br><br>
4-(3-{4-[4-(1-methyl-4-piperidinyl)butyl]-1-<br>
piperazinyl}propoxy)benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 1.21-1.45 (7H, m), 1.66-1.84 (4H,<br>
m), 2.20-2.29 (2H, m), 2.67 (3H, d, J = 4.8 Hz), 2.80-<br>
2.92 (2H, m), 3.00-3.20 (2H, m), 3.20-3.90 (15H, m),<br>
4.22 (2H, t, J = 6.4 Hz), 7.17 (2H, d, J = 8.8 Hz),<br>
7.89 (2H, d, J = 8.8 Hz), 9.12 (2H, s), 9.32 (2H, s)<br>
Example 8 9<br><br>
The following compond was obtained in the<br>
same manner as Example 40.<br>
4-(3-{4-[6- (1-piperazinyl)hexyl]-1-<br>
piperazinyl}propoxy)benzamidine hydrochloride<br>
1H-NMR (d6-DMSO) d: 1.26-1.42 (4H, m) , 1.62-1.82 (4H,<br>
m) , 2.14-2.30 (2H, m), 2.80-4.10 (25H, m), 4.14-4.26<br>
(2H, m), 7.17 (2H, d, J = 9.0 Hz), 7.86 (2H, d, J = 9.0<br>
Hz), 8.95 (2H, s), 9.23 (2H, s), 9.50-9.90 (2H, m).<br>
Example 90<br><br>
The following compond was obtained in the<br>
same manner as Example 11.<br><br>
4-{3-[(2-{ [4-(4-<br>
piperidinyl)butyl]amino}ethyl)aminojpropoxy}benzamidine<br>
hydrochloride<br>
1H-NMR (d5-DMSO) d: 1.24-1.35 (6H, m) , 1.50-1.80 (5H,<br>
m) , 2.12-2.23 (2H, m), 2.70-3.00 (4H, m) , 3.00-3.80<br>
(8H, m), 4.10-4.30 (2H, br), 7.18 (2H, d, J = 7.4 Hz),<br>
7.88 (2H, d, J = 7.4 Hz), 8.70-8.90 (1H, m) , 8.90-9.20<br>
(3H, m), 9.30 (2H, s), 9.40-10.20 (4H, m)<br>
Example 91<br><br>
0.44 g of 4-{3-[4~(3-{4-<br>
[amino(imino)methyl]phenoxy}propyl)-1-<br>
piperazinyl]propoxy}benzamidine was suspended in 5.0 ml<br>
of dimethyl sulfoxide, and 0.66 g of benzyl 4-<br>
nitrophenyl carbonate was added to the suspension at<br>
room temperature, followed by stirring for 27 hours.<br>
20 ml of chloroform, 50 ml of water, and 4 ml of a 1<br>
mol/L sodium hydroxide aqueous solution were added to<br>
the reaction solution, so that the organic layer was<br>
separated. The aqueous layer was extracted twice with<br>
20 ml of chloroform. The obtained organic layer was<br>
combined. The thus obtained layer was dried with<br>
anhydrous sodium sulfate, and then concentrated under a<br>
reduced pressure. The obtained solid was filtrated<br>
with ethyl acetate, and the product was then purified<br>
by silica gel column chromatography [eluent;<br><br>
chloroform : methanol =20 : 1] to obtain 0.43 g of a<br>
solid. Chloroform and ethanol were added to 0.24 g of<br>
the obtained solid to dissolve it, and then, 1 ml of a<br>
2.2 mol/L hydrogen chloride ethanol solution was added<br>
thereto at room temperature, followed by concentration<br>
under a reduced pressure. The obtained solid was<br>
filtrated with diethyl ether, and the solid was<br>
dissolved in methanol. Isopropanol was added to the<br>
solution, and a precipitate was filtrated to obtain<br>
0.25 g of a white solid, benzyl (4-{3-[4-(3-{4-<br>
[{[(benzyloxy)carbonyl]amino}(imino)methyl]phenoxy}prop<br>
yl)-1-<br>
piperazinyl]propoxy}phenyl)(imino)methylcarbamate.<br>
1H-NMR (d6-DMSO) d: 2.22-2.32 (4H, m) , 3.20-3.90 (12H,<br>
m), 4.23 (4H, t, J = 6.0 Hz), 5.36 (4H, s), 7.16 (4H,<br>
d, J = 8.8 Hz), 7.36-7.54 (10H, m), 7.86 (4H, d, J =<br>
8.8 Hz), 10.40 (2H, s), 11.20-11.60 (2H, br), 12.20-<br>
12.80 (2H, br)<br>
INDUSTRIAL APPLICABILITY<br>
A novel arylamidine derivative represented by<br>
general formula [1], or a salt thereof, has a strong<br>
antifungal activity, and it is useful for preventing or<br>
treating fungous diseases of humans and animals.<br><br>
WE CLAIM:<br>
1. An arylamldine derivative or a salt thereof represented by<br>
the following general formula:<br><br>
wherein X represents a lower alkylene or alkenylene group which<br>
may be substituted with a hydroxyl group which may be protected<br>
with an araikyl group; G1 represents an oxygen atom; G2<br>
represents a carbon atom; Ra represents a hydrogen atom; R1<br>
represents an amidino group which may be protected or<br>
substituted with a group selected from the group consisting of an<br>
acyl group, an alkoxycarbonyl group, an aralkyloxycarbonyl group,<br>
a lower alkyl group, a lower alkenyl group, a lower alkoxy group<br>
and a hydroxyi group which may be protected with an acyl group;<br>
and R2 represents a group represented by the following formula<br>
(1), (2) or (3):<br><br>
(0 <br>
wherein R3 represents a hydrogen atom, or an alkoxycarbonyl<br>
group, or a group represented by the following formula;<br><br>
wherein W represents a direct bond; Yc represents a C2-4 lower<br>
alkylene group; Yc represents a C1-4 lower alkylene group; and R7b<br>
represents a group representd by the following formula;<br><br><br>
wherein Z6 represents a lower alkylene group; G3b represents an<br>
oxygen atom, or a direct bond; G5b represents a carbon atom; Rbb<br>
represents a hydrogen atom; and R5b represents an amidino<br>
group, which binds with the binding site of G5b at Its para position;<br>
or<br>
R4 represents a hydrogen atom, or an alkyl group which may<br>
be substituted with amino, carboxyl and lower alkoxycarbonyl<br>
groups;<br><br>
wherein Y represents a C2-6 lower alkytene group; each of R5 and<br>
R6 identically or differently represents a hydrogen atom, an acyl<br>
group or an alkyl group which may be substituted with a<br>
carboxyl group; and R7 represents a hydrogen atom, an alkyl<br>
group which may be substituted with carboxyl and cyclic amino<br>
groups, or group represented by the following formula:<br><br><br>
wherein Z represents a lower alkylene group which may be substituted<br>
with a hydroxyl group; G3 represents an oxygen atom, or imino<br>
group; G5 represents a carbon atom; Rb represents a hydrogen atom,<br>
and Rb represents an amidino group, which binds with the binding<br>
site of G3 at its para or meta position; or<br><br>
wherein Ya represents C2-4 lower alkylene group which may be<br>
substituted with a carboxyl group; and Yb represents a C1-4 lower<br>
alkylene group which may be substituted with keto and carboxyl<br>
groups; G4 represents a carbon atom or nitrogen atom; R7a<br>
represents an alkyl group substituted by at least one group<br>
selected from the group consisting of an amino group which may<br><br>
be protected with an acyl group, a cyclic amino group and an<br>
alkoxycarbonyl group or group represented by the following<br>
formula:<br><br>
wherein Z1 represents a lower alkylene or alkenylene group<br>
which may be substituted with a hydroxyl group which may be<br>
protected with an aralkyl group; G3a represents an oxygen atom,<br>
imino group or a direct bond; G5a represents a carbon atom; Rba<br>
represents at least one group selected from the group consisting<br>
of a hydrogen atom, a halogen atom, an alkyl group and an alkoxy<br>
group; and R5a represents an amldlno group which may be<br>
protected or substituted with a group selected from the group<br>
consisting of<br>
an acyl group,<br>
a lower alkoxy group,<br>
a lower alkyl group,<br>
a lower alkenyl group,<br><br>
a hydroxyl group which may be protected with an acyl group<br>
and<br>
an alkoxycarbonyl group which may be substituted with an aryl<br>
group,<br>
which binds with the binding site of G3a at its para or meta position.<br>
2. The arylamldine derivative or a salt thereof as claimed in<br>
claim 1, wherein R2 represents a group represented by the<br>
following formula (1), (2) or (3):<br><br><br>
wherein R3c represents a hydrogen atom or an alkoxycarbonyl<br>
group; and R4c represents a hydrogen atom or an alkly group which<br>
may be substituted with amino, carboxyl and lower alkoxycarbonyl<br>
groups,<br><br>
wherein Yd represents a C2-6 lower alkylene group; each of R5d and<br>
R6d identically or differently represents a hydrogen atom, an acyl<br>
group or an alkyl group which may be substituted with a carboxyl<br>
group; and R7d represents a hydrogen atom, or an alkyl group which<br>
may be substituted with carboxyl and cyclic amino groups, or group<br>
represented by the following formula:<br><br><br>
wherein Zd represents a lower alkylene group which may be<br>
substituted with a hydroxyl group, R3d represents an amidino group;<br>
or<br><br>
wherein each of Ya and Ya Identically or differently represents a C2-4<br>
lower alkylene group which may be substituted with keto and<br>
carboxyl groups; Z represents a lower alkylene or alkenylene group<br>
which may be substituted with a hydroxyl group which may be<br>
protected with an aralkyl group; and R3d represents an amidino group<br>
which may be protected or substituted with a group selected from<br>
the group consisting of<br>
an acyl group,<br>
a tower alkoxyy group,<br>
a lower alkyl group,<br><br>
a tower alkenyl group,<br>
a hydroxyl group which may be protected with an acyl group<br>
and<br>
an alkoxycarbonyl group which may be substituted with an aryl<br>
group.<br>
3. The arylamldine derivative or a salt thereof as claimed in<br>
claim 1 or 2, wherein X represents a lower alkylene group which<br>
may be substituted with a hydroxyl group which may be protected<br>
with an araikyl group, R2 represents a group represented by the<br>
following formula:<br><br>
wherein each of Ye and Ye identically or differently represents a<br>
C2-4 lower alkylene group which may be substituted with keto and<br>
carboxyl groups; Ze represents a lower alkylene or alkenylene<br><br>
group which may be substituted with a hydroxyl group which may<br>
be protected with an aralkyl group; and R8e represents an amidino<br>
group which may be protected or substituted with a group<br>
selected from the group consisting of<br>
an acyl group,<br>
a lower alkoxy group,<br>
a lower alkyl group,<br>
a lower alkenyl group,<br>
a hydroxyl group which may be protected with an acyl group<br>
and<br>
an alkoxycarbonyi group which may be substituted with an<br>
aryl group.<br>
4. The arylamldlne derivative or a salt thereof as claimed in<br>
claim 1 , wherein X represents a lower alkylene group which may<br>
be substituted with a hydroxyl group which may be protected with<br>
an aralkyl group; Ra represents a hydrogen atom; and R2<br>
represents a group represented by the following formula (1), (2)<br>
or (3):<br><br><br>
wherein R3f represents a hydrogen atom or an alkoxycarbonyl<br>
group; and Rf represents a hydrogen atom or an alkyl group<br>
which may be substituted with amino, carboxyl and lower alkoxy-<br>
carbonyl groups,<br><br>
wherein YÂ° represents a C2-6 lower alkylene group; each of R5g and<br>
R6g identically or differently represents a hydrogen atom, an acyl<br>
group, or an alkyl, group which may be substituted with a<br>
carboxyl group; and R70 represents a hydrogen atom, an alkyl.<br>
group which may be substituted with carboxyl and cyclic amino<br>
groups, or group represented by the following formula:<br><br><br>
wherein Zg represents a lower alkylene group which may be<br>
substituted with a hydroxyl group, R8g represents an amidino<br>
group, or<br><br>
wherein each of Yh and Yh identically or differently represents a<br>
C2-4 lower alkylene group which may be substituted with keto and<br>
carboxyl groups; Zh represents a lower alkylene or alkenylene<br>
group which may be. substituted with a hydroxyl group which may<br>
be protected with an aralkyl group; and Rgh represents an amidino<br>
group which may be protected or substituted with a group<br>
selected from the group consisting of<br><br>
an acyl group,<br>
a lower alkoxy group,<br>
a lower alkyl group<br>
a lower alkenyl group,<br>
a hydroxyl group which may be protected with an acyl<br>
group and<br>
an alkoxycarbonyl group which may be substituted with an<br>
aryl group.<br>
5. The arylamidine derivative or a salt thereof as claimed in<br>
claim 1 or 4, wherein R2 represents a group represented by the<br>
following formula:<br><br>
wherein each of Yh and Yh Identically or differently represents a<br>
C2-4 lower alkylene group which may be substituted with keto and<br>
carboxyl groups; Zh represents a lower alkylene or alkenylene<br><br>
group which may be substituted with a hydroxyl group which may be<br>
protected with an araikyl group; and R8h represents an amidino group<br>
which may be protected or substituted with a group selected from<br>
the group consisting of<br>
an acyl group,<br>
a lower alkoxy group,<br>
a lower alkly group,<br>
a lower alkenyl group,<br>
a hydroxyl group which may be protected with an acyl group<br>
and<br>
an alkoxycarbonyl group which may be substituted with an ary)<br>
group.<br>
6.	4-{3-[4-(3-{4-[amino(imino)methyl]phenoxyl}propyl)-1-<br>
piperazinyl]propoxy}benzamidine or a salt thereof.<br>
7.	4-{2-[1-(3-{4-[amino(imino)methyl]phenoxy}propyl)-4-<br>
piperldinyl]ethoxy }benzamidine or a salt thereof.<br><br>
8. An antifungal agent comprising, as an active ingredient, a<br>
compound or a salt thereof as claimed in any one of claims 1 to 7<br>
and an excipient, carrier or diluent<br>
An arylamidine derivative represented by a<br>
general formula described below or a salt thereof has<br>
an excellent antifungal action and high safety, and it<br>
is useful as an antifungal agent with good<br>
pharmacokinetics and pharmacodynamic properties:<br>
wherein X represents an unsubstituted or substituted<br>
lower alkylene or alkenylene group; G1 represents an<br>
oxygen atom, a sulfur atom, or an imino group; G2<br>
represents a carbon atom or a nitrogen atom; Ra<br>
represents at least one group selected from the group<br>
consisting of a hydrogen atom, a halogen atom, and<br>
unsubstituted or substituted alkyl, cycloalkyl and<br>
alkoxy groups; R1 represents an unprotected or protected<br>
or unsubstituted or substituted amidino group; and R2<br>
represents a substituted amino or substituted cyclic<br>
amino group, or the like.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
		<br>
		<div class="pull-left">
			<a href="224134-a-process-for-producing-a-body-for-exhaust-gas-treatment.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="224136-gray-soda-lime-silicate-glass-composition-intended-for-the-manufacture-of-windows.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>224135</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>01208/KOLNP/2004</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>40/2008</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>03-Oct-2008</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>01-Oct-2008</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>19-Aug-2004</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>TOYAMA CHEMICAL CO. LTD.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>2-5 30CHOME, NISHISHINJUKU-KU, TOKYO</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>KAZUYA HAYASHI</td>
											<td>2764-4, SUMIYOSHI, UOZU-SHI, TOYAMA 937-0851</td>
										</tr>
										<tr>
											<td>2</td>
											<td>KATSUJI OJIMA</td>
											<td>2-1-22, OOIZUMIHONMACHI, TOYAMA-SHI, TOYAMA 939-8094</td>
										</tr>
										<tr>
											<td>3</td>
											<td>KOZO HORI</td>
											<td>2634-2, HIBARI, KOSUGI-MACHI, IMIZU-GUN, TOYAMA 939-0351</td>
										</tr>
										<tr>
											<td>4</td>
											<td>NORIYUKI OKUJO</td>
											<td>410-30, HATAMACHI, KISHIWADA-SHI, OSAKA 596-0831</td>
										</tr>
										<tr>
											<td>5</td>
											<td>JUNICHI MITSUYAMA</td>
											<td>126-33, HISAGANESHIN, KAMIICHI-MACHI, NAKANIIKAWA-GUN, TOYAMA 930-0388</td>
										</tr>
										<tr>
											<td>6</td>
											<td>KAZUTO KUNITANI</td>
											<td>2731-1, SANGA, KOSUGI-MACHI, IMIZU-GUN, TOYAMA 939-0341</td>
										</tr>
										<tr>
											<td>7</td>
											<td>KEISUKE TOHDO</td>
											<td>1-16, KUMONMYO, TOYAMA-SHI, TOYAMA 939-8002</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07C 257/18, C07D</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/JP03/02506</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2003-03-04</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>2002-60618</td>
									<td>2002-03-06</td>
								    <td>Japan</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/224135-novel-arylamidine-derivative-or-salt-thereof by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 03:31:13 GMT -->
</html>
